INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7001, 0, 'Gadobutrol', 'Asthma', 'Patients with history of bronchial asthma might have an increased risk for a hypersensitivity reaction to gadolinium-based contrast agents.  Patients should always be assessed for any history of a reaction to contrast media, asthma or other allergic disorders before the administration of these agents.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7002, 0, 'Gadobutrol', 'Vision Disorders', 'The use of certain Gadolinium-based contrast agents (GBCAs) in patients with severe renal or hepatic impairment may impair imaging performance.  If GBCAs are used in these patients, complete MRI no later than 60 minutes after GBCAs administration and use a paired non-contrast and contrast MRI set for diagnosis.  It is recommended to exercise caution when interpreting contrast MR images in the absence of companion non-contrast MR images', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7003, 0, 'Furosemide', 'Anuria', 'The use of loop diuretics is contraindicated in patients with anuria.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7004, 0, 'Furosemide', 'Fibrosis', 'Loop diuretic therapy should be initiated in the hospital under strict observation in patients with liver cirrhosis and ascites.  Sudden alteration of fluid and electrolyte balance may precipitate hepatic encephalopathy and coma in such patients, who are also at increased risk for the development of hypokalemia.  Supplemental potassium and/or concomitant use of an aldosterone antagonist or potassium-sparing agent may help prevent hypokalemia and metabolic alkalosis.  Loop diuretics should be withheld in patients with hepatic coma until the condition improves.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7005, 0, 'Furosemide', 'Water-Electrolyte Imbalance', 'The use of loop diuretics, particularly at high dosages or during chronic therapy, is commonly associated with loss of electrolytes, including potassium, sodium, chloride, magnesium, and calcium.  Potassium and magnesium depletion may lead to cardiac arrhythmias and cardiac arrest.  Other electrolyte-related complications include metabolic alkalosis and hyponatremia, which are rarely life-threatening.  Excessive diuresis, as indicated by rapid weight loss, may induce dehydration and hypovolemia, which can result in acute hypotension, orthostasis, circulatory collapse, vascular thrombosis and embolism, and abrupt reduction in glomerular filtration and renal blood flow.  Severe dehydration is most likely to occur in the elderly and patients under prolonged sodium restriction.  Therapy with loop diuretics should be administered cautiously in patients with or predisposed to fluid and electrolyte depletion, including patients with primary or secondary aldosteronism (may have low potassium levels); those with severe or prolonged diarrhea or vomiting; and those with poor nutritional status.  Fluid and electrolyte abnormalities should be corrected before initiating therapy, and blood pressure as well as serum electrolyte concentrations monitored periodically and maintained at normal ranges during therapy.  Patients should be advised to immediately report signs and symptoms of fluid or electrolyte imbalance, including dry mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, arrhythmia, or gastrointestinal disturbances such as nausea and vomiting.  Digitalized patients and patients with a history of ventricular arrhythmias should be monitored carefully, since the development of hypokalemia may be particularly dangerous in these patients.  The risk of hypokalemia may be minimized by slow diuresis, a lower diuretic dosage, potassium supplementation, or combined use with a potassium-sparing diuretic.  Similarly, to prevent excessive dehydration and hyponatremia, sodium intake should be liberalized if clinically feasible.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7006, 0, 'Furosemide', 'Ototoxicity', 'Tinnitus and hearing loss, both reversible and permanent, have been reported with the use of loop diuretics.  Ototoxic effects have generally been associated with rapid intravenous or intramuscular injection, severe renal impairment, unusually high dosages (i.e. several times the usual recommended dosages), and/or concomitant use of other ototoxic agents.  Therapy with loop diuretics should be administered cautiously in patients with preexisting vestibular and/or auditory impairment, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  High-dose parenteral therapy should be administered as controlled infusion.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7007, 0, 'Furosemide', 'Kidney Diseases', 'Impaired effectiveness and possible delayed excretion of loop diuretics may occur in patients with severe renal dysfunction.  These individuals may require high dosages that are associated with an increased risk of electrolyte abnormalities (hyponatremia, hypochloremic alkalosis, hypokalemia, hypomagnesemia, hypocalcemia) and ototoxicity (tinnitus, hearing loss).  Therapy with loop diuretics should be administered cautiously in patients with significantly impaired renal function.  Prolongation of the dosing intervals may be appropriate to prevent drug accumulation.  The patient should be monitored closely for the signs and symptoms of fluid or electrolyte imbalance, including dry mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, arrhythmia, or gastrointestinal disturbances such as nausea and vomiting.  Excessive diuresis should be avoided as it may induce dehydration and hypovolemia, which can result in an abrupt reduction in glomerular filtration and renal blood flow.  If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, or if renal function becomes progressively worse as indicated by rising BUN or serum creatinine levels, an interruption or discontinuation of therapy should be considered.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7008, 0, 'Furosemide', 'Lupus Erythematosus, Systemic', 'The use of furosemide has been associated with exacerbation or activation of systemic lupus erythematosus.  Therapy with furosemide should be administered cautiously in patients with a history of lupus.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7009, 0, 'Furosemide', 'Diabetes Mellitus', 'Loop diuretics may cause hyperglycemia, glycosuria, and alterations in glucose tolerance tests.  Rarely, precipitation of diabetes mellitus has been reported.  Therapy with loop diuretics should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during therapy, and their antidiabetic regimen adjusted accordingly.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7010, 0, 'Furosemide', 'Hyperuricemia', 'Loop diuretics may decrease the rate of uric acid excretion.  Hyperuricemia can occur but is usually asymptomatic and rarely leads to clinical gout except in patients with a history of gout or chronic renal failure.  Therapy with loop diuretics should be administered cautiously in such patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7011, 0, 'Furosemide', 'Urinary Retention', 'The use of loop diuretics can cause urinary retention in patients with bladder emptying disorders, prostate hyperplasia, narrowing of the urethra.  Caution and monitoring is recommended when using loop diuretics in these patients, especially when commencing therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7012, 0, 'Gabapentin', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7013, 0, 'Gabapentin', 'Kidney Diseases', 'Gabapentin is primarily eliminated unchanged by the kidney.  Therapy with gabapentin should be administered cautiously in patients with impaired renal function.  Dosage adjustments and titration should be made in accordance with product package labeling and individual patient response.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7014, 0, 'Gabapentin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7015, 0, 'Gabapentin', 'Diseases requiring hemodialysis', 'Gabapentin is removed by hemodialysis and should be administered after dialysis.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7016, 0, 'Amlodipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7017, 0, 'Amlodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7018, 0, 'Amlodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7019, 0, 'Amlodipine', 'Heart Failure', 'Calcium channel blockers (CCBs) may have varying degrees of negative inotropic effect.  Congestive heart failure (CHF), worsening of CHF, and pulmonary edema have occurred in some patients treated with a CCB, primarily verapamil.  Some CCBs have also caused mild to moderate peripheral edema due to localized vasodilation of dependent arterioles and small blood vessels, which can be confused with the effects of increasing left ventricular dysfunction.  Although some CCBs have been used in the treatment of CHF, therapy with CCBs should be administered cautiously in patients with severe left ventricular dysfunction (e.g., ejection fraction < 30%) or moderate to severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker.  Likewise, caution is advised in patients with acute myocardial infarction and pulmonary congestion documented by X-ray on admission, since associated heart failure may be acutely worsened by administration of a CCB.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7020, 0, 'Gadodiamide', 'Kidney Diseases', 'Gadolinium- based contrast agents (GBCAs) such as gadopentetate dimeglumine, gadoteridol and gadodiamide are contraindicated in patients with chronic, severe kidney disease (glomerular filtration rate, GFR < 30 mL/min), or acute kidney injury.  GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs.  Their use should be avoided in these patients unless the diagnostic information is essential and not available with non- contrasted MRI or other modalities.  NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.  Caution is advised in patients at risk for chronically reduced renal function (age >60 years, hypertension or diabetes).  Always estimate the glomerular filtration rate (GFR) through laboratory testing.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7021, 0, 'Gadodiamide', 'Hypersensitivity', 'Severe and fatal hypersensitivity reactions including anaphylaxis have been observed with administration of gadolinium based contrast agents, including gadoteridol.  Patients with a history of allergy, drug reactions or other hypersensitivity-like disorders should be closely observed during the procedure and for several hours after drug administration.  If a reaction occurs, stop administering and immediately begin appropriate therapy including resuscitation.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7022, 0, 'Ammonium chloride', 'Liver Diseases', 'Ammonium undergoes hepatic biotransformation to urea.  Ammonium toxicity resulting in irregular heart rate, bradycardia, arrhythmia. hyperglycemia, glucosuria, twitching, asterixis, tonic seizures, and calcium- deficient tetany have occurred in patients with hepatic impairment.  Therapy with ammonium chloride should be administered cautiously in patients with compromised hepatic function.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7023, 0, 'Ammonium chloride', 'Kidney Diseases', 'Ammonium chloride should be used cautiously and under medical supervision in patients with renal impairment as it can result in hyperchloremia and metabolic acidosis.  Ammonium chloride should not be administered alone in patients with severe renal impairment experiencing metabolic alkalosis secondary to vomiting of HCl and accompanied by substantial sodium loss.  Sodium chloride alone or in combination with ammonium chloride may be necessary to correct the sodium and chloride loss.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7024, 0, 'Gatifloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7025, 0, 'Gatifloxacin', 'Glucose Metabolism Disorders', 'The use of gatifloxacin is contraindicated in patients with diabetes mellitus.  Treatment with various quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  However, dysglycemia has been reported more frequently with gatifloxacin than with other quinolones.  Although typically reported in diabetic patients, hypoglycemia and particularly hyperglycemia have occurred in patients without a history of diabetes.  Gatifloxacin-induced hypoglycemic episodes have generally occurred within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurred 4 to 10 days after initiation of therapy.  Serious cases have resulted in hyperosmolar nonketotic hyperglycemic coma, diabetic ketoacidosis, hypoglycemic coma, convulsions, and mental status changes.  Rarely, death has been reported.  In addition to diabetes, other risk factors associated with dysglycemia while taking gatifloxacin include older age, renal insufficiency, and concomitant glucose-altering mediations.  Patients with these risk factors should be closely monitored for glucose disturbances.  Dosage adjustments may be necessary, particularly in elderly patients who may have unrecognized diabetes, age-related decrease in renal function, and/or other underlying medical problems.  The manufacturer recommends a dosage reduction to 200 mg/daily after an initial dose of 400 mg in patients with creatinine clearance below 40 mL/min.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7026, 0, 'Gatifloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7027, 0, 'Gatifloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7028, 0, 'Gatifloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7029, 0, 'Gatifloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7030, 0, 'Gatifloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7031, 0, 'Gatifloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7032, 0, 'Gatifloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7033, 0, 'Amobarbital', 'Alcoholic Intoxication', 'The use of barbiturates is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of barbiturates may be additive with those of alcohol.  Severe respiratory depression and death may occur.  Therapy with barbiturates should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7034, 0, 'Amobarbital', 'Substance-Related Disorders', 'Barbiturates have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages.  Abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance to a barbiturate, overdosage can still produce respiratory depression and death, and cross-tolerance usually will occur with other agents in the class.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with barbiturates.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of barbiturates should be undertaken gradually using a dosage-tapering schedule.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7035, 0, 'Amobarbital', 'Liver Diseases', 'Barbiturates are extensively metabolized by the liver.  The plasma clearance of barbiturates may be decreased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with barbiturates should be administered cautiously and initiated at reduced dosages in patients with liver disease.  Barbiturates are not recommended for use in patients with cirrhosis, hepatic failure, hepatic coma, or other severe hepatic impairment.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7036, 0, 'Amobarbital', 'Porphyrias', 'The use of barbiturates is contraindicated in patients with a history of porphyria.  Barbiturates may exacerbate acute intermittent porphyria or porphyria variegata by inducing the enzymes responsible for porphyrin synthesis.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7037, 0, 'Amobarbital', 'Exanthema', 'Skin eruptions may precede rare but potentially fatal barbiturate-induced reactions such as systemic lupus erythematosus and exfoliative dermatitis, the latter of which may be accompanied by hepatitis and jaundice.  Therapy with barbiturates should be administered cautiously in patients with preexisting drug-induced dermatitis, since it may delay the recognition of a potential reaction to barbiturates.  Barbiturate therapy should be withdrawn promptly at the first sign of a dermatologic adverse effect.  However, cutaneous reactions may proceed to an irreversible stage even after cessation of medication due to the slow rate of metabolism and excretion of barbiturates.  Patients should be advised to promptly report signs that may indicate impending development of barbiturate-related cutaneous lesions, including high fever, severe headache, stomatitis, conjunctivitis, rhinitis, urethritis, and balanitis.  Rashes may be more likely to occur with phenobarbital and mephobarbital.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7038, 0, 'Amobarbital', 'Respiratory Insufficiency', 'Barbiturates may produce severe respiratory depression, apnea, laryngospasm, bronchospasm and cough, particularly during rapid intravenous administration.  In usual hypnotic dosages, the degree of respiratory depression produced is similar to that which occurs during physiologic sleep, while at higher dosages, the rate, depth and volume of respiration may be markedly decreased.  However, some patients may be susceptible at commonly used dosages, including the elderly, debilitated or severely ill patients, those receiving other CNS depressants, and those with limited ventilatory reserve, chronic pulmonary insufficiency or other respiratory disorders.  Therapy with barbiturates should be administered cautiously in these patients.  Appropriate monitoring and individualization of dosage are particularly important, and equipment for resuscitation should be immediately available if the parenteral route is used.  Barbiturates, especially injectable formulations, should generally be avoided in patients with sleep apnea, hypoxia, or severe pulmonary diseases in which dyspnea or obstruction is evident.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7039, 0, 'Amobarbital', 'Cardiovascular Diseases', 'The intravenous administration of barbiturates may produce severe cardiovascular reactions such as bradycardia, hypertension, or vasodilation with fall in blood pressure, particularly during rapid infusion.  Parenteral therapy with barbiturates should be administered cautiously in patients with hypertension, hypotension, or cardiac disease.  The intravenous administration of barbiturates should be reserved for emergency treatment of acute seizures or for anesthesia.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7040, 0, 'Amobarbital', 'Hypotension', 'Barbiturates should not be administered by injection to patients in shock or coma or who have recently received another respiratory depressant.  The hypnotic and hypotensive effects of these agents may be prolonged and intensified in such patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7041, 0, 'Amobarbital', 'Adrenal Insufficiency', 'Barbiturates, especially phenobarbital, secobarbital and butabarbital, may diminish the systemic effects of exogenous and endogenous corticosteroids via induction of hepatic microsomal enzymes, thereby accelerating the metabolism of corticosteroids.  In addition, barbiturates may interfere with pituitary corticotropin production.  Therapy with barbiturates should be administered cautiously in patients with adrenal insufficiency.  Patients with borderline hypoadrenalism should be monitored closely, and patients receiving steroid supplementation may require an adjustment in dosage when barbiturates are added to or withdrawn from their medication regimen.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7042, 0, 'Amobarbital', 'Depressive Disorder', 'Barbiturates depress the central nervous system and may cause or exacerbate mental depression.  Therapy with barbiturates should be administered cautiously in patients with a history of depression or suicidal tendencies.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7043, 0, 'Amobarbital', 'Hematologic Diseases', 'Hematologic toxicity, including agranulocytosis, thrombocytopenic purpura and megaloblastic anemia, has been reported rarely during use of barbiturates.  Therapy with barbiturates should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression.  Blood counts are recommended prior to and periodically during long-term therapy, and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, easy bruising, petechiae, bleeding, pallor, dizziness, or jaundice.  Barbiturate therapy should be discontinued if blood dyscrasias occur.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7044, 0, 'Amobarbital', 'Osteomalacia', 'Rickets and osteomalacia have rarely been reported following prolonged use of barbiturates, possibly due to increased metabolism of vitamin D as a result of enzyme induction by barbiturates.  Long-term therapy with barbiturates should be administered cautiously in patients with vitamin D deficiency.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7045, 0, 'Amobarbital', 'Psychotic Disorders', 'Paradoxical reactions characterized by excitability and restlessness may occur in pediatric patients with hyperactive aggressive disorders.  Such patients should be monitored for signs of paradoxical stimulation during therapy with barbiturates.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7046, 0, 'Gefitinib', 'Stevens-Johnson Syndrome', 'Cutaneous reactions, in some cases severe, have been reported with the use of EGFR inhibitors.  Monitor patients who develop dermatologic or soft tissue toxicities while receiving these agents for the development of inflammatory or infectious sequelae.  It is recommended to withhold treatment, and appropriate measures should be instituted as appropriate or discontinue the use of these agents for dermatologic or soft tissue toxicity associated with severe or life-threatening inflammatory or infectious complications.  Advise patients to wear sunscreen and hats and limit sun exposure while receiving therapy with these agents as exposure to sunlight can exacerbate dermatologic toxicities.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7047, 0, 'Gefitinib', 'Gastrointestinal Diseases', 'The use of some EGFR inhibitors may be associated with gastrointestinal perforation and fatal cases have been reported.  Patients receiving concomitant anti-angiogenic agents, corticosteroids, NSAIDs, or taxane-based chemotherapy, or who have prior history of peptic ulceration or diverticular disease may be at increased risk of perforation.  Permanently discontinue these agents in patients who develop gastrointestinal perforation.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7048, 0, 'Gefitinib', 'Eye Diseases', 'Some epidermal growth factor receptor (EGFR) inhibitors should be administered cautiously in patients with ocular disorders such as primary keratitis, ulcerative keratitis, or conjunctivitis.  It is recommended to interrupt or discontinue treatment with these agents if patients present with acute or worsening ocular disorders.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7049, 0, 'Gefitinib', 'Lung Diseases', 'The use of certain EGFR inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7050, 0, 'Gefitinib', 'Liver Diseases', 'Gefitinib undergoes extensive hepatic metabolism.  Obtain periodic liver function testing and withhold gefitinib for up to 14 days in patients with worsening liver function (Grade 2 or higher for ALT and/or AST elevations) and resume treatment when the adverse reaction fully resolves or improves to NCI CTCAE Grade 1.  Permanently discontinue therapy in patients with severe hepatic impairment.  Monitor adverse reactions when gefitinib is administered to patients with moderate and severe hepatic impairment.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7051, 0, 'Gefitinib', 'Kidney Diseases', 'Less than four percent (<4%) of gefitinib and its metabolites are excreted via the kidney.  Population pharmacokinetic analyses suggest that creatinine clearance (above 20 mL/min) has no clinically meaningful effect on predicted steady state trough concentration of gefitinib.  No clinical studies were conducted with gefitinib in patients with severe renal impairment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7052, 0, 'Gemfibrozil', 'Liver Cirrhosis, Biliary', 'The use of fibric acid derivatives is contraindicated in patients with primary biliary cirrhosis.  These agents may further raise the already elevated cholesterol in these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7053, 0, 'Gemfibrozil', 'Cholelithiasis', 'The use of fibric acid derivatives is contraindicated in patients with gallbladder disease.  A significantly increased incidence of cholelithiasis has been observed in patients treated with the fibric acid derivative, clofibrate, presumably because of increased cholesterol excretion into the bile.  Based on two separate studies (the WHO study and the Coronary Drug Project study), clofibrate use was associated with twice the risk of developing cholelithiasis and cholecystitis requiring surgery.  Due to their structural and pharmacologic similarities, use of other fibric acid derivatives may be expected to carry the same risk.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7054, 0, 'Gemfibrozil', 'Hypolipoproteinemias', 'There have been reports of severe decreases in HDL cholesterol (HDL-C) levels (as low as 2 mg/dL) occurring in diabetic and non-diabetic patients initiated on fibric acid derivatives therapy.  The decrease has been reported to occur within 2 weeks to years after initiation of therapy.  It is recommended that HDL-C levels be checked within the first few months after initiation therapy and if a severely depressed HDL-C level is detected, therapy with these agents should be withdrawn.  Monitor HDL-C level until it has returned to baseline, and therapy with these agents should not be re-initiated in these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7055, 0, 'Gemfibrozil', 'Rhabdomyolysis', 'Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of fibric acid derivatives.  The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal.  Therapy with fibric acid derivatives should be administered cautiously in patients with preexisting myopathy or a myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain.  Therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7056, 0, 'Gemfibrozil', 'Liver Diseases', 'The use of gemfibrozil is considered by the manufacturer to be contraindicated in patients with hepatic impairment.  Gemfibrozil is primarily metabolized by the liver.  Decreased drug metabolism may lead to accumulation and increased risk of toxicity, including biochemical abnormalities of liver function and musculoskeletal adverse effects.  Therapy with gemfibrozil should be administered cautiously in patients with active liver disease.  Liver function tests, including serum transaminase levels, should be performed periodically.  Therapy should be withdrawn if persistent abnormalities occur and are thought to be related to the drug.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7057, 0, 'Gemfibrozil', 'Kidney Diseases', 'The use of gemfibrozil is considered by the manufacturer to be contraindicated in patients with severely impaired renal function.  The rate of clearance of gemfibrozil may be decreased in such patients, with possible accumulation during chronic dosing.  Increased adverse effects, including rhabdomyolysis (with or without secondary renal failure) and severe hyperkalemia, have been associated with the use of fibric acid derivatives in patients with renal insufficiency.  Some patients, usually those with baseline plasma creatinine above 2.0 mg/dL, have also experienced a deterioration of renal function when treated with gemfibrozil.  Therapy with gemfibrozil should be administered cautiously in patients with significant renal impairment.  Reduced dosages and close clinical monitoring are recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7058, 0, 'Gemfibrozil', 'Hematologic Diseases', 'Mild to moderate hemoglobin, hematocrit and white blood cell decreases have been observed in patients following initiation of fibric acid derivatives therapy.  However, these levels stabilize during long-term administration.  Thrombocytopenia and agranulocytosis have been reported in individuals treated with these agents.  Caution is recommended when treating patients predisposed to hematologic changes.  Periodic monitoring of red and white blood cell counts is recommended during the first 12 months of therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7059, 0, 'Gadoversetamide', 'Kidney Diseases', 'Gadolinium- based contrast agents (GBCAs) such as gadopentetate dimeglumine, gadoteridol and gadodiamide are contraindicated in patients with chronic, severe kidney disease (glomerular filtration rate, GFR < 30 mL/min), or acute kidney injury.  GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs.  Their use should be avoided in these patients unless the diagnostic information is essential and not available with non- contrasted MRI or other modalities.  NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.  Caution is advised in patients at risk for chronically reduced renal function (age >60 years, hypertension or diabetes).  Always estimate the glomerular filtration rate (GFR) through laboratory testing.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7060, 0, 'Gadoversetamide', 'Seizures', 'Seizures have been reported during post-approval use of gadoversetamide.  Although is not possible to reliably estimate their frequency or establish a causal relationship, caution is advised in patients with seizure disorders.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7061, 0, 'Gadoversetamide', 'Hypersensitivity', 'Severe and fatal hypersensitivity reactions including anaphylaxis have been observed with administration of gadolinium based contrast agents, including gadoteridol.  Patients with a history of allergy, drug reactions or other hypersensitivity-like disorders should be closely observed during the procedure and for several hours after drug administration.  If a reaction occurs, stop administering and immediately begin appropriate therapy including resuscitation.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7062, 0, 'Ganciclovir', 'Bone Marrow Failure Disorders', 'The use of ganciclovir is commonly associated with bone marrow toxicity.  Neutropenia, anemia and thrombocytopenia have been reported.  Therapy with ganciclovir should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression.  Routine blood counts are recommended, and dosing adjusted or discontinued accordingly.  Ganciclovir should not be used in patients with an absolute neutrophil count < 500/mcL or a platelet count < 25,000/mcL.  Some neutropenic patients requiring ganciclovir may be candidates for granulocyte colony stimulating factor.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7063, 0, 'Ganciclovir', 'Kidney Diseases', 'Ganciclovir is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for toxicity from ganciclovir due to decreased drug clearance.  Therapy with ganciclovir should be administered cautiously in these patients at reduced dosages.  Serum creatinine values should be monitored frequently, and the dosing further adjusted or discontinued accordingly.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7064, 0, 'Ganciclovir', 'Diseases requiring hemodialysis', 'Ganciclovir is substantially removed by hemodialysis.  Plasma levels of ganciclovir have been shown to reduce by 50% following hemodialysis.  Ganciclovir should be administered on non-dialysis days or following dialysis sessions.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7065, 0, 'Galantamine', 'Bradycardia', 'Due to their pharmacological action, cholinesterase inhibitors can have a vagotonic effect on the sinoatrial and atrioventricular nodes producing bradycardia or heart block.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with preexisting bradycardia or underlying cardiac conduction abnormalities.  Syncopal episodes have been reported in patients with and without cardiac abnormalities.  Atropine may be used to reverse bradycardia produced by cholinesterase inhibitors.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7066, 0, 'Galantamine', 'Bronchial Spasm', 'Cholinesterase inhibitors inhibit the hydrolysis of acetylcholine.  The enhanced effect of acetylcholine produces constriction of the bronchi, increased bronchial secretions, and bronchospasm.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with respiratory dysfunction, history of asthma or obstructive pulmonary disease.  Monitoring respiratory function during dosage initiation and adjustment is recommended.  Use of atropine along with discontinuation of the cholinesterase inhibitor may be required for serious respiratory distress.  Neostigmine may produce more severe muscarinic side effects than does pyridostigmine and ambenonium.  However, the duration of action is longest for ambenonium and shortest for edrophonium.  Echothiophate iodide ophthalmic may be systemically absorbed and cautious use is recommended in these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7067, 0, 'Galantamine', 'Peptic Ulcer', 'The use of cholinesterase inhibitors is associated with an increase in gastric acid secretion and gastric contractions.  Therapy with cholinesterase inhibitors should be administered cautiously in patients with peptic ulcer disease.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7068, 0, 'Galantamine', 'Hepatic Insufficiency', 'In patients with moderate hepatic impairment (Child-Pugh score of 7 to 9), the dosage of galantamine should generally not exceed 16 mg/day.  The use of galantamine hydrobromide tablets in patients with severe hepatic impairment (Child-Pugh score of 10 to 15) is not recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7069, 0, 'Galantamine', 'Kidney Diseases', 'In patients with creatinine clearance of 9 to 59 mL/min, the dosage of galantamine should generally not exceed 16 mg/day.  In patients with creatinine clearance less than 9 mL/min, the use of galantamine hydrobromide tablets is not recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7070, 0, 'Gemifloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7071, 0, 'Gemifloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7072, 0, 'Gemifloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7073, 0, 'Gemifloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7074, 0, 'Gemifloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7075, 0, 'Gemifloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7076, 0, 'Gemifloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7077, 0, 'Gemifloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7078, 0, 'Gemifloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7079, 0, 'Gadoteridol', 'Kidney Diseases', 'Gadolinium- based contrast agents (GBCAs) such as gadopentetate dimeglumine, gadoteridol and gadodiamide are contraindicated in patients with chronic, severe kidney disease (glomerular filtration rate, GFR < 30 mL/min), or acute kidney injury.  GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs.  Their use should be avoided in these patients unless the diagnostic information is essential and not available with non- contrasted MRI or other modalities.  NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.  Caution is advised in patients at risk for chronically reduced renal function (age >60 years, hypertension or diabetes).  Always estimate the glomerular filtration rate (GFR) through laboratory testing.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7080, 0, 'Gadoteridol', 'Anemia, Hemolytic', 'Gadoteridol has not been studied in patients with hemolytic anemia and other hemoglobinopathies.  The possibility of increased hemolysis has not been excluded.  Caution and close monitoring is advised if used on these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7081, 0, 'Gadoteridol', 'Hepatic Insufficiency', 'Dose adjustments of gadoteridol in hepatic impairment have not been studied.  Therefore, caution should be exercised in patients with hepatic impairment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7082, 0, 'Gadoteridol', 'Seizures', 'In patients with a history of grand mal seizures, the possibility to induce such a seizure by gadoteridol is unknown.  Caution and close monitoring is advised in patients with a history of seizures.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7083, 0, 'Gadoteridol', 'Hypersensitivity', 'Severe and fatal hypersensitivity reactions including anaphylaxis have been observed with administration of gadolinium based contrast agents, including gadoteridol.  Patients with a history of allergy, drug reactions or other hypersensitivity-like disorders should be closely observed during the procedure and for several hours after drug administration.  If a reaction occurs, stop administering and immediately begin appropriate therapy including resuscitation.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7084, 0, 'Gemtuzumab ozogamicin', 'Liver Failure', 'Hepatotoxicity, including severe or fatal hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), has been reported in association with the use of gemtuzumab ozogamicin as a single agent, and as part of a combination chemotherapy regimen.  Patients who had moderate/severe hepatic impairment prior to treatment were 8.7 times more likely to develop VOD compared to patients without moderate/severe hepatic impairment at baseline.  Caution is advised in patients with hepatic impairment, with close monitoring of ALT, AST, total bilirubin, and alkaline phosphatase prior to each dose.  After treatment, signs and symptoms of VOD should be monitored frequently; these may include elevations in ALT, AST, total bilirubin, hepatomegaly (which may be painful), rapid weight gain, and ascites.  Monitoring only total bilirubin may not identify all patients at risk of VOD.  For patients who develop abnormal liver tests, more frequent monitoring of liver tests and clinical signs and symptoms of hepatotoxicity is recommended.  Treatment should be discontinued in patients that develop VOD.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7085, 0, 'Gemtuzumab ozogamicin', 'Pancytopenia', 'Gemtuzumab ozogamicin is a myelosuppressive agent.  Assess blood counts prior to each dose and monitor blood counts frequently after treatment until resolution of cytopenias.  Monitor patients for signs and symptoms of bleeding during treatment with gemtuzumab ozogamicin .  Manage severe bleeding, hemorrhage or persistent thrombocytopenia using dose delay or permanent discontinuation of treatment, and provide supportive care per standard practice.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7086, 0, 'Gemtuzumab ozogamicin', 'Long QT Syndrome', 'QT interval prolongation has been observed in patients treated with drugs containing calicheamicin.  When administering gemtuzumab ozogamicin to patients who have a history of or predisposition for QTc prolongation, who are taking medicinal products that are known to prolong QT interval, and in patients with electrolyte disturbances, obtain electrocardiograms (ECGs) and electrolytes prior to the start of treatment and as needed during administration.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7087, 0, 'Gemtuzumab ozogamicin', 'Kidney Diseases', 'The pharmacokinetics of gemtuzumab ozogamicin in patients with severe renal impairment (CrCL 15-29 mL/min) is unknown.  Caution is advised if used on these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7088, 0, 'Ganirelix', 'Hypersensitivity', 'Treatment with ganirelix is not advised in women with severe allergic conditions.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7089, 0, 'Ganirelix', 'Liver Diseases', 'The pharmacokinetics of ganirelix acetate injection have not been determined in special populations such as renally impaired and hepatically impaired patients.  Caution is advised.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7090, 0, 'Gentamicin', 'Dehydration', 'Adequate hydration is crucial to minimize the risk of oto- and nephrotoxicity associated with the use of aminoglycosides.  Dehydration should preferably be corrected prior to initiation of therapy.  In patients who may be at risk for dehydration, such as those with severe and/or prolonged diarrhea or vomiting, fluid status should be monitored closely.  If signs of renal irritation develop during therapy, hydration should be increased as indicated, accompanied by a reduction in dosage if necessary.  Therapy should be withdrawn if urinary output decreases progressively or azotemia increases.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7091, 0, 'Gentamicin', 'Neuromuscular Diseases', 'Aminoglycosides can cause dose-related neuromuscular blockade and muscle weakness, particularly in patients with neuromuscular disease or hypocalcemia and in patients receiving general anesthetics, neuromuscular blocking agents, or massive transfusions of citrate-anticoagulated blood.  Although aminoglycoside- induced neuromuscular blockade is generally self-limiting, it may rarely result in respiratory paralysis.  Neomycin is thought to be the most potent neuromuscular blocking agent in the class.  However, the risk is greatest with intraperitoneal or intrapleural instillation of large doses or rapid intravenous administration of parenteral aminoglycosides.  Therapy with aminoglycosides should be administered cautiously in patients with neuromuscular disorders (e.g., myasthenia gravis, parkinsonian syndrome, botulism) or hypocalcemia.  If signs of respiratory paralysis occur during aminoglycoside therapy, the drug should be discontinued and mechanical respiratory assistance provided if necessary.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7092, 0, 'Gentamicin', 'Ototoxicity', 'Aminoglycosides can cause eighth cranial nerve damage, resulting in vestibular and/or auditory toxicities.  Symptoms include dizziness, nystagmus, vertigo, ataxia, tinnitus, and varying degrees of hearing impairment.  Permanent hearing loss may occur, including, rarely, total or partial irreversible bilateral deafness after the drug has been discontinued.  Therapy with aminoglycosides, particularly if prolonged (> 10 days), should be administered cautiously in patients with preexisting vestibular and/or auditory impairment, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  To minimize the risk of toxicity, patients should be adequately hydrated, the usual aminoglycoside dosage should not be exceeded, use with other ototoxic agents should be avoided, and peak and trough serum aminoglycoside concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Serial audiograms should be obtained in patients old enough to be tested, since loss of high- frequency perception usually precedes clinical hearing loss.  The dosage should be reduced or therapy withdrawn promptly if signs and symptoms of toxicity develop.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7093, 0, 'Gentamicin', 'Kidney Diseases', 'Aminoglycosides are potentially oto- and nephrotoxic.  Eighth cranial nerve damage may manifest as vestibular and/or auditory toxicities, including dizziness, nystagmus, vertigo, ataxia, tinnitus, and varying degrees of hearing impairment.  Nephrotoxicity is usually evidenced by tubular necrosis; increases in BUN, nonprotein nitrogen, and serum creatinine concentration; decreases in urine specific gravity and creatinine clearance; proteinuria; and cells or casts in the urine.  Rarely, renal electrolyte wasting may occur, resulting in hypocalcemia, hypomagnesemia, and hypokalemia that may be associated with paresthesia, tetany, confusion, and positive Chvostek and Trousseau signs.  Although aminoglycoside- induced nephrotoxicity is generally reversible following discontinuation of the drug, death from uremia has occurred rarely.  Therapy with aminoglycosides should be administered cautiously at reduced dosages in patients with renal impairment, since they may be at increased risk for oto- and nephrotoxicity due to drug accumulation.  To minimize the risk of toxicity, patients should be adequately hydrated, the usual aminoglycoside dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and peak and trough serum aminoglycoside concentrations should be periodically determined and dosage adjusted to maintain desired levels.  Renal and eighth cranial nerve function should be closely monitored, and the dosage reduced or therapy withdrawn if toxicity develops.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7094, 0, 'Amoxapine', 'Neuroleptic Malignant Syndrome', 'Although not a neuroleptic agent, amoxapine has substantive neuroleptic activity due to its dopaminergic receptor-blocking effects and may precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, involuntary movements, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Amoxapine therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of amoxapine therapy should be carefully considered, since NMS may recur.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7095, 0, 'Amoxapine', 'Tardive Dyskinesia', 'Although not a neuroleptic agent, amoxapine has substantive neuroleptic activity due to its postsynaptic dopamine-blocking effects and may precipitate or aggravate symptoms of tardive dyskinesia (TD) following chronic use.  Neuroleptic-induced TD may or may not be reversible depending, at least partially, on the duration and total cumulative dose of neuroleptic therapy administered.  The use of amoxapine should preferably be avoided in patients with TD.  If amoxapine is given to these patients and worsening of TD occurs, prompt withdrawal of therapy will provide better chances of improving the condition.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7096, 0, 'Amoxapine', 'Anticholinergic Syndrome', 'Tricyclic and tetracyclic antidepressants (TCAs) have anticholinergic activity, to which elderly patients are particularly sensitive.  Tertiary amines such as amitriptyline and trimipramine tend to exhibit greater anticholinergic effects than other agents in the class.  Therapy with TCAs should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.  In patients with angle-closure glaucoma, even average doses can precipitate an attack.  Glaucoma should be treated and under control prior to initiation of therapy with TCAs, and intraocular pressure monitored during therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7097, 0, 'Amoxapine', 'Cardiovascular Diseases', 'Tricyclic and tetracyclic antidepressants (TCAs) may cause orthostatic hypotension, reflex tachycardia, syncope, and dizziness, particularly during initiation of therapy or rapid escalation of dosage.  Imipramine appears to have the greatest propensity to induce these effects, while secondary amines such as nortriptyline may do so less frequently.  Tolerance to the hypotensive effects often develops after a few doses to a few weeks.  Rarely, collapse and sudden death have occurred secondary to severe hypotension.  Other reported adverse cardiovascular effects include tachycardia, arrhythmias, heart block, hypertension, thrombosis, thrombophlebitis, myocardial infarction, strokes, congestive heart failure, and ECG abnormalities such as PR and QT interval prolongation.  Therapy with TCAs should be avoided during the acute recovery phase following myocardial infarction, and should be administered only with extreme caution in patients with hyperthyroidism, a history of cardiovascular or cerebrovascular disease, or a predisposition to hypotension.  Close monitoring of cardiovascular status, including ECG changes, is recommended at all dosages.  Many of the newer antidepressants, including bupropion and the selective serotonin reuptake inhibitors (SSRIs), are considerably less or minimally cardiotoxic and may be appropriate alternatives.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7098, 0, 'Amoxapine', 'Pheochromocytoma', 'Tricyclic and tetracyclic antidepressants (TCAs) may potentiate the effects of circulating catecholamines.  Enhanced sympathetic activity can provoke hypertensive crises in patients with pheochromocytoma or other tumors of the adrenal medulla, such as some neuroblastomas.  Therapy with TCAs should be administered cautiously in patients with these tumors.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7099, 0, 'Amoxapine', 'Acute Myocardial Infarction Recovery', 'The use of most tricyclic antidepressants is contraindicated in patients that are going through the acute recovery period after a myocardial infarction.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7100, 0, 'Amoxapine', 'Depressive Disorder', 'Adult and pediatric patients with depression may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7101, 0, 'Amoxapine', 'Epilepsy', 'Tricyclic antidepressants (TCAs), can lower the seizure threshold and trigger seizures.  These drugs should be used with extreme caution in patients with a history of seizures, or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.  Daily dose restrictions might apply for specific antidepressants.  Physicians are encouraged to get additional dosing recommendations on the manufacturer''s prescribing information.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7102, 0, 'Amoxapine', 'Bone Marrow Failure Disorders', 'The use of tricyclic and tetracyclic antidepressants (TCAs) has rarely been associated with bone marrow suppression.  Leukopenia, agranulocytosis, thrombocytopenia, anemia, eosinophilia, purpura, and pancytopenia have been reported with some TCAs.  Patients with preexisting bone marrow suppression or blood dyscrasias receiving TCAs should be monitored closely during therapy for further decreases in blood counts.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7103, 0, 'Amoxapine', 'Diabetes Mellitus', 'Both elevation and lowering of blood sugar levels have been reported with the use of some tricyclic antidepressants (TCAs).  Rarely, these effects have also occurred with maprotiline, a tetracyclic antidepressant.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents, particularly during dosage escalation or whenever dosage has been altered.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7104, 0, 'Amoxapine', 'Liver Diseases', 'Tricyclic and tetracyclic antidepressants (TCAs) are known to undergo metabolism in the liver.  Some of the metabolites, such as those of imipramine, clomipramine and desipramine, may be pharmacologically active.  Many of the metabolites are also excreted by the kidney.  There are very limited data concerning the use of TCAs in patients with renal and/or liver disease.  Therapy with TCAs should be administered cautiously in patients with significantly impaired renal or hepatic function.  Dosage adjustments may be necessary.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7105, 0, 'Amoxapine', 'Schizophrenia', 'Tricyclic antidepressants (TCAs) may aggravate symptoms of psychosis in schizophrenic patients, particularly those with paranoid symptomatology.  Depressed patients, usually those with bipolar disorder, may experience a switch from depression to mania or hypomania.  These occurrences have also been reported rarely with the tetracyclic antidepressant, maprotiline.  Therapy with these agents should be administered cautiously in patients with schizophrenia, bipolar disorder, or a history of mania.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7106, 0, 'Amoxapine', 'Alcoholic Intoxication', 'Tricyclic antidepressants can enhance the response to alcohol.  In patients who may use alcohol excessively, it should be borne in mind that the potentiation may increase the danger inherent in any suicide attempt or overdosage.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7107, 0, 'Amoxapine', 'Bipolar Disorder', 'A major depressive episode can be the initial presentation of bipolar disorder.  Patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder prior to initiating treatment with a tricyclic antidepressant.  This screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression.  It should be noted that tricyclic antidepressants are not approved for use in treating bipolar depression.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7108, 0, 'Amoxapine', 'Glaucoma', 'Tricyclic antidepressants as other type of antidepressants have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with anatomically narrow angle or history of glaucoma.  Doxepin hydrochloride capsules are contraindicated in patients with glaucoma.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7109, 0, 'Amoxapine', 'Neutropenia', 'The use of some tricyclic antidepressants has been associated with neutropenia (ANC < 500/mm3) and agranulocytosis (ANC < 500/mm3).  Leukocyte and differential blood counts should be performed in patients that develop fever and sore throat during treatment.  Therapy should be discontinued if there is evidence of pathologic neutrophil depression.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7110, 0, 'Amoxapine', 'Thyroid Diseases', 'Most tricyclic antidepressants should be administered with caution in hyperthyroid patients or those receiving thyroid medication as they may develop arrhythmias when these drugs are given.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7111, 0, 'Amoxapine', 'Urinary Retention', 'Due to their anticholinergic properties, tricyclic antidepressants should be administered with caution in patients with history of urinary retention.  Particularly doxepin hydrochloride capsules are contraindicated in patients with tendency to urinary retention.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7112, 0, 'Gilteritinib', 'Hepatic Insufficiency', 'The effect of severe hepatic (Child-Pugh Class C) or severe renal impairment (Clcr = 29 mL/min) on gilteritinib pharmacokinetics is unknown.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7113, 0, 'Gilteritinib', 'Long QT Syndrome', 'Gilteritinib has been associated with prolonged cardiac ventricular repolarization (QT interval).  Perform electrocardiogram (ECG) prior to initiation of treatment with gilteritinib, on days 8 and 15 of cycle 1, and prior to the start of the next two subsequent cycles.  Interrupt and reduce the dosage of gilteritinib in patients who have a QTcF >500 msec.  Hypokalemia or hypomagnesemia may increase the QT prolongation risk.  Correct hypokalemia or hypomagnesemia prior to and during treatment administration.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7114, 0, 'Abiraterone', 'Hepatic Insufficiency', 'Postmarketing studies have associated the use of abiraterone with severe hepatic toxicity, including fulminant hepatitis, acute liver failure and deaths.  Serum transaminases and bilirubin levels should be measured before starting treatment and every 2 weeks for the first three months of treatment and then monthly thereafter.  Any liver test elevations should prompt more frequently monitoring.  Treatment should be discontinued permanently in patients with concurrent elevations of ALT greater than 3 x ULN and total bilirubin greater than 2 x ULN.  In patients with baseline moderate hepatic impairment (Child-Pugh Class B), the recommended dose should be reduced to 250 mg once daily.  Abiraterone should not be used in patients with severe hepatic impairment (Child-Pugh Class C).', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7115, 0, 'Abiraterone', 'Cardiovascular Diseases', 'Abiraterone may cause hypertension, hypokalemia and fluid retention as a consequence of increased mineralocorticoid levels resulting from CYP17 inhibition.  Use caution when treating patients whose underlying medical conditions might be compromised by increases in blood pressure, hypokalemia or fluid retention such as patients with heart failure, recent myocardial infarction, ventricular arrhythmias.  Use with caution in patients with cardiovascular disease and monitor regularly.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7116, 0, 'Gentamicin (topical)', 'Burns', 'Topical aminoglycosides should not be used on serious burns.  When applied locally, aminoglycosides are generally not absorbed to a significant extent through intact skin but readily absorbed through denuded, burned, or granulating skin.  Systemic adverse effects of aminoglycosides include nephrotoxicity and ototoxicity to vestibular and auditory functions.  In general, topical aminoglycosides should not be used on large areas of the body or for more than 7 days without medical supervision.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7117, 0, 'Glimepiride', 'Cardiovascular Diseases', 'The use of oral hypoglycemic agents may be associated with an increased risk of cardiovascular mortality compared to treatment with diet alone or diet with insulin.  This warning is based on the University Group Diabetes Program (UGDP) study, a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes.  Patients treated with diet plus a fixed dosage of either tolbutamide (a sulfonylurea) or phenformin (a biguanide) for 5 to 8 years had a cardiovascular mortality rate approximately 2.5 times that of patients treated with diet alone, resulting in discontinuation of both these treatments in the study.  Despite controversy regarding interpretation of these results, clinicians and patients should be aware of the potential risk when making treatment decisions for diabetes, particularly in the presence of underlying cardiovascular disease.  Data are not available for other sulfonylureas or biguanides, nor for hypoglycemic agents belonging to other classes.  However, given the similarities in chemical structure and/or mode of action, the same caution should be applied.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7118, 0, 'Glimepiride', 'Liver Diseases', 'Sulfonylureas are metabolized in the liver, and their metabolites (some with pharmacologic activity) are excreted in the urine and feces.  Patients with impaired liver and/or renal function treated with sulfonylureas may be exposed to higher serum drug concentrations, which can increase the potential for severe hypoglycemic episodes induced by these agents.  In the presence of hepatic impairment, gluconeogenic capacity may also be diminished, further compounding the risk.  Therapy with sulfonylureas should be administered cautiously in patients with liver and/or renal disease.  Reduced dosages and longer intervals between dosage adjustments may be required.  Hypoglycemia, if it occurs during treatment, may be prolonged in these patients because of slowed metabolism and/or excretion of the drugs.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7119, 0, 'Glimepiride', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7120, 0, 'Glimepiride', 'Glucosephosphate Dehydrogenase Deficiency', 'Sulfonylureas can cause hemolytic anemia in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency.  Therapy with these agents should be used with caution in patients with G6PD deficiency and consider the use of a non-sulfonylurea alternative.  There have been postmarketing reports of hemolytic anemia in patients receiving these drugs who did not have known G6PD deficiency.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7121, 0, 'Glimepiride', 'Hyponatremia', 'Treatment with sulfonylureas may cause hyponatremia, in patients who are on other medications or have medical conditions known to cause hyponatremia or increase release of antidiuretic hormone.  The syndrome of inappropriate antidiuretic hormone (SIADH) secretion has been reported with certain sulfonylureas and these drugs may augment the peripheral (antidiuretic) action of ADH and/or increase release of ADH.  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7122, 0, 'Glucagon', 'Insulinoma', 'The use of glucagon is contraindicated in patients with insulinoma or glucagonoma as it may cause secondary hypoglycemia.  Test patients suspected of having glucagonoma for blood levels of glucagon prior to treatment, and monitor for changes in blood glucose levels during treatment.  If a patient develops symptoms of hypoglycemia after a dose of glucagon, administer glucose orally or intravenously.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7123, 0, 'Glucagon', 'Pheochromocytoma', 'The use of glucagon is contraindicated in patients with pheochromocytoma because glucagon may stimulate the release of catecholamines from the tumor, which may result in a sudden and marked increase in blood pressure.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7124, 0, 'Glucagon', 'Heart Diseases', 'Glucagon for injection may increase myocardial oxygen demand, blood pressure, and pulse rate which may be life-threatening in patients with cardiac disease.  Cardiac monitoring is recommended in patients with cardiac disease during glucagon treatment, and an increase in blood pressure and pulse rate may require therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7125, 0, 'Glucagon', 'Hypoglycemia', 'Glucagon reverses hypoglycemia via mobilization of hepatic glycogen.  It is not useful for treating hypoglycemic patients who are glycogen-depleted, a condition that can occur in starvation, adrenal insufficiency, or chronic hypoglycemia.  Glucose administration should be considered in such cases.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7126, 0, 'Glipizide', 'Cardiovascular Diseases', 'The use of oral hypoglycemic agents may be associated with an increased risk of cardiovascular mortality compared to treatment with diet alone or diet with insulin.  This warning is based on the University Group Diabetes Program (UGDP) study, a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes.  Patients treated with diet plus a fixed dosage of either tolbutamide (a sulfonylurea) or phenformin (a biguanide) for 5 to 8 years had a cardiovascular mortality rate approximately 2.5 times that of patients treated with diet alone, resulting in discontinuation of both these treatments in the study.  Despite controversy regarding interpretation of these results, clinicians and patients should be aware of the potential risk when making treatment decisions for diabetes, particularly in the presence of underlying cardiovascular disease.  Data are not available for other sulfonylureas or biguanides, nor for hypoglycemic agents belonging to other classes.  However, given the similarities in chemical structure and/or mode of action, the same caution should be applied.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7127, 0, 'Glipizide', 'Diabetic Ketoacidosis', 'The use of some sulfonylurea agents is contraindicated for the treatment of patients with diabetic ketoacidosis, with or without coma.  In addition, these agents should not be used as sole therapy in patients with type I diabetes mellitus.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7128, 0, 'Glipizide', 'Liver Diseases', 'Sulfonylureas are metabolized in the liver, and their metabolites (some with pharmacologic activity) are excreted in the urine and feces.  Patients with impaired liver and/or renal function treated with sulfonylureas may be exposed to higher serum drug concentrations, which can increase the potential for severe hypoglycemic episodes induced by these agents.  In the presence of hepatic impairment, gluconeogenic capacity may also be diminished, further compounding the risk.  Therapy with sulfonylureas should be administered cautiously in patients with liver and/or renal disease.  Reduced dosages and longer intervals between dosage adjustments may be required.  Hypoglycemia, if it occurs during treatment, may be prolonged in these patients because of slowed metabolism and/or excretion of the drugs.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7129, 0, 'Glipizide', 'Intestinal Obstruction', 'The extended-release formulation of glipizide (Glucotrol XL) contains a non-deformable material.  There have been rare reports of obstructive symptoms in patients with known strictures following the ingestion of similar sustained-release products.  Therapy with the extended-release formulation of glipizide should be administered cautiously in patients with preexisting severe gastrointestinal narrowing or obstruction, whether pathologic or iatrogenic.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7130, 0, 'Glipizide', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7131, 0, 'Glipizide', 'Glucosephosphate Dehydrogenase Deficiency', 'Sulfonylureas can cause hemolytic anemia in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency.  Therapy with these agents should be used with caution in patients with G6PD deficiency and consider the use of a non-sulfonylurea alternative.  There have been postmarketing reports of hemolytic anemia in patients receiving these drugs who did not have known G6PD deficiency.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7132, 0, 'Glipizide', 'Hyponatremia', 'Treatment with sulfonylureas may cause hyponatremia, in patients who are on other medications or have medical conditions known to cause hyponatremia or increase release of antidiuretic hormone.  The syndrome of inappropriate antidiuretic hormone (SIADH) secretion has been reported with certain sulfonylureas and these drugs may augment the peripheral (antidiuretic) action of ADH and/or increase release of ADH.  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7133, 0, 'Amoxicillin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7134, 0, 'Amoxicillin', 'Infectious Mononucleosis', 'Patients with mononucleosis treated with an aminopenicillin antibiotic, may develop a pruritic erythematous maculopapular skin rash.  The rash is usually self-limiting and resolves within days of discontinuing the offending agent.  An altered drug metabolism or an immune-mediated process unrelated to drug hypersensitivity has been proposed as the underlying mechanism.  Therapy with aminopenicillin antibiotics should not be administered in patients with mononucleosis.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7135, 0, 'Amoxicillin', 'Diabetes Mellitus', 'High urine concentrations of ampicillin may result in false-positive reactions when testing for the presence of glucose in urine using Clinitest, Benedict''s Solution or Fehling''s Solution.  Since this effect may also occur with amoxicillin, it is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix) be used.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7136, 0, 'Amoxicillin', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7137, 0, 'Amoxicillin', 'Diseases requiring hemodialysis', 'Penicillin antibiotics (except for agents in the penicillinase-resistant class) are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7138, 0, 'Glycerin', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7139, 0, 'Glycerin', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7140, 0, 'Glyburide', 'Cardiovascular Diseases', 'The use of oral hypoglycemic agents may be associated with an increased risk of cardiovascular mortality compared to treatment with diet alone or diet with insulin.  This warning is based on the University Group Diabetes Program (UGDP) study, a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes.  Patients treated with diet plus a fixed dosage of either tolbutamide (a sulfonylurea) or phenformin (a biguanide) for 5 to 8 years had a cardiovascular mortality rate approximately 2.5 times that of patients treated with diet alone, resulting in discontinuation of both these treatments in the study.  Despite controversy regarding interpretation of these results, clinicians and patients should be aware of the potential risk when making treatment decisions for diabetes, particularly in the presence of underlying cardiovascular disease.  Data are not available for other sulfonylureas or biguanides, nor for hypoglycemic agents belonging to other classes.  However, given the similarities in chemical structure and/or mode of action, the same caution should be applied.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7141, 0, 'Glyburide', 'Diabetic Ketoacidosis', 'The use of some sulfonylurea agents is contraindicated for the treatment of patients with diabetic ketoacidosis, with or without coma.  In addition, these agents should not be used as sole therapy in patients with type I diabetes mellitus.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7142, 0, 'Glyburide', 'Liver Diseases', 'Sulfonylureas are metabolized in the liver, and their metabolites (some with pharmacologic activity) are excreted in the urine and feces.  Patients with impaired liver and/or renal function treated with sulfonylureas may be exposed to higher serum drug concentrations, which can increase the potential for severe hypoglycemic episodes induced by these agents.  In the presence of hepatic impairment, gluconeogenic capacity may also be diminished, further compounding the risk.  Therapy with sulfonylureas should be administered cautiously in patients with liver and/or renal disease.  Reduced dosages and longer intervals between dosage adjustments may be required.  Hypoglycemia, if it occurs during treatment, may be prolonged in these patients because of slowed metabolism and/or excretion of the drugs.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7143, 0, 'Glyburide', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7144, 0, 'Glyburide', 'Glucosephosphate Dehydrogenase Deficiency', 'Sulfonylureas can cause hemolytic anemia in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency.  Therapy with these agents should be used with caution in patients with G6PD deficiency and consider the use of a non-sulfonylurea alternative.  There have been postmarketing reports of hemolytic anemia in patients receiving these drugs who did not have known G6PD deficiency.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7145, 0, 'Glyburide', 'Hyponatremia', 'Treatment with sulfonylureas may cause hyponatremia, in patients who are on other medications or have medical conditions known to cause hyponatremia or increase release of antidiuretic hormone.  The syndrome of inappropriate antidiuretic hormone (SIADH) secretion has been reported with certain sulfonylureas and these drugs may augment the peripheral (antidiuretic) action of ADH and/or increase release of ADH.  Caution should be used when treating patients with hyponatremia or at greater risk of developing hyponatremia such as elderly patients, patients taking diuretics or those who are volume-depleted.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7146, 0, 'Amphetamine', 'Cardiovascular Diseases', 'The use of amphetamines and amphetamine-like drugs is contraindicated in patients with advanced arteriosclerosis, symptomatic or unstable cardio- or cerebrovascular disease, moderate to severe hypertension, or hyperthyroidism.  Like other sympathomimetic amines, amphetamines may cause cardiovascular adverse effects such as palpitation, tachycardia, cardiac arrhythmias, and elevation of blood pressure.  Rarely, cardiomyopathy manifested as ventricular hypertrophy and/or congestive heart failure has been reported during chronic amphetamine use.  In addition, sudden death has been reported in association with amphetamine therapy at usual dosages in children with structural cardiac abnormalities.  In general, amphetamines should not be used in patients with structural cardiac abnormalities.  If not otherwise contraindicated, therapy with amphetamines should be administered cautiously in patients with a current or past history of cardiovascular or cerebrovascular disease.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7147, 0, 'Amphetamine', 'Glaucoma', 'The use of amphetamines and amphetamine-like drugs is contraindicated in patients with narrow-angle glaucoma or anatomically narrow angles.  Like other sympathomimetic amines, amphetamines can induce transient mydriasis.  In patients with narrow angles, pupillary dilation can provoke an acute attack of angle-closure glaucoma.  If possible, these agents should also be avoided in patients with other forms of glaucoma, since mydriasis may occasionally increase intraocular pressure.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7148, 0, 'Amphetamine', 'Mental Disorders', 'The use of central nervous system (CNS) stimulants is contraindicated in patients with marked agitation and/or anxiety, since these symptoms may be aggravated.  CNS stimulants may also exacerbate symptoms of behavior disturbance and thought disorder in psychotic patients, particularly children.  Therapy with CNS stimulants should be administered cautiously in patients with a history of psychosis or a predisposition to agitated states.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7149, 0, 'Amphetamine', 'Heart Diseases', 'The use of CNS stimulants is contraindicated in patients with significant cardiovascular impairment such as uncompensated heart failure, severe coronary disease, severe hypertension (including that associated with hyperthyroidism or pheochromocytoma), cardiac structural abnormalities, serious arrhythmias, etc.  Sudden death has been reported in adults and children taking CNS stimulant treatment.  Additionally, stroke, myocardial infarction, chest pain, syncope, arrhythmias and other symptoms have been reported in adults under treatment.  A careful assessment of the cardiovascular status should be done in patients being considered for treatment.  This includes family history, physical exam and further cardiac evaluation (EKG and echocardiogram).  Patients who develop symptoms should have a detailed cardiac evaluation and if needed, treatment should be suspended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7150, 0, 'Amphetamine', 'Hypertension', 'CNS stimulant medications have shown to increase blood pressure, and their use might be contraindicated in patients with severe hypertension.  Caution should be used when administering to patients with preexisting high blood pressure and other cardiovascular conditions.  All patients under treatment should be regularly monitored for changes in blood pressure and heart rate.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7151, 0, 'Amphetamine', 'Liver Diseases', 'In general, CNS stimulants are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with CNS stimulants should be administered cautiously in patients with moderate to severe liver disease, and the dosage should be adjusted accordingly.  Additionally, postmarketing reports have shown that atomoxetine can cause severe liver injury.  Laboratory testing should be done at the first sign or symptom of liver dysfunction (jaundice, dark urine, upper quadrant tenderness) and treatment should be discontinued in patients with evidence of liver injury.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7152, 0, 'Amphetamine', 'Substance-Related Disorders', 'Central nervous system (CNS) stimulants, especially amphetamines, have significant potential for habituation and abuse.  Tolerance, psychological dependence and severe social dysfunction can develop after prolonged use.  Frank psychotic episodes may also occur in association with chronic intoxication.  Therapy with CNS stimulants should be administered cautiously, if at all, in patients with a history of alcohol or substance abuse.  The use of amphetamines is considered by manufacturers to be contraindicated in such patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7153, 0, 'Amphetamine', 'Tics', 'Central nervous system (CNS) stimulants have been reported to exacerbate Tourette''s syndrome and other motor and phonic tics.  Therapy with CNS stimulants, if necessary, should be administered cautiously in patients with tic disorders or family history of Tourette''s syndrome.  The manufacturers of the CNS stimulants, methylphenidate (racemic) and dexmethylphenidate (the more pharmacologically active d-enantiomer), consider their use to be contraindicated in such patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7154, 0, 'Amphetamine', 'Bipolar Disorder', 'Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder.  Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression).  Close monitoring is recommended when using these agents in patients with bipolar disorders.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7155, 0, 'Amphetamine', 'Psychotic Disorders', 'Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder.  Close monitoring is recommended when using these agents in patients with psychotic disorders.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7156, 0, 'Amphetamine', 'Kidney Diseases', 'Overall CNS stimulants should be administered with caution in patients with significantly impaired renal function as the reduction in the rate of elimination may alter the therapeutic response.  The dosage should be adjusted accordingly.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7157, 0, 'Amphetamine', 'Epilepsy', 'Due to general central nervous system stimulation, therapy with CNS stimulant drugs may cause seizures.  These drugs may lower the convulsive threshold in patients with prior history of seizures or EEG abnormalities, and very rarely in patients with no previous history of seizures.  Therapy with CNS stimulants should be used with caution in patients with or predisposed to seizures.  If seizures appear, therapy should be discontinued.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7158, 0, 'Amphetamine', 'Diabetes Mellitus, Type 2', 'Obese, type 2 diabetic patients who achieve weight loss may demonstrate improved metabolic control of their disease as a result of their reduced weight.  Therefore, patients with type 2 diabetes mellitus should be monitored during weight-reduction therapy (or therapy that may be expected to induce significant weight loss as a secondary effect) for hypoglycemia and reduced need for oral hypoglycemic medication or insulin, and the dosages of these agents adjusted accordingly.  Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitation.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7159, 0, 'Griseofulvin', 'Liver Diseases', 'The use of griseofulvin is contraindicated in patients with hepatocellular failure, as animal data has shown that this drug may cause hepatocellular necrosis.  The use of griseofulvin has not been adequately studied in patients with liver disease, although it is known that griseofulvin is primarily metabolized by the liver.  Therapy with griseofulvin should be administered very cautiously in patients with liver impairment, and the dosing adjusted or discontinued according to clinical response.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7160, 0, 'Griseofulvin', 'Porphyrias', 'The use of griseofulvin is contraindicated in patients with porphyria.  Griseofulvin has been shown to cause disturbances in porphyrin metabolism in laboratory animals.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7161, 0, 'Griseofulvin', 'Lupus Erythematosus, Systemic', 'The use of griseofulvin has been associated with the development of lupus erythematosus and lupus-like syndromes, as well as exacerbation of the disease.  Griseofulvin therapy should be withdrawn in patients experiencing worsening of preexisting lupus until another cause can be identified.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7162, 0, 'Guanabenz', 'Bradycardia', 'Central alpha-2 adrenoreceptor agonists reduce sympathetic outflow from the central nervous system.  Heart rate is decreased, which may lead to or exacerbate sinus bradycardia and atrioventricular block.  Therapy with central alpha-2 adrenoreceptor agonists should be administered cautiously in patients with conduction disturbances such as sinus node dysfunction or AV nodal disease.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7163, 0, 'Guanabenz', 'Depressive Disorder', 'Central alpha-2 adrenoreceptor agonists may occasionally cause mental depression and should be used cautiously in patients with a history of depression.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7164, 0, 'Guanabenz', 'Hypotension', 'Central alpha-2 adrenoreceptor agonists reduce sympathetic outflow from the central nervous system, resulting in decreases in heart rate, peripheral and renovascular resistance, and blood pressure.  Therapy with these agents should be administered cautiously in patients with hypotension or conditions that may be exacerbated by decreased blood pressure and perfusion, such as coronary insufficiency, peripheral vascular disease (e.g., Raynaud''s syndrome), cerebrovascular disease, or recent myocardial infarction.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7165, 0, 'Guanabenz', 'Liver Diseases', 'Guanabenz is primarily metabolized by the liver.  Pharmacokinetic data indicate that the plasma clearance of guanabenz is significantly reduced and its elimination half-life significantly prolonged in patients with liver disease.  Therapy with guanabenz should be administered cautiously in patients with impaired hepatic function.  Careful monitoring of blood pressure during dosage titration is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7166, 0, 'Guanabenz', 'Kidney Diseases', 'The disposition of orally administered guanabenz is altered modestly in renal impairment.  The manufacturer states that the plasma clearance of guanabenz is reduced and its half-life prolonged in patients with impaired renal function, and more so in those on hemodialysis.  The clinical significance of these findings is unknown.  Careful monitoring of blood pressure during dosage titration is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7167, 0, 'Glycopyrronium', 'Arrhythmias, Cardiac', 'Patients with tachycardia should be supervised closely during treatment with anticholinergic agents.  Tachycardia is produced by blocking normal vagal inhibition of the SA node.  Paradoxically, bradycardia may occur due to central vagal stimulation which may occur prior to peripheral cholinergic blockade.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7168, 0, 'Glycopyrronium', 'Diabetic Neuropathies', 'Agents with anticholinergic activity can exacerbate many of the manifestations of autonomic neuropathy, including tachycardia, anhidrosis, bladder atony, obstipation, dry mouth and eyes, cycloplegia and blurring of vision, and sexual impotence in males.  Therapy with antimuscarinic agents and higher dosages of antispasmodic agents (e.g., dicyclomine or oxybutynin) should be administered cautiously in patients with autonomic neuropathy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7169, 0, 'Glycopyrronium', 'Intestinal Obstruction', 'Anticholinergics are contraindicated in patients with obstructive diseases such as achalasia, esophageal stricture or stenosis, pyloroduodenal stenosis, stenosing peptic ulcer, pyloric obstruction, and paralytic ileus.  Anticholinergics may further suppress intestinal motility with resultant precipitation or aggravation of toxic megacolon.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7170, 0, 'Glycopyrronium', 'Glaucoma', 'Anticholinergic agents are contraindicated in patients with primary glaucoma, a tendency toward glaucoma (narrow anterior chamber angle), or adhesions (synechiae) between the iris and lens, as well as for the elderly and others in whom undiagnosed glaucoma or excessive pressure in the eye may be present.  Because anticholinergics cause mydriasis, they may exacerbate these conditions.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7171, 0, 'Glycopyrronium', 'Urinary Bladder Neck Obstruction', 'In general, the use of anticholinergic agents is contraindicated in patients with urinary retention and bladder neck obstruction caused by prostatic hypertrophy.  Dysuria may occur and may require catheterization.  Also, anticholinergic drugs may aggravate partial obstructive uropathy.  Caution is advised even when using agents with mild to moderate anticholinergic activity, particularly in elderly patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7172, 0, 'Glycopyrronium', 'Tardive Dyskinesia', 'Anticholinergic agents and agents with secondary anticholinergic activity may aggravate tardive dyskinesia or induce previously suppressed symptoms.  Therapy with these agents should be avoided, if possible, or administered cautiously in patients with preexisting tardive dyskinesia, particularly in the elderly.  If tardive dyskinesia symptoms develop or worsen during treatment with an anticholinergic agent, prompt withdrawal of therapy will provide better chances of improving the condition.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7173, 0, 'Glycopyrronium', 'Dysentery', 'The use of drugs with antiperistaltic activity (primarily antidiarrheal and antimuscarinic agents, but also antispasmodic agents such as dicyclomine or oxybutynin at high dosages) is contraindicated in patients with diarrhea due to pseudomembranous enterocolitis or enterotoxin-producing bacteria.  These drugs may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella and Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  In general, because antiperistaltic agents decrease gastrointestinal motility, they may delay the excretion of infective gastroenteric organisms or toxins and should be used cautiously in patients with any infectious diarrhea, particularly if accompanied by high fever or pus or blood in the stool.  Some cough and cold and other combination products may occasionally include antimuscarinic agents for their drying effects and may, therefore, require careful selection when necessary.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7174, 0, 'Glycopyrronium', 'Myasthenia Gravis', 'The use of glycopyrrolate is contraindicated in patients with myasthenia gravis.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7175, 0, 'Glycopyrronium', 'Psychotic Disorders', 'Toxic psychosis manifested as confusion, disorientation, agitation, excitation, memory impairment, delusions and hallucinations may develop at toxic and therapeutic dosages of antimuscarinic agents.  Therapy with these agents should be administered cautiously in patients with mental disorders receiving antimuscarinic agents for control of drug-induced extrapyramidal effects, especially at the beginning of therapy or during dosage adjustment.  Psychiatric deterioration and psychotic flare-ups have also been reported following withdrawal of therapy.  Symptoms include delusions, hallucinations, aggression or violent behavior, and suicidal tendencies.  In high dosages, antimuscarinic agents may sometimes produce euphorigenic effects.  For this reason, it can be a drug of abuse.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7176, 0, 'Glycopyrronium', 'Hypertension', 'Cardiovascular effects of anticholinergics may exacerbate hypertension.  Therapy with anticholinergic agents should be administered cautiously in patients with hypertension.', '1', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7177, 0, 'Glycopyrronium', 'Fever', 'Atropine-like agents may increase the risk of hyperthermia in patients with fever by producing anhidrosis.  Therapy with atropine-like agents should be administered cautiously in febrile patients.', '1', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7178, 0, 'Glycerol phenylbutyrate', 'Malabsorption Syndromes', 'Pancreatic enzymes hydrolyze glycerol phenylbutyrate in the small intestine.  Intestinal disease resulting in fat malabsorption may result in reduced digestion of glycerol phenylbutyrate.  It is recommended to monitor the ammonia levels closely in patients with pancreatic insufficiency or intestinal malabsorption.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7179, 0, 'Glycerol phenylbutyrate', 'Hepatic Insufficiency', 'Patients with hepatic impairment may have higher plasma phenylacetate (PAA) and phenylacetate to phenylacetylglutamine (PAGN) ratio due to a reduced conversion capability of PAA to PAGN in the liver.  Patients with moderate to severe hepatic impairment may require lower dosages of glycerol phenylbutyrate than normal to control the patient''s ammonia levels.  Caution is recommended in patients with hepatic impairment as no studies have been conducted.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7180, 0, 'Glycerol phenylbutyrate', 'Peripheral Nervous System Diseases', 'The major metabolite of glycerol phenylbutyrate, PAA, is associated with neurotoxicity.  Cases of exacerbation of preexisting neuropathy have been documented in patients using this agent.  It is recommended to exercise caution when using glycerol phenylbutyrate in patients with neuropathy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7181, 0, 'Glycerol phenylbutyrate', 'Kidney Diseases', 'The efficacy and safety of glycerol phenylbutyrate in patients with renal impairment are unknown.  It is recommended to monitor ammonia levels closely when using this agent in patients with impaired renal function.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7182, 0, 'Guselkumab', 'Infections', 'There have been reports of serious infections, including infections with opportunistic pathogens, and reactivation of latent infections in patients receiving interleukin inhibitors.  Treatment with these agents should not be initiated in patients with an active infection until the infection resolves or is adequately treated.  Caution is recommended when considering the use of interleukin inhibitors in patients with a history of recurrent infections, underlying conditions which may predispose them to infections, or chronic, latent, or localized infections.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7183, 0, 'Guselkumab', 'Tuberculosis', 'Before initiating certain interleukin inhibitors, patients should be screened for latent tuberculosis infection with a tuberculin skin test.  Do not administer these agents to patients with an active tuberculosis infection.  Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy.  Anti-tuberculosis therapy should be considered prior to initiation of therapy in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7184, 0, 'Golimumab', 'Infections', 'There have been reports of serious infections, including sepsis and opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis with TNF blockers.  Treatment with these agents should not be initiated in patients with an active infection, including clinically important localized infections.  Caution and close monitoring is recommended when considering their use in patients with a history of recurrent infections, underlying conditions which may predispose them to infections, or chronic, latent, or localized infections.  Administration of these agents should be discontinued if a patient develops a serious infection or sepsis.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7185, 0, 'Golimumab', 'Neoplasms', 'In clinical trials malignancies have been observed in patients receiving TNF-blockers agents.  Patients with psoriasis should be monitored for non-melanoma skin cancers (NMSCs), particularly those patients who have had prior prolonged phototherapy treatment.  Melanoma and Merkel cell carcinoma have been reported in patients treated with TNF blocker therapy.  Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer.  Postmarketing cases of fatal hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients treated with TNF blockers.  Caution should be exercised when considering these agents in the treatment of patients with a history of malignancies or in continuing treatment in patients who develop malignancies while receiving these agents.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7186, 0, 'Golimumab', 'Neurotoxicity Syndromes', 'The use of TNF blocking agents has been associated with rare cases of CNS manifestations of systemic vasculitis, seizure and new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disorders, including multiple sclerosis and optic neuritis, and peripheral demyelinating disorders, including Guillain-Barr syndrome.  Care should be exercised when considering the use of these agents in patients with neurologic disorders and discontinuing the agent is recommended if these disorders develop during therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7187, 0, 'Golimumab', 'Tuberculosis', 'Cases of reactivation of tuberculosis or new tuberculosis infections have been observed in patients receiving TNF blocking agents, including patients who have previously received treatment for latent or active tuberculosis.  Cases of active tuberculosis have also occurred in patients being treated with these agents during treatment for latent tuberculosis.  Prior to initiating TNF blocking agents, patients should be screened for latent tuberculosis infection with a tuberculin skin test and periodically during therapy.  Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy with TNF blocking agents.  Anti-tuberculosis therapy should also be considered prior to initiation of therapy in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection.  Tuberculosis should be strongly considered in patients who develop a new infection during treatment, especially in patients who have previously or recently traveled to countries with a high prevalence of tuberculosis, or who have had close contact with a person with active tuberculosis.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7188, 0, 'Golimumab', 'Heart Failure', 'Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with the use of golimumab.  This agent has not been studied in patients with a history of CHF and golimumab should be used with caution in patients with CHF.  If a decision is made to administer golimumab to patients with CHF, these patients should be closely monitored during therapy, and the product should be discontinued if new or worsening symptoms of CHF appear.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7189, 0, 'Golimumab', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, thrombocytopenia, and pancytopenia, some with a fatal outcome, have been reported in patients treated with TNF blocking agents.  Caution should be exercised when treating patients who have ongoing or a history of significant hematologic abnormalities.  Discontinuation of therapy should be considered in patients with confirmed significant hematologic abnormalities.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7190, 0, 'Golimumab', 'Hepatitis B', 'The use of TNF blockers has been associated with reactivation of hepatitis B, in some cases fatal, in patients who were previously infected with the hepatitis B virus (HBV).  Therefore, screening for viral hepatitis should be performed in accordance with published guidelines before starting therapy with these agents.  Monitor patients at risk or with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation.  Prescribers should exercise caution in prescribing TNF blockers in patients previously infected with HBV.  It is recommended to monitor patients with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation during and for several months following therapy.  In patients who develop HBV reactivation, therapy should be stopped and antiviral therapy with appropriate supportive treatment should be initiated.  The safety of resuming these agents after HBV reactivation is controlled is not known.  Therefore, prescribers should weigh the risks and benefits when considering resumption of therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7191, 0, 'Amphotericin B', 'Anemia', 'Intravenous amphotericin B therapy may depress erythropoietin and red blood cell production and commonly causes a normocytic, normochromic anemia.  Although the anemia is well tolerated by most patients and usually reverses completely within several months of stopping therapy, it may be problematic in patients with preexisting anemia.  Intravenous therapy with amphotericin B should be administered cautiously in anemic patients or those predisposed to anemia.  Frequent monitoring of blood counts and hemoglobin concentrations are recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7192, 0, 'Amphotericin B', 'Water-Electrolyte Imbalance', 'Intravenously administered amphotericin B is nephrotoxic and may commonly cause hypo- or hyperkalemia, hypomagnesemia, and hypocalcemia secondary to renal impairment.  Renal function and serum electrolytes should be closely monitored in all patients receiving intravenous therapy with amphotericin B, but in particular, those with preexisting renal and/or electrolyte abnormalities.  Mineral and electrolyte supplementation is frequently required.  Complications of electrolyte imbalances include muscle weakness, tetany, seizures and cardiac disturbances.  Amphotericin B-related electrolyte abnormalities generally improve following cessation of therapy but may persist long after because of the drug''s long terminal elimination half-life.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7193, 0, 'Amphotericin B', 'Kidney Diseases', 'Intravenously administered amphotericin B is nephrotoxic and may commonly cause decreased renal function and abnormalities including azotemia, hypo- and hyperkalemia, hypomagnesemia, hyposthenuria, renal tubular acidosis, and nephrocalcinosis.  Renal function should be closely monitored in all patients receiving intravenous therapy with amphotericin B but in particular, patients with preexisting renal impairment.  Dosage reductions are recommended.  Serum creatinine, BUN, potassium and magnesium levels should be evaluated frequently, and dosing adjusted or discontinued accordingly.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7194, 0, 'Guanfacine', 'Bradycardia', 'Central alpha-2 adrenoreceptor agonists reduce sympathetic outflow from the central nervous system.  Heart rate is decreased, which may lead to or exacerbate sinus bradycardia and atrioventricular block.  Therapy with central alpha-2 adrenoreceptor agonists should be administered cautiously in patients with conduction disturbances such as sinus node dysfunction or AV nodal disease.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7195, 0, 'Guanfacine', 'Depressive Disorder', 'Central alpha-2 adrenoreceptor agonists may occasionally cause mental depression and should be used cautiously in patients with a history of depression.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7196, 0, 'Guanfacine', 'Hypotension', 'Central alpha-2 adrenoreceptor agonists reduce sympathetic outflow from the central nervous system, resulting in decreases in heart rate, peripheral and renovascular resistance, and blood pressure.  Therapy with these agents should be administered cautiously in patients with hypotension or conditions that may be exacerbated by decreased blood pressure and perfusion, such as coronary insufficiency, peripheral vascular disease (e.g., Raynaud''s syndrome), cerebrovascular disease, or recent myocardial infarction.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7197, 0, 'Guanfacine', 'Attention Deficit Disorder with Hyperactivity', 'The safety and effectiveness of guanfacine in children under 12 years of age has not been demonstrated and its use in this age group is not recommended.  However, there have been some spontaneous postmarketing reports of mania and aggressive behavioral changes in pediatric patients with attention- deficit hyperactivity disorder (ADHD) that received this drug.  All patients had medical or family risks of bipolar disorder, and all of them recovered after treatment discontinuation.  Hallucinations have also been reported in pediatric patients receiving guanfacine for the treatment of ADHD.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7198, 0, 'Guanfacine', 'Liver Diseases', 'Normally, approximately 50% of a guanfacine dose is eliminated unchanged by the kidney and the rest metabolized by the liver.  However, neither the parent drug nor its metabolites accumulate significantly during chronic dosing in patients with severe renal impairment due to increased hepatic metabolism of the drug in these patients.  Thus, initial dosage adjustments are generally not necessary in renal impairment.  Dosage titration, however, should be made cautiously if hepatic function is also compromised.  The pharmacokinetics of guanfacine has not been studied in patients with liver disease.  The manufacturer recommends caution when the drug is used in such patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7199, 0, 'Guanidine', 'Bone Marrow Failure Disorders', 'The use of guanidine has been rarely associated with dose-related bone marrow suppression, sometimes fatal.  Therapy with guanidine should be administered cautiously in patients with preexisting bone marrow suppression.  Monitoring complete blood cell counts (CBC) and differential counts at baseline and periodically is recommended.  Discontinue guanidine if bone marrow suppression occurs.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression, such as fever, sore throat, local infection, bleeding, or symptoms of anemia.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7200, 0, 'Guanidine', 'Kidney Failure, Chronic', 'The use of guanidine has been associated with exacerbation of renal dysfunction.  Therapy with guanidine should be administered cautiously in patients with preexisting renal disease.  Monitoring renal function regularly is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7201, 0, 'Halcinonide (topical)', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration.  Use of occlusive dressings over the applied areas may also increase percutaneous absorption.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7202, 0, 'Halcinonide (topical)', 'Diaper Rash', 'Topical corticosteroids, especially the potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol), are generally not recommended for use in the treatment of diaper rash.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are usually at the greatest risk for systemic toxicity such as adrenal suppression, Cushing''s syndrome and intracranial hypertension because of their larger skin surface to body mass ratios.  If topical corticosteroids are necessary to treat diaper rash, medium- to low-potency agents should preferably be used, and parents should be advised not to put tight-fitting diapers or plastic pants over the rash, since occlusion of treated area may increase percutaneous drug absorption.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7203, 0, 'Halcinonide (topical)', 'Adrenocortical Hyperfunction', 'The use of topical corticosteroids may precipitate or aggravate conditions of hyperadrenocorticism.  Systemic absorption of these agents can produce reversible hypothalamic-pituitary-adrenal axis suppression.  Systemic absorption, depends on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Patients with an altered skin barrier or liver failure are also at increased risk.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during topical corticosteroid therapy may indicate excessive use.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7204, 0, 'Halcinonide (topical)', 'Infections', 'Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Clinically significant local as well as systemic immunosuppressant and anti-inflammatory effects may occur, which can cause or exacerbate an infection.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Therapy with topical corticosteroids should be administered cautiously in patients with latent or active infections, particularly if a potent agent is used on a large area for prolonged periods or if occlusive dressings are used.  Effective antimicrobial therapy or other appropriate treatment should be instituted to treat the infection.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  Occlusive dressings should not be used in patients with skin infection.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7205, 0, 'Halcinonide (topical)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure, especially when potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) are used in the periorbital area.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7206, 0, 'Halothane', 'Cardiomyopathies', 'Inhalation anesthetics causes hypotension, frequently decreases pulse rate and induces supraventricular arrhythmias, and increase cerebral spinal fluid.  Ventricular arrhythmia has occurred during administration of halothane due to sensitization of myocardial conduction tissue to epinephrine and norepinephrine.  Therapy with inhalation anesthetics should be administered cautiously in patients with cardiovascular disorders including hemodynamic impairment or conduction disorders, significantly increased intracranial pressure, or impaired cerebral circulation.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7207, 0, 'Hemin', 'Blood Coagulation Disorders, Inherited', 'Hemin for injection has exhibited transient, mild anticoagulant effects during clinical studies, therefore, concurrent anticoagulant therapy should be avoided.  The extent and duration of the hypocoagulable state induced by hemin has not been established.  Caution should be exercised when using hemin therapy in patients with coagulation defects or risk of bleeding.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7208, 0, 'Haloperidol', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7209, 0, 'Haloperidol', 'Hyperthyroidism', 'The use of neuroleptic agents in the presence of thyrotoxicosis has been associated with severe neurotoxicity that includes rigidity and inability to walk or talk.  Therapy with haloperidol should be administered cautiously in patients with thyrotoxicosis or hyperthyroidism.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7210, 0, 'Haloperidol', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo- parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill- rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects.  The manufacturers of haloperidol consider its use to be contraindicated in patients with Parkinson''s disease.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7211, 0, 'Haloperidol', 'Central Nervous System Diseases', 'The use of most miscellaneous antipsychotics is contraindicated in patients with severe central nervous system depression or comatose states from any cause (e.g., lesion, disease, drug or alcohol induced).', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7212, 0, 'Haloperidol', 'Neuroleptic Malignant Syndrome', 'Neuroleptic Malignant Syndrome (NMS), a potentially fatal symptom complex, has been reported in association with the use of antipsychotic drugs.  The diagnostic evaluation is complicated and the management requires immediate discontinuation of the antipsychotic therapy and intensive symptomatic treatment and medical monitoring.  If a patient that has recovered from NMS requires antipsychotic drug treatment again, the reintroduction of therapy should be carefully considered as NMS recurrences have been reported.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7213, 0, 'Haloperidol', 'Epilepsy', 'Antipsychotics can lower the seizure threshold and trigger seizures in a dose-dependent manner.  Seizures have been reported in patients receiving antipsychotic therapy and may occur in epileptic patients even with maintenance of routine anticonvulsant treatment.  Therapy with antipsychotics should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.  High dosages should be avoided if possible.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7214, 0, 'Haloperidol', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7215, 0, 'Haloperidol', 'Cardiovascular Diseases', 'Neuroleptic agents may cause hypotension (including orthostatic hypotension), reflex tachycardia, increased pulse rate, syncope and dizziness, particularly during initiation of therapy or rapid escalation of dosage.  Tolerance to the hypotensive effects often develops after a few doses to a few weeks.  Rarely, fatal cardiac arrest has occurred secondary to severe hypotension.  Other reported adverse cardiovascular effects include hypertension, edema, arrhythmias, thrombophlebitis, myocarditis, angina, myocardial infarction, congestive heart failure, and ECG abnormalities such as PR and QT interval prolongation, diffuse T-wave flattening, and ST segment depression.  Therapy with neuroleptic agents should be administered cautiously in patients with severe cardiovascular disease, pheochromocytoma, a predisposition to hypotension, or conditions that could be exacerbated by hypotension such as a history of myocardial infarction, angina, or ischemic stroke.  Close monitoring of cardiovascular status, including ECG changes, is recommended at all dosages.  If parenteral therapy is given, patients should be in a supine position during administration and for at least 30 to 60 minutes afterwards.  Patients who experience orthostatic hypotension should be cautioned not to rise too abruptly.  Occasionally, when severe, hypotension may require treatment with vasoconstrictive agents such as norepinephrine or phenylephrine.  Epinephrine should not be used, however, since neuroleptic agents can reverse its vasopressor effects and cause a further lowering of blood pressure.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7216, 0, 'Haloperidol', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7217, 0, 'Haloperidol', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7218, 0, 'Haloperidol', 'Alcoholism', 'The use of alcohol with haloperidol should be avoided due to possible additive effects and hypotension.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7219, 0, 'Haloperidol', 'Long QT Syndrome', 'Cases of sudden death, QT interval prolongation and ventricular arrhythmias including Torsade de Pointes have been reported in patients using haloperidol.  Although cases have been reported even in the absence of predisposing factors, special caution is advised in treating patients with other QT- prolonging conditions (including electrolyte imbalance such as hypokalemia and hypomagnesemia), using QT- prolonging drugs, with underlying cardiac abnormalities, hypothyroidism and familial long QT syndrome.  Consider periodic EKG assessment on these patients.  Treatment should be discontinued and a cardiac evaluation should be considered if a patient develops signs or symptoms of ventricular arrhythmia.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7220, 0, 'Haloperidol', 'Liver Diseases', 'Haloperidol appears to be primarily converted in the liver to several metabolites, one of which is believed to be pharmacologically active.  The metabolites and approximately 1% of the parent drug are excreted in the urine.  Patients with impaired renal and/or hepatic function may be at greater risk for adverse effects due to drug and metabolite accumulation.  Therapy with haloperidol should be administered cautiously in such patients.  Lower initial dosages and slower titration may be appropriate.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7221, 0, 'Haloperidol', 'Hyperprolactinemia', 'Antipsychotic drugs can elevate serum prolactin concentrations, and this elevation persists during chronic administration.  This should be considered if therapy will be prescribed in patients with previously detected breast cancer as one-third of human breast cancers are prolactin-dependent in vitro.  Associated disturbances such as galactorrhea, amenorrhea, gynecomastia, and impotence have been reported.  Appropriate laboratory testing and follow-up is advised.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7222, 0, 'Haloperidol', 'Neutropenia', 'The use of antipsychotics has been associated with events of leukopenia, neutropenia and agranulocytosis.  Possible risk factors include preexisting low white blood cell count, and history of drug induced leukopenia/neutropenia.  Patients with these risk factors should have complete blood count monitored frequently during the first few months of therapy.  Patients should also be monitored for any signs or symptoms of infection.  Treatment should be discontinued in any patient who develops a sore throat, fever, stomatitis, or other signs of infection along with a low WBC count or severe neutropenia (ANC < 1000/mm3).', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7223, 0, 'Haloperidol', 'Dehydration', 'Neuroleptic agents may cause hypotension (including orthostatic hypotension) and associated reflex tachycardia, syncope or dizziness, particularly during initiation of therapy or rapid escalation of dosage.  Tolerance to the hypotensive effects often develops after a few doses to a few months.  Rarely, fatal cardiac arrest has occurred secondary to severe hypotension.  Therapy with neuroleptic agents should be administered cautiously in patients with conditions that would predispose them to hypotension, such as hypovolemia or dehydration (e.g., due to severe diarrhea or vomiting).  In addition, neuroleptic agents can interfere with the body''s ability to regulate core body temperature, occasionally producing hyperthermia during strenuous exercise, exposure to hot weather, and concomitant treatment with anticholinergic medications.  Patients who are dehydrated may be particularly susceptible.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7224, 0, 'Haloperidol', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7225, 0, 'Hepatitis A Vaccine', 'Liver Diseases', 'The use of hepatitis A adult vaccine in patients with chronic liver disease may have lower antibody response to the vaccine.  Monitoring is recommended when vaccinating these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7226, 0, 'Hepatitis A Vaccine', 'IMMUNE SUPPRESSION', 'The use of hepatitis A vaccine in immunocompromised persons, including individuals receiving immunosuppressive therapy, may result in diminished immune response to the vaccine and these patients may not be protected against hepatitis A virus.  Monitoring is recommended when vaccinating these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7227, 0, 'Heparin (flush)', 'Peptic Ulcer', 'Anticoagulants are contraindicated in patients with active major bleeding or those patients at risk for hemorrhage.  Hemorrhage due to heparin derivatives may be treated with protamine sulfate 1%.  However, protamine sulfate may not completely neutralize the anti- Factor Xa activity.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7228, 0, 'Heparin (flush)', 'Premature Birth', 'The use of certain heparin sodium injections and heparin lock flush solutions is considered by the manufacturers to be contraindicated in premature infants and infants of low birth weight.  Some formulations of these drugs contain benzyl alcohol which, in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, has been associated with fatalities and severe respiratory and metabolic complications in low-birthweight premature infants.  Symptoms include a striking onset of gasping respiration, hypotension, bradycardia, and cardiovascular collapse.  The manufacturers further recommend that use of these products be avoided in all neonates whenever possible.  Neonates requiring heparin lock flush solution should be given a preservative-free formulation.  Nevertheless, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.The use of heparin for maintaining patency of umbilical artery catheters may be associated with an increased risk of germinal matrix intraventricular hemorrhage in low-birthweight neonates.  Although a definitive causal relationship has not been established, caution may be appropriate when heparin lock flush solutions are used.Due to the risk of overdose, heparin lock flush solutions containing 100 units/mL should not be used in neonates, particularly those who are premature or have low birthweight.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7229, 0, 'Heparin (flush)', 'Thrombocytopenia', 'The use of heparin is contraindicated in patients with severe thrombocytopenia.  Acute thrombocytopenia can occur in patients receiving heparin, with a reported incidence of up to 30%.  Platelet counts should be obtained before and periodically during heparin administration, including regular and repeated use of heparin flush solutions if given for longer than 5 days.  Mild thrombocytopenia with counts above 100,000/mm3 may remain stable or reverse despite continued heparin administration.  However, thrombocytopenia of any degree should be closely monitored.  Therapy should be discontinued if the count falls below 100,000/mm3 or if recurrent thrombosis develops, and an alternative, nonheparin anticoagulant (e.g., argatroban, bivalirudin, lepirudin) administered if necessary.  Heparin-induced thrombocytopenia (HIT) is a serious antibody-mediated reaction resulting from irreversible aggregation of platelets.  HIT may progress to the development of venous and arterial thromboses, a condition referred to as heparin-induced thrombocytopenia and thrombosis (HITT).  Thrombotic events may also be the initial presentation for HITT, and may include deep vein thrombosis, pulmonary embolism, cerebral vein thrombosis, limb ischemia, stroke, myocardial infarction, mesenteric thrombosis, renal artery thrombosis, skin necrosis, gangrene of the extremities that may lead to amputation, and possibly death.  Both HIT and HITT can occur up to several weeks after the discontinuation of heparin therapy.  Patients presenting with thrombocytopenia or thrombosis after discontinuation of heparin should be evaluated for HIT and HITT.  Following an episode, any future use of heparin should be avoided, and use of low-molecular weight heparin should consider the potential for cross-reactivity with the HIT antibody and approached with extreme caution, if not otherwise contraindicated.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7230, 0, 'Goserelin', 'Bone Diseases, Metabolic', 'The use of GnRH agonists in women may cause a reduction in bone mineral density.  In women, current available data suggest that recovery of bone loss occurs on cessation of therapy in the majority of patients.  Postmarketing data has also shown osteoporosis, decreased bone mineral density and bone fracture in men.  Therapy with goserelin should be administered cautiously in patients with major risk factors for decreased bone mineral content, such as chronic alcohol and/or tobacco use, a strong family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, corticosteroids).', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7231, 0, 'Goserelin', 'Cardiovascular Diseases', 'Increased risk of developing myocardial infarction, sudden cardiac death and stroke has been reported in association with use of GnRH agonists such as goserelin in men.  The risk appears low based on the reported odds ratios, and should be evaluated carefully along with cardiovascular risk factors when determining a treatment for patients with prostate cancer.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7232, 0, 'Goserelin', 'Hyperglycemia', 'Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists such as goserelin.  Hyperglycemia may represent development of diabetes mellitus or worsening of glycemic control in patients with diabetes.  Monitor blood glucose and/or glycosylated hemoglobin (HbA1c) periodically in patients receiving goserelin and manage with current practice for treatment of hyperglycemia or diabetes.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7233, 0, 'Goserelin', 'Long QT Syndrome', 'Androgen deprivation therapy may prolong the QT/QTc interval.  Health care providers should consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, frequent electrolyte abnormalities, and in patients taking drugs known to prolong the QT interval.  Electrolyte abnormalities should be corrected.  Consider periodic monitoring of electrocardiograms and electrolytes.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7234, 0, 'Heparin', 'Peptic Ulcer', 'Anticoagulants are contraindicated in patients with active major bleeding or those patients at risk for hemorrhage.  Hemorrhage due to heparin derivatives may be treated with protamine sulfate 1%.  However, protamine sulfate may not completely neutralize the anti- Factor Xa activity.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7235, 0, 'Heparin', 'Hemorrhage', 'The use of heparin is contraindicated in patients with uncontrollable active bleeding, except when the bleeding is due to disseminated intravascular coagulation.  Hemorrhage can occur at virtually any site in patients receiving heparin.  An unexplained drop in hematocrit or blood pressure, or any other unexplained symptom, should lead to serious consideration of a hemorrhagic event.  Therapy with heparin should be used with extreme caution in patients with known bleeding disorders or disease states that may predispose to hemorrhage during heparin administration, including hemophilia, thrombocytopenia, certain vascular purpuras, ulcerative gastrointestinal lesions, diverticulitis, ulcerative colitis, severe liver disease, subacute bacterial endocarditis, severe hypertension, myeloproliferative disorders, and threatened abortion.  Blood coagulation tests (e.g., whole blood clotting time, activated partial thromboplastin time) should be performed at appropriate intervals during full-dose heparin administration.  In addition, periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy.  There is usually no need to monitor coagulation parameters in patients receiving low-dose heparin, except in patients undergoing major surgery.  For low molecular weight heparin (LMWH), coagulation tests such as prothrombin time (PT) and aPTT are relatively insensitive measures of LMWH activity and not suitable for routine monitoring.  Anti-Factor Xa may be used to monitor the anticoagulant effect of LMWH in patients with significant renal impairment, abnormal coagulation parameters, or bleeding during therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7236, 0, 'Heparin', 'Hypertension', 'Heparin should be used with extreme caution in patients with uncontrolled or severe hypertension as these conditions may predispose the patient to hemorrhage during heparin administration.  Blood coagulation tests (e.g., whole blood clotting time, activated partial thromboplastin time) should be performed at appropriate intervals during full-dose heparin administration.  In addition, periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy.  Clinical monitoring of blood pressure is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7237, 0, 'Heparin', 'Premature Birth', 'The use of certain heparin sodium injections and heparin lock flush solutions is considered by the manufacturers to be contraindicated in premature infants and infants of low birth weight.  Some formulations of these drugs contain benzyl alcohol which, in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, has been associated with fatalities and severe respiratory and metabolic complications in low-birthweight premature infants.  Symptoms include a striking onset of gasping respiration, hypotension, bradycardia, and cardiovascular collapse.  The manufacturers further recommend that use of these products be avoided in all neonates whenever possible.  Neonates requiring heparin lock flush solution should be given a preservative-free formulation.  Nevertheless, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.The use of heparin for maintaining patency of umbilical artery catheters may be associated with an increased risk of germinal matrix intraventricular hemorrhage in low-birthweight neonates.  Although a definitive causal relationship has not been established, caution may be appropriate when heparin lock flush solutions are used.Due to the risk of overdose, heparin lock flush solutions containing 100 units/mL should not be used in neonates, particularly those who are premature or have low birthweight.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7238, 0, 'Heparin', 'Kidney Diseases', 'Systemic exposure and the risk of bleeding may be increased when heparin is used in the presence of severe renal impairment.  Therapy with heparin should be administered cautiously in patients with significantly impaired renal function.  A reduction in dosage may be necessary.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7239, 0, 'Heparin', 'Thrombocytopenia', 'The use of heparin is contraindicated in patients with severe thrombocytopenia.  Acute thrombocytopenia can occur in patients receiving heparin, with a reported incidence of up to 30%.  Platelet counts should be obtained before and periodically during heparin administration, including regular and repeated use of heparin flush solutions if given for longer than 5 days.  Mild thrombocytopenia with counts above 100,000/mm3 may remain stable or reverse despite continued heparin administration.  However, thrombocytopenia of any degree should be closely monitored.  Therapy should be discontinued if the count falls below 100,000/mm3 or if recurrent thrombosis develops, and an alternative, nonheparin anticoagulant (e.g., argatroban, bivalirudin, lepirudin) administered if necessary.  Heparin-induced thrombocytopenia (HIT) is a serious antibody-mediated reaction resulting from irreversible aggregation of platelets.  HIT may progress to the development of venous and arterial thromboses, a condition referred to as heparin-induced thrombocytopenia and thrombosis (HITT).  Thrombotic events may also be the initial presentation for HITT, and may include deep vein thrombosis, pulmonary embolism, cerebral vein thrombosis, limb ischemia, stroke, myocardial infarction, mesenteric thrombosis, renal artery thrombosis, skin necrosis, gangrene of the extremities that may lead to amputation, and possibly death.  Both HIT and HITT can occur up to several weeks after the discontinuation of heparin therapy.  Patients presenting with thrombocytopenia or thrombosis after discontinuation of heparin should be evaluated for HIT and HITT.  Following an episode, any future use of heparin should be avoided, and use of low-molecular weight heparin should consider the potential for cross-reactivity with the HIT antibody and approached with extreme caution, if not otherwise contraindicated.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7240, 0, 'Heparin', 'Hyperkalemia', 'Heparin can suppress adrenal secretion of aldosterone and cause hyperkalemia, particularly in patients with diabetes mellitus, chronic renal failure, preexisting metabolic acidosis, or elevated serum potassium levels.  The risk of hyperkalemia appears to increase with duration of therapy, but is usually reversible.  Therapy with heparin should be administered cautiously in patients with preexisting hyperkalemia or risk factors for hyperkalemia.  Serum potassium should be measured before initiating treatment and also during treatment, especially if heparin is given for longer than 7 days.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7241, 0, 'Hexachlorophene (topical)', 'Skin Manifestations', 'Percutaneous and/or transmucosal absorption during use on generalized dermatologic conditions has resulted in CNS toxicity such as irritability and seizures.  Hexachlorophene should not be applied to burned or denuded skin, used as occlusive dressing or routinely for total body washing, as a vaginal pack, or on any mucous membrane.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7242, 0, 'Hepatitis B Vaccine (Recombinant)', 'Hemophilia A', 'Hepatitis B vaccine (adult and pediatric) is usually for intramuscular administration.  However, it may be administered subcutaneously to persons at risk for hemorrhage following intramuscular injections (e.g., hemophiliacs), although it may result in lower antibody response.  Additionally, when other aluminum- absorbed vaccines have been administered subcutaneously, an increased incidence of local reactions including subcutaneous nodules has been observed.  Therefore, consider subcutaneous administration only in persons who are at risk of hemorrhage following intramuscular injections.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7243, 0, 'Amphotericin B (cholesteryl sulfate)', 'Water-Electrolyte Imbalance', 'All amphotericin B formulations may cause hypokalemia, hypomagnesemia, and less frequently, hypocalcemia.  Therapy with these agents should be administered cautiously in patients with preexisting electrolyte disturbances.  Serum electrolytes should be monitored closely.  Mineral and electrolyte supplementation may likely be required.  Complications of electrolyte imbalances include muscle weakness, tetany, seizures and cardiac disturbances.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7244, 0, 'Homatropine (ophthalmic)', 'Glaucoma', 'Anticholinergic agents are contraindicated in patients with primary glaucoma, a tendency toward glaucoma (narrow anterior chamber angle), or adhesions (synechiae) between the iris and lens, as well as for the elderly and others in whom undiagnosed glaucoma or excessive pressure in the eye may be present.  Because anticholinergics cause mydriasis, they may exacerbate these conditions.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7245, 0, 'Hexaminolevulinate', 'Cystitis', 'Inflammation of the bladder may interfere with the diagnostic utility of hexaminolevulinate, which is an ester of the heme precursor, aminolevulinic acid.  Following intravesical instillation of hexaminolevulinate, photoactive porphyrins are formed and accumulate intracellularly in bladder wall lesions.  In humans, a higher degree of accumulation of porphyrins has been demonstrated in neoplastic or inflamed cells compared to normal bladder urothelium.  As such, inflammation may lead to increased porphyrin buildup and higher risk of local toxicity upon illumination as well as false-positive fluorescence.  Hexaminolevulinate should not be used in patients at high risk of bladder inflammation, such as those who received BCG immunotherapy or intravesical chemotherapy within the past 90 days.  Widespread inflammation of the bladder should be excluded by cystoscopy before hexaminolevulinate is administered.  If a widespread inflammation in the bladder becomes evident during white light inspection, the blue light inspection should be avoided.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7246, 0, 'Hexaminolevulinate', 'Hematuria', 'The use of hexaminolevulinate is contraindicated in patients with gross hematuria.  The presence of blood within the bladder may interfere with the detection of tissue fluorescence.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7247, 0, 'Hexaminolevulinate', 'Porphyrias', 'The use of hexaminolevulinate is contraindicated in patients with a diagnosis or a family history of porphyria.  Hexaminolevulinate is an ester of the heme precursor, aminolevulinic acid.  Following intravesical instillation, photoactive porphyrins are formed and accumulate intracellularly in bladder wall lesions.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7248, 0, 'Human C1-esterase inhibitor', 'Thromboembolism', 'Serious arterial and venous thromboembolic (TE) events have been reported at the recommended dose of C1 Esterase Inhibitor (Human) products.  Benefits of C1 Esterase Inhibitor (Human) products for routine prophylaxis of hereditary angioedema attacks should be weighed against the risks of TE events in patients with underlying risk factors.  It is recommended to monitor patients with known risk factors for thrombotic events.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7249, 0, 'Amphotericin B (lipid complex)', 'Anemia', 'Amphotericin B lipid complex may depress red blood cell production and occasionally causes a normocytic, normochromic anemia.  A 4% incidence was reported during clinical trials.  Although the anemia is generally well tolerated and reverses completely after discontinuation of therapy, it may be problematic in patients with preexisting anemia.  Therapy with amphotericin B lipid complex should be administered cautiously in anemic patients.  Frequent blood counts and hematocrit levels are recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7250, 0, 'Amphotericin B (lipid complex)', 'Water-Electrolyte Imbalance', 'Amphotericin B lipid complex is substantially less nephrotoxic than traditional amphotericin B but may still cause hypo- and hyperkalemia, hypomagnesemia, and hypocalcemia secondary to renal impairment.  Renal function and serum electrolytes should be monitored in all patients receiving therapy with amphotericin B lipid complex but particularly closely in patients with preexisting electrolyte abnormalities.  Mineral and electrolyte supplementation may likely be required.  Complications of electrolyte imbalances include muscle weakness, tetany, seizures and cardiac disturbances.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7251, 0, 'Amphotericin B (lipid complex)', 'Kidney Diseases', 'Amphotericin B lipid complex is substantially less nephrotoxic than traditional amphotericin B but may still cause decreased renal function and abnormalities such as hypo- and hyperkalemia, hypomagnesemia, and renal tubular acidosis.  Renal function should be monitored in all patients receiving therapy with amphotericin B lipid complex but particularly closely in patients with preexisting renal impairment.  Serum creatinine, BUN, potassium and magnesium levels should be evaluated regularly, and dosing adjusted or discontinued if necessary.  Hydration with normal saline may decrease the risk for nephrotoxicity.  In addition, administration of alkali medication may help to prevent renal tubular acidosis.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7252, 0, 'Human immunoglobulin G (subcutaneous)', 'Kidney Diseases', 'Renal abnormalities such as acute tubular necrosis, proximal tubular nephropathy, osmotic nephrosis, including acute renal dysfunction/failure and death have been reported after immune globulin intravenous (IGIV) products.  Cases of renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose as a stabilizer.  Ensure that patients are not volume-depleted before administering these agents and assess renal function, including measurement of blood urea nitrogen (BUN) and serum creatinine, before initiating the infusion and at appropriate intervals thereafter.  If renal function deteriorates, consider discontinuation of the product.  Periodic monitoring of renal function and urine output is important in patients at increased risk of developing acute renal failure.  Administer these agents at the minimum dose and rate of infusion practicable in patients at risk for renal dysfunction or failure.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7253, 0, 'Human immunoglobulin G (subcutaneous)', 'Thrombosis', 'Thrombosis has been reported after treatment with immune globulin products.  In general, patients at greatest risk of thromboembolic events are those of advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors.  Thrombosis may occur in the absence of known risk factors; therefore, it is recommended that patients treated with these agents should be monitored for signs and symptoms of thrombosis and assess blood viscosity in patients at risk.  Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7254, 0, 'Hydrocodone', 'Gastrointestinal Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the gastrointestinal tract and decrease peristalsis, which can lead to elevated intraluminal pressure, spasm, and constipation following prolonged use.  In patients with severe or acute inflammatory bowel disease, the decrease in colonic motility may induce toxic megacolon.  Therapy with opioids should be administered cautiously in patients with gastrointestinal obstruction, constipation, inflammatory bowel disease, or recent gastrointestinal tract surgery.  Gastrointestinal effects appear to be the most pronounced with morphine.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7255, 0, 'Hydrocodone', 'Dysentery', 'Narcotic (opioid) analgesic agents may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella, Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  These agents decrease gastrointestinal motility, which may delay the excretion of infective gastroenteric organisms and/or their toxins.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  Therapy with opioids should be avoided or administered cautiously in patients with infectious diarrhea, particularly that due to pseudomembranous enterocolitis or enterotoxin-producing bacteria or if accompanied by high fever, pus, or blood in the stool.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7256, 0, 'Hydrocodone', 'Liver Diseases', 'Narcotic (opioid) analgesic agents are extensively metabolized by the liver, and several of them (e.g., codeine, hydrocodone, meperidine, methadone, morphine, propoxyphene) have active metabolites that are further converted to inactive substances.  The serum concentrations of these agents and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with liver disease.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7257, 0, 'Hydrocodone', 'Premature Birth', 'The use of narcotic (opioid) analgesic agents is contraindicated in premature infants.  These agents may cross the immature blood-brain barrier to a greater extent than in adults, resulting in disproportionate respiratory depression.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7258, 0, 'Hydrocodone', 'Alcoholic Intoxication', 'The use of opiate agonists is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of opiate agonists may be additive with those of alcohol.  Severe respiratory depression and death may occur.  Therapy with opiate agonists should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7259, 0, 'Hydrocodone', 'Substance-Related Disorders', 'Opiate agonists have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop after prolonged use.  Abrupt cessation, reduction in dosage, or administration of an opiate antagonist such as naloxone may precipitate withdrawal symptoms.  In patients who have developed tolerance to an opiate agonist, overdosage can still produce respiratory depression and death, and cross-tolerance usually will occur with other agents in the class.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with opiate agonists.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of opiate therapy should be undertaken gradually using a dosage-tapering schedule.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7260, 0, 'Hydrocodone', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7261, 0, 'Hydrocodone', 'Hypotension', 'Opiate agonists can induce vasodilation and significant hypotension, particularly when given in high dosages and/or by rapid intravenous administration.  Opiate analgesics cause vasodilatation that may exacerbate hypotension and hypoperfusion and, therefore, are contraindicated in circulatory shock.  At therapeutic analgesic dosages, ambulatory patients are more likely to experience dizziness and hypotension than patients who are confined to bed.  However, orthostatic hypotension may occur in supine patients upon rising.  Therapy with opiate agonists should be administered cautiously and initiated at reduced dosages in patients with hypovolemia, or a predisposition to hypotension.  When given by intramuscular or subcutaneous administration, clinicians should also be aware that impaired perfusion in these patients may prevent complete absorption of the drug.  With repeated injections, an excessive amount may be absorbed suddenly if normal circulation is reestablished.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7262, 0, 'Hydrocodone', 'Intracranial Hypertension', 'The hypoventilation associated with administration of opiate agonists, particularly by the intravenous route, can induce cerebral hypoxia and vasodilatation with resultant increase in intracranial pressure.  Opiate agonists should not be used in patients with suspected or known head injury or increased intracranial pressure.  Also, clinicians treating such patients should be aware that opiate agonists may interfere with the evaluation of CNS function, especially with respect to consciousness levels, respiratory status, and pupillary changes.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7263, 0, 'Hydrocodone', 'Respiratory Insufficiency', 'Opiate agonists may produce significant central nervous system and respiratory depression of varying duration, particularly when given in high dosages and/or by rapid intravenous administration.  Apnea may result from decreased respiratory drive as well as increased airway resistance, and rigidity of respiratory muscles may occur during rapid IV administration or when these agents are used in the induction of anesthesia.  At therapeutic analgesic dosages, the respiratory effects are usually not clinically important except in patients with preexisting pulmonary impairment.  Therapy with opiate agonists should be avoided or administered with extreme caution and initiated at reduced dosages in patients with severe CNS depression; sleep apnea; hypoxia, anoxia, or hypercapnia; upper airway obstruction; chronic pulmonary insufficiency; a limited ventilatory reserve; or other respiratory disorders.  In the presence of excessive respiratory secretions, the use of opiate agonists may also be problematic because they decrease ciliary activity and reduce the cough reflex.  Caution is also advised in patients who may be at increased risk for respiratory depression, such as comatose patients or those with head injury, intracranial lesions, or intracranial hypertension.  Clinical monitoring of pulmonary function is recommended, and equipment for resuscitation should be immediately available if parenteral or neuraxial routes are used.  Naloxone may be administered to reverse clinically significant respiratory depression, which may be prolonged depending on the opioid agent, cumulative dose, and route of administration.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7264, 0, 'Hydrocodone', 'Adrenal Insufficiency', 'Patients with Addison''s disease may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  Conversely, these agents may cause or potentiate adrenal insufficiency.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with adrenocortical insufficiency.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7265, 0, 'Hydrocodone', 'Gallbladder Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the biliary tract, which can lead to spasm and elevated biliary tract pressure, especially in the sphincter of Oddi.  Biliary effects appear to be the most pronounced with morphine, although they do not always occur with therapeutic doses.  Therapy with opioids should be administered cautiously in patients with biliary or gallbladder disease.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7266, 0, 'Hydrocodone', 'Hypothyroidism', 'Patients with hypothyroidism may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  These agents may also exacerbate the effects of hypothyroidism such as lethargy, impaired mentation, depression, and constipation.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with uncontrolled hypothyroidism or myxedema.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7267, 0, 'Hydrocodone', 'Kidney Diseases', 'Although narcotic (opioid) analgesic agents are generally metabolized by the liver, renal impairment can alter the elimination of these agents and their metabolites (some of which are pharmacologically active), resulting in drug accumulation and increased risk of toxicity.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with significantly impaired renal function.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7268, 0, 'Hydrocodone', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7269, 0, 'Hydrocodone', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7270, 0, 'Hydrocodone', 'Arrhythmias, Cardiac', 'Opiate agonists have cholinergic activity.  Large doses and/or rapid intravenous administration may produce bradycardia and arrhythmia via stimulation of medullary vagal nuclei.  Unlike other agents in the class, meperidine also has anticholinergic activity and may cause either bradycardia or tachycardia.  Therapy with opiate agonists should be administered cautiously in patients with a history of arrhythmias.  Clinical monitoring of cardiovascular status is recommended during therapy.  Bradycardia and other cholinergic effects produced by these agents may be controlled with atropine.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7271, 0, 'Hydrocortisone (topical)', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration.  Use of occlusive dressings over the applied areas may also increase percutaneous absorption.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7272, 0, 'Hydrocortisone (topical)', 'Diaper Rash', 'Topical corticosteroids, especially the potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol), are generally not recommended for use in the treatment of diaper rash.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are usually at the greatest risk for systemic toxicity such as adrenal suppression, Cushing''s syndrome and intracranial hypertension because of their larger skin surface to body mass ratios.  If topical corticosteroids are necessary to treat diaper rash, medium- to low-potency agents should preferably be used, and parents should be advised not to put tight-fitting diapers or plastic pants over the rash, since occlusion of treated area may increase percutaneous drug absorption.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7273, 0, 'Hydrocortisone (topical)', 'Adrenocortical Hyperfunction', 'The use of topical corticosteroids may precipitate or aggravate conditions of hyperadrenocorticism.  Systemic absorption of these agents can produce reversible hypothalamic-pituitary-adrenal axis suppression.  Systemic absorption, depends on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Patients with an altered skin barrier or liver failure are also at increased risk.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during topical corticosteroid therapy may indicate excessive use.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7274, 0, 'Hydrocortisone (topical)', 'Infections', 'Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Clinically significant local as well as systemic immunosuppressant and anti-inflammatory effects may occur, which can cause or exacerbate an infection.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Therapy with topical corticosteroids should be administered cautiously in patients with latent or active infections, particularly if a potent agent is used on a large area for prolonged periods or if occlusive dressings are used.  Effective antimicrobial therapy or other appropriate treatment should be instituted to treat the infection.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  Occlusive dressings should not be used in patients with skin infection.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7275, 0, 'Hydrocortisone (topical)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure, especially when potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) are used in the periorbital area.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7276, 0, 'Human immunoglobulin G (intravenous)', 'Fructose Intolerance', 'The immune globulin intravenous (human) injection, Flebogamma 10% DIF and Gammaplex contain sorbitol and should not be administered to patients with hereditary fructose intolerance (HFI).', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7277, 0, 'Human immunoglobulin G (intravenous)', 'Kidney Diseases', 'Renal abnormalities such as acute tubular necrosis, proximal tubular nephropathy, osmotic nephrosis, including acute renal dysfunction/failure and death have been reported after immune globulin intravenous (IGIV) products.  Cases of renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose as a stabilizer.  Ensure that patients are not volume-depleted before administering these agents and assess renal function, including measurement of blood urea nitrogen (BUN) and serum creatinine, before initiating the infusion and at appropriate intervals thereafter.  If renal function deteriorates, consider discontinuation of the product.  Periodic monitoring of renal function and urine output is important in patients at increased risk of developing acute renal failure.  Administer these agents at the minimum dose and rate of infusion practicable in patients at risk for renal dysfunction or failure.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7278, 0, 'Human immunoglobulin G (intravenous)', 'Thrombosis', 'Thrombosis has been reported after treatment with immune globulin products.  In general, patients at greatest risk of thromboembolic events are those of advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors.  Thrombosis may occur in the absence of known risk factors; therefore, it is recommended that patients treated with these agents should be monitored for signs and symptoms of thrombosis and assess blood viscosity in patients at risk.  Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7279, 0, 'Human immunoglobulin G (intravenous and subcutaneous)', 'Kidney Diseases', 'Renal abnormalities such as acute tubular necrosis, proximal tubular nephropathy, osmotic nephrosis, including acute renal dysfunction/failure and death have been reported after immune globulin intravenous (IGIV) products.  Cases of renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose as a stabilizer.  Ensure that patients are not volume-depleted before administering these agents and assess renal function, including measurement of blood urea nitrogen (BUN) and serum creatinine, before initiating the infusion and at appropriate intervals thereafter.  If renal function deteriorates, consider discontinuation of the product.  Periodic monitoring of renal function and urine output is important in patients at increased risk of developing acute renal failure.  Administer these agents at the minimum dose and rate of infusion practicable in patients at risk for renal dysfunction or failure.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7280, 0, 'Human immunoglobulin G (intravenous and subcutaneous)', 'Thrombosis', 'Thrombosis has been reported after treatment with immune globulin products.  In general, patients at greatest risk of thromboembolic events are those of advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors.  Thrombosis may occur in the absence of known risk factors; therefore, it is recommended that patients treated with these agents should be monitored for signs and symptoms of thrombosis and assess blood viscosity in patients at risk.  Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7281, 0, 'Hydrocortisone', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  In general, corticosteroids should not be used in patients with active infections, especially systemic fungal infections, unless they are medically necessary and effective antimicrobial therapy or other appropriate treatment has been instituted.  However, for corticosteroid-dependent patients who develop a severe or life-threatening infection, continuation of corticosteroid therapy with at least physiologic replacement dosages should be considered, since these patients may have secondary adrenocortical insufficiency.  Removal of external steroid during periods of stress may be detrimental to these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7282, 0, 'Hydrocortisone', 'Premature Birth', 'The use of certain parenteral formulations of dexamethasone, hydrocortisone, methylprednisolone, prednisolone and triamcinolone is considered by the drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  Some formulations of these drugs contain benzyl alcohol which, when used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  Continuous infusions of high dosages of medications containing benzyl alcohol may, however, cause toxicity and should be avoided if possible.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7283, 0, 'Hydrocortisone', 'Latent Tuberculosis', 'In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of corticosteroids may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if corticosteroid therapy is administered to patients with a history of tuberculosis or tuberculin reactivity.  During prolonged corticosteroid therapy, tuberculosis chemoprophylaxis may be considered.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7284, 0, 'Hydrocortisone', 'Fibrosis', 'Corticosteroids may have enhanced effects on patients with cirrhosis due to decreased metabolism of these agents.  Patients with cirrhosis should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required in these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7285, 0, 'Hydrocortisone', 'Psychotic Disorders', 'Corticosteroids may aggravate the symptoms of psychosis and emotional instability.  Patients with these conditions should be monitored for increased or worsened symptoms during corticosteroid therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7286, 0, 'Hydrocortisone', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with corticosteroids should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during corticosteroid therapy, and their antidiabetic regimen adjusted accordingly.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7287, 0, 'Hydrocortisone', 'Water-Electrolyte Imbalance', 'Corticosteroids can cause hypernatremia, hypokalemia, and fluid retention.  These mineralocorticoid effects are most significant with fludrocortisone, followed by hydrocortisone and cortisone, then by prednisone and prednisolone.  The remaining corticosteroids, betamethasone, dexamethasone, methylprednisolone, and triamcinolone, have little mineralocorticoid activities.  However, large doses of any corticosteroid can demonstrate these effects, particularly if given for longer than brief periods.  All corticosteroids also increase excretion of calcium and can cause hypocalcemia.  Therapy with corticosteroids should be administered cautiously in patients with preexisting electrolyte disturbances.  Caution is also advised when treating patients with seizure disorders, since electrolyte disturbances may trigger seizure activity.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7288, 0, 'Hydrocortisone', 'Peptic Ulcer Perforation', 'Corticosteroids may cause gastrointestinal perforation and hemorrhage, usually when given in high dosages or for prolonged periods.  They may also mask symptoms of complications such as peritonitis or intraabdominal sepsis.  Therapy with corticosteroids should be avoided or administered cautiously in patients with diverticulitis, nonspecific ulcerative colitis (if there is a probability of impending perforation, abscess, or other pyogenic infection), or recent intestinal anastomoses.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7289, 0, 'Hydrocortisone', 'Cushing Syndrome', 'Corticosteroids mimic the effects of endogenous cortisol and aldosterone.  Use of these agents may aggravate conditions of hyperadrenocorticalism in a dose-dependent manner.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7290, 0, 'Hydrocortisone', 'Hyperlipidemias', 'Corticosteroids may elevate serum triglyceride and LDL cholesterol levels if used for longer than brief periods.  Patients with preexisting hyperlipidemia may require closer monitoring during prolonged corticosteroid therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7291, 0, 'Hydrocortisone', 'Hypothyroidism', 'Corticosteroids may have enhanced effects in hypothyroidism due to decreased metabolism of these agents.  Patients with hypothyroidism should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required secondary to changes in their thyroid condition.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7292, 0, 'Hydrocortisone', 'Liver Diseases', 'Corticosteroids are primarily metabolized by the liver and may have enhanced effects in patients with liver disease.  Dosage adjustments may be necessary in these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7293, 0, 'Hydrocortisone', 'Myocardial Infarction', 'The use of corticosteroids may be associated with left ventricular free-wall rupture in patients who have had a recent myocardial infarction.  Pharmacologic dosages of corticosteroids should be administered with great caution in such patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7294, 0, 'Hydrocortisone', 'Myasthenia Gravis', 'Although corticosteroids are commonly used in the treatment of myasthenia gravis to increase muscle strength, these agents should nevertheless be administered with caution in such setting.  Patients should be treated in an intensive care unit and receive respiratory support, since muscle strength may markedly decrease initially, particularly with high dosages.  Preferably, therapy should begin with relatively low dosages (15 to 25 mg/day of prednisone or equivalent) and be increased stepwise as tolerated (approximately 5 mg/day of prednisone or equivalent at 2- to 3-day intervals until marked clinical improvement or a dosage of 50 mg/day is reached).  Improvement may be delayed and gradual.  Thus, it is important not to discontinue therapy prematurely.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7295, 0, 'Hydrocortisone', 'Muscular Diseases', 'Toxic myopathy has been observed with the chronic use or the administration of large doses of corticosteroids, often in patients with disorders of neuromuscular transmission such as myasthenia gravis or in patients receiving neuromuscular blocking agents.  Fluorinated corticosteroids such as betamethasone, dexamethasone, and triamcinolone appear to cause more severe muscle atrophy and weakness than the nonfluorinated agents.  Moreover, multiple-daily doses are more toxic than once-daily or, preferably, alternate-day morning doses.  Steroid myopathy is generalized and sometimes accompanied by respiratory weakness and dyspnea.  In some cases, it has resulted in quadriparesis.  Elevations of creatine kinase (CK) may also occur, albeit infrequently.  After withdrawal of corticosteroid therapy, recovery may be slow and incomplete.  Therapy with corticosteroids should be administered cautiously in patients with preexisting myopathy or myoneural disorders since these conditions may confound the diagnosis of steroid-induced myopathy.  The presence of a normal serum CK level, minimal/no changes of myopathy on electromyography, and type 2 muscle fiber atrophy on biopsy are helpful in suggesting steroid-induced weakness.  If steroid myopathy is suspected, a dosage reduction or discontinuation of the steroid should be considered.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7296, 0, 'Hydrocortisone', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids should be used cautiously in patients with ocular herpes simplex because of the risk of corneal perforation.  Corticosteroids are not recommended for patients with active ocular herpes simplex.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7297, 0, 'Hydrocortisone', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Long-term therapy with corticosteroids should be administered cautiously in patients with a history of cataracts, glaucoma, or increased intraocular pressure.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7298, 0, 'Hydrocortisone', 'Osteoporosis', 'Corticosteroids reduce osteoblastic function and inhibit the absorption of intestinal calcium, which can result in bone resorption and bone loss during prolonged therapy.  In addition, bone matrix may be affected by the protein-catabolic effects of corticosteroids, especially when given in high dosages or for prolonged periods, leading to aseptic necrosis and fractures.  Long-term or high-dose corticosteroid therapy should be administered cautiously and only if necessary in patients with or at risk for osteoporosis.  Adverse skeletal effects may be minimized by alternate-day or intermittent administration.  Any patient receiving prolonged therapy with the equivalent of 7.5 mg prednisone/day or more are at risk for glucocorticoid-induced osteoporosis and should be managed according to The American College of Rheumatology (ACR) guidelines.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7299, 0, 'Hydrocortisone', 'Peptic Ulcer', 'Corticosteroids may cause peptic ulcer disease and gastrointestinal (GI) hemorrhage, usually when given in high dosages or for prolonged periods.  However, even conventional dosages may aggravate symptoms in patients with a history of peptic ulcers.  Delayed healing of ulcers has also been reported.  Therapy with corticosteroids should be avoided or administered cautiously in patients with active or latent peptic ulcers or other risk factors for GI bleeding.  Some clinicians recommend the use of prophylactic antacids or H2-antagonists between meals when large doses of corticosteroids are necessary.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7300, 0, 'Hydrocortisone', 'Scleroderma, Localized', 'In patients with scleroderma, corticosteroids may precipitate renal crisis with malignant hypertension, possibly via steroid-induced increases in renin substrate and angiotensin II levels and decreases in vasodilator prostaglandin production.  Renal failure may ensue.  Therapy with corticosteroids should be administered cautiously in patients with scleroderma.  In addition, they should be limited to short-term use.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7301, 0, 'Hydrocortisone', 'Strongyloidiasis', 'Unlike most helminths, Strongyloides stercoralis has the ability to replicate in the human host.  In patients with strongyloidiasis, the use of pharmacologic or immunosuppressive dosages of corticosteroids may result in Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.  Therapy with corticosteroids should be administered with extreme caution, if at all, in these patients.  For patients on corticosteroids who develop known or suspected Strongyloides infestation, withdrawal of corticosteroids or reduction of the dose of corticosteroids is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7302, 0, 'Hydrocortisone', 'Thromboembolism', 'Corticosteroids may increase blood coagulability and have rarely been associated with the development of intravascular thrombosis, thromboembolism, and thrombophlebitis.  Therapy with corticosteroids should be administered cautiously in patients who have or may be predisposed to thrombotic or thromboembolic disorders.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7303, 0, 'Hydromorphone', 'Gastrointestinal Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the gastrointestinal tract and decrease peristalsis, which can lead to elevated intraluminal pressure, spasm, and constipation following prolonged use.  In patients with severe or acute inflammatory bowel disease, the decrease in colonic motility may induce toxic megacolon.  Therapy with opioids should be administered cautiously in patients with gastrointestinal obstruction, constipation, inflammatory bowel disease, or recent gastrointestinal tract surgery.  Gastrointestinal effects appear to be the most pronounced with morphine.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7304, 0, 'Hydromorphone', 'Dysentery', 'Narcotic (opioid) analgesic agents may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella, Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  These agents decrease gastrointestinal motility, which may delay the excretion of infective gastroenteric organisms and/or their toxins.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  Therapy with opioids should be avoided or administered cautiously in patients with infectious diarrhea, particularly that due to pseudomembranous enterocolitis or enterotoxin-producing bacteria or if accompanied by high fever, pus, or blood in the stool.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7305, 0, 'Hydromorphone', 'Liver Diseases', 'Narcotic (opioid) analgesic agents are extensively metabolized by the liver, and several of them (e.g., codeine, hydrocodone, meperidine, methadone, morphine, propoxyphene) have active metabolites that are further converted to inactive substances.  The serum concentrations of these agents and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with liver disease.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7306, 0, 'Hydromorphone', 'Premature Birth', 'The use of narcotic (opioid) analgesic agents is contraindicated in premature infants.  These agents may cross the immature blood-brain barrier to a greater extent than in adults, resulting in disproportionate respiratory depression.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7307, 0, 'Hydromorphone', 'Alcoholic Intoxication', 'The use of opiate agonists is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of opiate agonists may be additive with those of alcohol.  Severe respiratory depression and death may occur.  Therapy with opiate agonists should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7308, 0, 'Hydromorphone', 'Substance-Related Disorders', 'Opiate agonists have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop after prolonged use.  Abrupt cessation, reduction in dosage, or administration of an opiate antagonist such as naloxone may precipitate withdrawal symptoms.  In patients who have developed tolerance to an opiate agonist, overdosage can still produce respiratory depression and death, and cross-tolerance usually will occur with other agents in the class.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with opiate agonists.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of opiate therapy should be undertaken gradually using a dosage-tapering schedule.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7309, 0, 'Hydromorphone', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7310, 0, 'Hydromorphone', 'Hypotension', 'Opiate agonists can induce vasodilation and significant hypotension, particularly when given in high dosages and/or by rapid intravenous administration.  Opiate analgesics cause vasodilatation that may exacerbate hypotension and hypoperfusion and, therefore, are contraindicated in circulatory shock.  At therapeutic analgesic dosages, ambulatory patients are more likely to experience dizziness and hypotension than patients who are confined to bed.  However, orthostatic hypotension may occur in supine patients upon rising.  Therapy with opiate agonists should be administered cautiously and initiated at reduced dosages in patients with hypovolemia, or a predisposition to hypotension.  When given by intramuscular or subcutaneous administration, clinicians should also be aware that impaired perfusion in these patients may prevent complete absorption of the drug.  With repeated injections, an excessive amount may be absorbed suddenly if normal circulation is reestablished.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7311, 0, 'Hydromorphone', 'Intracranial Hypertension', 'The hypoventilation associated with administration of opiate agonists, particularly by the intravenous route, can induce cerebral hypoxia and vasodilatation with resultant increase in intracranial pressure.  Opiate agonists should not be used in patients with suspected or known head injury or increased intracranial pressure.  Also, clinicians treating such patients should be aware that opiate agonists may interfere with the evaluation of CNS function, especially with respect to consciousness levels, respiratory status, and pupillary changes.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7312, 0, 'Hydromorphone', 'Respiratory Insufficiency', 'Opiate agonists may produce significant central nervous system and respiratory depression of varying duration, particularly when given in high dosages and/or by rapid intravenous administration.  Apnea may result from decreased respiratory drive as well as increased airway resistance, and rigidity of respiratory muscles may occur during rapid IV administration or when these agents are used in the induction of anesthesia.  At therapeutic analgesic dosages, the respiratory effects are usually not clinically important except in patients with preexisting pulmonary impairment.  Therapy with opiate agonists should be avoided or administered with extreme caution and initiated at reduced dosages in patients with severe CNS depression; sleep apnea; hypoxia, anoxia, or hypercapnia; upper airway obstruction; chronic pulmonary insufficiency; a limited ventilatory reserve; or other respiratory disorders.  In the presence of excessive respiratory secretions, the use of opiate agonists may also be problematic because they decrease ciliary activity and reduce the cough reflex.  Caution is also advised in patients who may be at increased risk for respiratory depression, such as comatose patients or those with head injury, intracranial lesions, or intracranial hypertension.  Clinical monitoring of pulmonary function is recommended, and equipment for resuscitation should be immediately available if parenteral or neuraxial routes are used.  Naloxone may be administered to reverse clinically significant respiratory depression, which may be prolonged depending on the opioid agent, cumulative dose, and route of administration.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7313, 0, 'Hydromorphone', 'Adrenal Insufficiency', 'Patients with Addison''s disease may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  Conversely, these agents may cause or potentiate adrenal insufficiency.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with adrenocortical insufficiency.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7314, 0, 'Hydromorphone', 'Gallbladder Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the biliary tract, which can lead to spasm and elevated biliary tract pressure, especially in the sphincter of Oddi.  Biliary effects appear to be the most pronounced with morphine, although they do not always occur with therapeutic doses.  Therapy with opioids should be administered cautiously in patients with biliary or gallbladder disease.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7315, 0, 'Hydromorphone', 'Hypothyroidism', 'Patients with hypothyroidism may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  These agents may also exacerbate the effects of hypothyroidism such as lethargy, impaired mentation, depression, and constipation.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with uncontrolled hypothyroidism or myxedema.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7316, 0, 'Hydromorphone', 'Kidney Diseases', 'Although narcotic (opioid) analgesic agents are generally metabolized by the liver, renal impairment can alter the elimination of these agents and their metabolites (some of which are pharmacologically active), resulting in drug accumulation and increased risk of toxicity.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with significantly impaired renal function.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7317, 0, 'Hydromorphone', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7318, 0, 'Hydromorphone', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7319, 0, 'Hydromorphone', 'Arrhythmias, Cardiac', 'Opiate agonists have cholinergic activity.  Large doses and/or rapid intravenous administration may produce bradycardia and arrhythmia via stimulation of medullary vagal nuclei.  Unlike other agents in the class, meperidine also has anticholinergic activity and may cause either bradycardia or tachycardia.  Therapy with opiate agonists should be administered cautiously in patients with a history of arrhythmias.  Clinical monitoring of cardiovascular status is recommended during therapy.  Bradycardia and other cholinergic effects produced by these agents may be controlled with atropine.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7320, 0, 'Human Rho(D) immune globulin', 'Anemia', 'The use of RHo (D) immune globulin is contraindicated in patients with autoimmune hemolytic anemia, with preexisting hemolysis or at high risk for hemolysis.  Patients that have lower than normal hemoglobin levels (less than 10 g/dL), a reduced dose of 125 to 200 international unit/kg (25 to 40 mcg/kg) should be given to minimize the risk of increasing the severity of anemia.  Alternative treatments should be used in patients with hemoglobin levels that are less than 8 g/dL due to the risk of increasing the severity of the anemia.  Patients should be monitored to determine clinical response by assessing platelet counts, RBCs, hemoglobin, and reticulocyte levels.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7321, 0, 'Human Rho(D) immune globulin', 'Diabetes Mellitus', 'The use of RHo (D) immune globulin should be used with caution in diabetic patients as immune globulin intravenous products containing maltose, such as the liquid formulation of WinRho SDF, have been shown to give falsely high blood glucose in certain types of blood glucose testing system.  It is recommended to use only test systems that are glucose-specific to test or monitor blood glucose levels in patients receiving maltose-containing parenteral products.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7322, 0, 'Human Rho(D) immune globulin', 'Kidney Diseases', 'The use of RHo (D) immune globulin should be used with caution in volume-depleted patients as these agents may cause acute renal dysfunction/failure, osmotic nephropathy, and death.  Ensure that patients are not volume depleted before administering this agent.  It is advisable to administer RHo (D) immune globulin at the minimum infusion rate practicable in patients at risk of renal dysfunction or failure, including those with any degree of preexisting renal insufficiency.  Also, in patients with diabetes mellitus, advanced age (above 65 years of age), volume depletion, sepsis, paraproteinemia, or receiving known nephrotoxic drugs.  It is recommended to assess renal function, including measurement of blood urea nitrogen (BUN) and serum creatinine, before the initial infusion.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7323, 0, 'Human Rho(D) immune globulin', 'Thromboembolism', 'The use of immune globulin intravenous products, including RHo (D) immune globulin may cause thromboembolism.  Care should be taken when using these agents in patients with a history of atherosclerosis, multiple cardiovascular risk factors, advanced age, impaired cardiac output, coagulation disorders, prolonged periods of immobilization, and/or known/suspected hyperviscosity.  It is recommended to assess blood viscosity in patients at risk of hyperviscosity and in those at risk of developing thromboembolic events, these agents should be administered at the minimum rate of infusion practicable.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7324, 0, 'Hyaluronic acid', 'Hemorrhagic Disorders', 'Hyaluronan should not be administered to patients with known systemic bleeding disorders or to patients with infections or skin diseases in the area of the injection site or joint.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7325, 0, 'Hydralazine', 'Bone Marrow Failure Disorders', 'Hydralazine may rarely cause blood dyscrasias at recommended dosages.  Reduction in hemoglobin, red cell count, agranulocytosis, leukopenia, and purpura have been reported.  Therapy with hydralazine should be administered cautiously in patients with these preexisting conditions and if such abnormalities develop during the course of therapy, treatment should be discontinued.  Monitoring blood counts should be considered for those patients at higher risk.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7326, 0, 'Hydralazine', 'Coronary Artery Disease', 'The use of hydralazine is contraindicated in patients with coronary artery disease.  Reflex tachycardia may commonly occur.  Palpitations and chest pain have also been reported.  Myocardial infarction has been associated with the use of hydralazine.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7327, 0, 'Hydralazine', 'Lupus Erythematosus, Systemic', 'The use of hydralazine has been associated with the development of lupus erythematosus and lupus-like syndromes, as well as exacerbation of the disease.  Hydralazine therapy should be withdrawn in patients experiencing worsening of preexisting lupus.  Monitoring complete blood counts, and antinuclear antibody titers before and during prolonged therapy is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7328, 0, 'Hydralazine', 'Heart Valve Diseases', 'The use of hydralazine is contraindicated in patients with mitral valvular rheumatic heart disease.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7329, 0, 'Hydralazine', 'Cardiovascular Diseases', 'The vasodilatory effects of hydralazine may aggravate cerebral vasculopathy.  Therapy with hydralazine should be administered cautiously in patients with cerebral vasculopathy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7330, 0, 'Hydralazine', 'Kidney Diseases', 'The use of hydralazine has been associated with the development of glomerulonephritis.  Hydralazine should be used with caution in patients with advanced renal damage and these patients may require a lower dose.  Renal function should be monitored and supported as required.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7331, 0, 'Amphotericin B (liposomal)', 'Water-Electrolyte Imbalance', 'All amphotericin B formulations may cause hypokalemia, hypomagnesemia, and less frequently, hypocalcemia.  Therapy with these agents should be administered cautiously in patients with preexisting electrolyte disturbances.  Serum electrolytes should be monitored closely.  Mineral and electrolyte supplementation may likely be required.  Complications of electrolyte imbalances include muscle weakness, tetany, seizures and cardiac disturbances.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7332, 0, 'Human immunoglobulin G (intramuscular)', 'Thrombosis', 'Thrombosis has been reported after treatment with immune globulin products.  In general, patients at greatest risk of thromboembolic events are those of advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors.  Thrombosis may occur in the absence of known risk factors; therefore, it is recommended that patients treated with these agents should be monitored for signs and symptoms of thrombosis and assess blood viscosity in patients at risk.  Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7333, 0, 'Ampicillin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7334, 0, 'Ampicillin', 'Infectious Mononucleosis', 'Patients with mononucleosis treated with an aminopenicillin antibiotic, may develop a pruritic erythematous maculopapular skin rash.  The rash is usually self-limiting and resolves within days of discontinuing the offending agent.  An altered drug metabolism or an immune-mediated process unrelated to drug hypersensitivity has been proposed as the underlying mechanism.  Therapy with aminopenicillin antibiotics should not be administered in patients with mononucleosis.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7335, 0, 'Ampicillin', 'Heart Failure', 'Parenteral ampicillin sodium contains approximately 67 to 71 mg (2.9 to 3.1 mEq) of sodium per each gram of ampicillin activity.  The combination, ampicillin-sulbactam, contains approximately 115 mg (5 mEq) of sodium per 1.5 gram of total drug.  The sodium content should be considered when these products are used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7336, 0, 'Ampicillin', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7337, 0, 'Ampicillin', 'Diseases requiring hemodialysis', 'Penicillin antibiotics (except for agents in the penicillinase-resistant class) are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7338, 0, 'Hydrochlorothiazide', 'Anuria', 'The use of thiazide diuretics is contraindicated in patients with anuria.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7339, 0, 'Hydrochlorothiazide', 'Water-Electrolyte Imbalance', 'The use of thiazide diuretics is commonly associated with loss of electrolytes, most significantly potassium but also sodium, chloride, bicarbonate, and magnesium.  The loss of other electrolytes such as phosphate, bromide and iodide is usually slight.  Potassium and magnesium depletion may lead to cardiac arrhythmias and cardiac arrest.  Other electrolyte-related complications include metabolic alkalosis and hyponatremia, which are rarely life-threatening.  Therapy with thiazide diuretics should be administered cautiously in patients with or predisposed to fluid and electrolyte depletion, including patients with primary or secondary aldosteronism (may have low potassium levels); those with severe or prolonged diarrhea or vomiting; and those with poor nutritional status.  Fluid and electrolyte abnormalities should be corrected prior to initiating therapy, and blood pressure as well as serum electrolyte concentrations monitored periodically and maintained at normal ranges during therapy.  Patients should be advised to immediately report signs and symptoms of fluid or electrolyte imbalance, including dry mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, arrhythmia, or gastrointestinal disturbances such as nausea and vomiting.  Digitalized patients and patients with a history of ventricular arrhythmias should be monitored carefully, since development of hypokalemia may be particularly dangerous in these patients.  The risk of hypokalemia may be minimized by slow diuresis, a lower thiazide dosage, potassium supplementation, or combined use with a potassium-sparing diuretic.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7340, 0, 'Hydrochlorothiazide', 'Liver Diseases', 'Patients with severe liver disease or cirrhosis are very susceptible to thiazide-induced hypokalemic hypochloremic alkalosis.  Blood ammonia concentrations may be further increased in patients with previously elevated concentrations.  Hepatic encephalopathy and death have occurred secondary to the electrolyte alterations accompanying diuretic use.  Therapy with thiazide diuretics should be administered cautiously in patients with impaired hepatic function or progressive liver disease, and discontinued promptly if signs of impending hepatic coma appear (e.g., tremors, confusion, and increased jaundice).', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7341, 0, 'Hydrochlorothiazide', 'Lupus Erythematosus, Systemic', 'The use of thiazide diuretics has been reported to possibly exacerbate or activate systemic lupus erythematosus.  Reported cases have generally been associated with chlorothiazide and hydrochlorothiazide.  Therapy with thiazide diuretics should be administered cautiously in patients with a history or risk of SLE.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7342, 0, 'Hydrochlorothiazide', 'Kidney Failure, Chronic', 'Thiazide diuretics may be ineffective when the glomerular filtration rate is low (GFR < 25 mL/min) because they are not expected to be filtered into the renal tubule, their site of action.  In addition, thiazide diuretics decrease the GFR and may precipitate azotemia in renal disease.  Cumulative effects may also develop because most of these drugs are excreted unchanged in the urine by glomerular filtration and active tubular secretion.  Therapy with thiazide diuretics should be administered cautiously at reduced dosages in patients with renal impairment.  If renal function becomes progressively worse, as indicated by rising BUN or serum creatinine levels, an interruption or discontinuation of thiazide therapy should be considered.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7343, 0, 'Hydrochlorothiazide', 'Asthma', 'Thiazide diuretics should be used with caution in patients with history of bronchial asthma as sensitivity reactions may occur.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7344, 0, 'Hydrochlorothiazide', 'Diabetes Mellitus', 'Thiazide diuretics may cause hyperglycemia and glycosuria in patients with diabetes.  They may also precipitate diabetes in prediabetic patients.  These effects are usually reversible following discontinuation of the drugs.  Therapy with thiazide diuretics should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during thiazide therapy, and their antidiabetic regimen adjusted accordingly.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7345, 0, 'Hydrochlorothiazide', 'Hyperlipidemias', 'Thiazide diuretics may increase serum triglyceride and cholesterol levels, primarily LDL and VLDL.  Whether these effects are dose-related and sustained during chronic therapy are unknown.  Patients with preexisting hyperlipidemia may require closer monitoring during thiazide therapy, and adjustments made accordingly in their lipid-lowering regimen', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7346, 0, 'Hydrochlorothiazide', 'Hyperparathyroidism', 'Urinary calcium excretion is decreased by thiazide diuretics during chronic administration.  Pathologic changes in the parathyroid gland with hypercalcemia and hypophosphatemia have been reported during prolonged therapy.  However, the common complications of hyperparathyroidism such as renal lithiasis, bone resorption, and peptic ulceration have not been seen.  Clinicians should be cognizant of these effects when prescribing or administering thiazide therapy to patients with hyperparathyroidism.  These drugs should be discontinued before carrying out tests for parathyroid function.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7347, 0, 'Hydrochlorothiazide', 'Hyperuricemia', 'Thiazide diuretics decrease the rate of uric acid excretion.  Hyperuricemia occurs frequently but is usually asymptomatic and rarely leads to clinical gout except in patients with a history of gout or chronic renal failure.  Therapy with thiazide diuretics should be administered cautiously in such patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7348, 0, 'Hydrochlorothiazide', 'Thyroid Diseases', 'Thiazide diuretics may decrease serum PBI (protein-bound iodine) levels without associated thyroid disturbance.  Clinicians should be cognizant of this effect when prescribing or administering thiazide therapy to patients with thyroid disorders.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7349, 0, 'Human papillomavirus type 11 L1 capsid protein antigen', 'Infections', 'Ideally, vaccination should occur when an individual is healthy, thus minimizing the risk of an adverse host reaction and/or vaccine failure.  However, a current or recent infection does not necessarily preclude the use of vaccines, depending on the severity of the patient''s symptoms and their etiology.  Superficial infections and minor acute illnesses such as a mild upper respiratory infection with or without low-grade fever do not contraindicate immunization, particularly if prompt administration of a vaccine is deemed necessary or beneficial.  In fact, when vaccines are administered during the course of a minor illness, the risk of adverse events is not increased, and serum antibody response is not often diminished.  On the other hand, if fever or symptoms suggest a moderate or severe illness, it is usually appropriate to withhold vaccination until the patient has recovered.  In addition to the potential risks already mentioned, evolving signs and symptoms of the illness can sometimes confound the diagnosis of a vaccine reaction if it develops.  In the presence of any infection, the decision to administer or withhold/defer immunization should take into consideration the benefits versus the risks to an individual patient.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7350, 0, 'Human papillomavirus type 11 L1 capsid protein antigen', 'Syncope', 'The administration of human papillomavirus vaccine has been associated with syncope, sometimes resulting in falling with injury.  The syncope sometimes is associated with tonic-clonic movements and other seizure-like activity.  Caution is recommended when administering the vaccine to individuals susceptible to syncope.  Observation for 15 minutes is recommended after its administration.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7351, 0, 'Human papillomavirus type 11 L1 capsid protein antigen', 'Immune Deficiency Disease', 'The expected serum antibody responses may not be obtained when vaccines and/or toxoids are administered to patients with primary or acquired immunodeficiency, including those with severe combined immunodeficiency, hypogammaglobulinemia or agammaglobulinemia, HIV infection, altered immune states (due to diseases such as leukemia, lymphoma, or generalized malignancy), or immunosuppression due to drug or other treatments (e.g., corticosteroids, alkylating agents, antimetabolites, or radiation).', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7352, 0, 'Hydroxocobalamin', 'Hypokalemia', 'Hypokalemia (resulting in death) has occurred during vitamin B12 therapy as a result of increased red blood cell requirements during hematopoiesis.  Clinical monitoring and correction of potassium levels prior to and during vitamin B12 therapy is necessary.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7353, 0, 'Hydroxocobalamin', 'Optic Atrophy, Hereditary, Leber', 'The use of cyanocobalamin is contraindicated in patients with Leber''s disease (hereditary optic nerve atrophy).  Cyanocobalamin has induced severe and rapid optic nerve atrophy in patient''s with early Leber''s disease.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7354, 0, 'Hydroxocobalamin', 'Malabsorption Syndromes', 'Absorption of vitamin B12 is decreased in malabsorption syndromes and in pernicious anemia without coadministration of intrinsic factor (IF).  Cyanocobalamin is rapidly absorbed following IM or subcutaneous injections.  Hydroxocobalamin (cyanocobalamin analog) functions the same a cyanocobalamin, but has induced antibody formation to the hydroxocobalamin-transcobalamin II complex.  The use of cyanocobalamin may be preferred in patients with these conditions.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7355, 0, 'Hydroxyurea', 'Bone Marrow Failure Disorders', 'The use of hydroxyurea is contraindicated in patients with marked myelosuppression.  Hydroxyurea induces myelosuppression, primarily leukopenia.  Thrombocytopenia and anemia occur less frequently.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.  Hydroxyurea should not be administered if the white blood cell count falls below 2500/mm3 and/or the platelet count falls below 100,000/mm3, or in the presence of severe anemia.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7356, 0, 'Hydroxyurea', 'Kidney Diseases', 'Hydroxyurea is primarily eliminated by the kidney.  Approximately 80% of urea is excreted in the urine as unchanged drug or urea.  Patients with marked renal impairment (CrCl < 60 mL/min or ESRD) may be at increased risk of toxicity associated with administration of hydroxyurea.  Therapy with hydroxyurea should be administered cautiously to patients with compromised renal function.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7357, 0, 'Hydroxyurea', 'Liver Diseases', 'There are no data supporting specific guidance for hydroxyurea dosage adjustment in patients with hepatic impairment.  Caution and close monitoring is advised in these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7358, 0, 'Hydroxyurea', 'Epilepsy', 'Seizures have been noted very rarely during hydroxyurea therapy.  Therapy with hydroxyurea should be administered cautiously in patients with seizure disorders.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7359, 0, 'Hydroxyurea', 'Nervous System Diseases', 'Neurological symptoms such as disorientation or hallucinations have been reported very rarely during hydroxyurea therapy.  Therapy with hydroxyurea should be administered cautiously to patients with or predisposed to neurological disorders.', '1', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7360, 0, 'Hydroxychloroquine', 'Toxic Optic Neuropathy', 'The use of 4-aminoquinolines is generally considered contraindicated in the presence of retinal or visual field changes, whether attributable to 4-aminoquinoline compounds or to any other etiology.  However, in the treatment of acute attacks of malaria caused by susceptible strains of plasmodia, these agents may be considered if potential benefits are anticipated to outweigh the risks.  4-aminoquinolines are oculotoxic and can cause dose-related, irreversible retinal damage and vision loss during and up to several years after long-term or high-dose therapy (e.g., in the treatment of systemic lupus erythematosus or rheumatoid arthritis).  Ophthalmologic monitoring, including visual acuity, expert slit-lamp, funduscopic, and visual field tests, is recommended at baseline and every three months during prolonged use.  Therapy should be discontinued immediately if abnormalities develop in visual acuity, visual field, or retinal macular areas (e.g., pigmentary changes, loss of foveal reflex), or if the patient experiences visual symptoms such as light flashes and streaks that are not fully explainable by difficulties of accommodation or corneal opacities.  Other common symptoms that may indicate retinopathy include nyctalopia, photophobia, blurred distance vision, difficulty reading or seeing (e.g., words or letters disappearing or parts of objects missing; misty vision; fog before the eyes), and missing or blacked out areas in the central or peripheral visual field.  Retinal changes and visual disturbances may progress even after cessation of therapy.  However, in a number of patients, early retinopathy (macular pigmentation sometimes with central field defects) diminished or regressed completely after therapy was discontinued.  Paracentral scotoma to red targets, sometimes termed premaculopathy, is indicative of early retinal dysfunction and is usually reversible with cessation of therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7361, 0, 'Hydroxychloroquine', 'Porphyrias', 'The use of aminoquinolines in patients with porphyria may exacerbate the condition.  Aminoquinolines should not be used in these patients unless the potential benefits are anticipated to outweigh the risks.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7362, 0, 'Hydroxychloroquine', 'Arrhythmias, Cardiac', 'The use of 4-aminoquinolines such as hydroxychloroquine and chloroquine prolong the QT interval.  Ventricular arrhythmias and torsades de pointes have been reported in patients taking these agents.  Care should be exercised in patients with a prolonged QT interval at baseline or at increased risk for arrythmia.  A baseline electrocardiogram should be obtained to assess for QT interval prolongation and other abnormalities.  It is recommended to use appropriate diagnostic tools such as ECG to monitor patients during therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7363, 0, 'Hydroxychloroquine', 'Bone Marrow Failure Disorders', 'Adverse hematologic effects including neutropenia, agranulocytosis, aplastic anemia, and thrombocytopenia have been rarely associated with 4-aminoquinolines.  Therapy with 4-aminoquinolines should be administered cautiously in patients with preexisting bone marrow suppression.  A complete blood count should be performed periodically in patients on prolonged therapy.  If any severe blood disorder appears which is not attributable to the disease under treatment, discontinuance of the drug should be considered.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7364, 0, 'Hydroxychloroquine', 'Ototoxicity', 'The use of 4-aminoquinolines has been associated rarely with ototoxicity.  Nerve-type deafness, which is usually irreversible, has occurred during long-term, high-dose therapy.  Deafness may not be apparent until several weeks after 4-aminoquinoline therapy.  Tinnitus and reduced hearing have been reported in patients with preexisting auditory damage.  Therapy with 4-aminoquinolines should be administered cautiously in such patients.  If new auditory defects develop or if hearing loss becomes worse, therapy should be immediately discontinued and the patient closely monitored.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7365, 0, 'Hydroxychloroquine', 'Seizures', '4-aminoquinolines may cause epileptic seizures in susceptible individuals.  Patients with epilepsy or an otherwise low seizure threshold may be at greater risk.  Therapy with 4-aminoquinolines, particularly chloroquine, should be administered cautiously in patients with epilepsy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7366, 0, 'Hydroxychloroquine', 'Glucosephosphate Dehydrogenase Deficiency', 'Hemolysis and acute renal failure have been reported during use of aminoquinolines in patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  Therapy with aminoquinolines should be administered cautiously in these patients.  Blood cell counts and hemoglobin determinations should be performed regularly.  Aminoquinoline therapy should be discontinued immediately if signs suggestive of hemolytic anemia occur, such as marked darkening of the urine or sudden decrease in hemoglobin concentration or erythrocytic count.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7367, 0, 'Hydroxychloroquine', 'Liver Diseases', 'Aminoquinolines may concentrate in the liver.  Isolated cases of abnormal liver function and fulminant hepatic failure have been reported.  Therapy with aminoquinolines should be administered cautiously in patients with hepatic disease or alcoholism and in patients receiving other hepatotoxic drugs.  Periodic evaluation of hepatic function should be performed during prolonged therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7368, 0, 'Hydroxychloroquine', 'Myasthenia Gravis', 'Certain aminoquinolines such as chloroquine, and hydroxychloroquine should be used with caution in patients with myasthenia gravis (MG).  These agents may exacerbate or trigger new onset of symptoms in patients with previously diagnosed MG.  It is recommended to advise patients with MG about this possible side effect.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7369, 0, 'Hydroxychloroquine', 'Psoriasis', 'The use of aminoquinolines in patients with psoriasis may precipitate a severe attack of psoriasis. Aminoquinolines should not be used in these patients unless the potential benefits are anticipated to outweigh the risks.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7370, 0, 'Hydroxychloroquine', 'Diabetes Mellitus', 'Hydroxychloroquine has been shown to cause severe hypoglycemia including loss of consciousness that could be life threatening in patients treated with or without antidiabetic.  Care should be exercised when using hydroxychloroquine in diabetic patients.  Patients presenting with clinical symptoms suggestive of hypoglycemia during treatment with hydroxychloroquine should have their blood glucose checked and treatment instituted as necessary.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7371, 0, 'Hydroxychloroquine', 'Heart Diseases', 'Cardiomyopathy has been rarely reported with high daily dosages of hydroxychloroquine.  Therapy with hydroxychloroquine should be monitored in patients with heart conditions.  If cardiotoxicity is suspected, it is recommended to discontinue treatment with hydroxychloroquine to prevent life-threatening complications.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7372, 0, 'Hydroxychloroquine', 'Kidney Diseases', 'Hydroxychloroquine is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.  A dosage adjustment is not required for patients with renal impairment.  Caution and monitoring should be exercised in patients with impaired renal function.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7373, 0, 'Hydroxyzine', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7374, 0, 'Hydroxyzine', 'Long QT Syndrome', 'Hydroxyzine is contraindicated in patients with a QT prolonged interval.  Cases of QT prolongation and Torsade de Pointes have been reported during postmarketing studies.  Most of the cases reported occurred in patients with other risk factors for QT prolongation, such as preexisting heart disease, electrolyte imbalances or arrhythmogenic drug use.  Therefore, hydroxyzine should be used with caution in patients with risk factors for QT prolongation, congenital long QT syndrome, family history of long QT syndrome or other predisposing conditions, as well as myocardial infarction, uncompensated heart failure, and bradyarrhythmias.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7375, 0, 'Hydroxyzine', 'Anticholinergic Syndrome', 'Antihistamines often have anticholinergic activity, to which elderly patients are particularly sensitive.  Therapy with antihistamines should be administered cautiously, if at all, in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.  Conventional, first-generation antihistamines such as the ethanolamines (bromodiphenhydramine, carbinoxamine, clemastine, dimenhydrinate, diphenhydramine, doxylamine, phenyltoloxamine) tend to exhibit substantial anticholinergic effects.  In contrast, the newer, relatively nonsedating antihistamines (e.g., cetirizine, fexofenadine, loratadine) reportedly have low to minimal anticholinergic activity at normally recommended dosages and may be appropriate alternatives.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7376, 0, 'Hydroxyzine', 'Asthma', 'It has been suggested that the anticholinergic effect of antihistamines may reduce the volume and cause thickening of bronchial secretions, resulting in obstruction of respiratory tract.  Some manufacturers and clinicians recommend that therapy with antihistamines be administered cautiously in patients with asthma or chronic obstructive pulmonary disease.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7377, 0, 'Hydroxyzine', 'Cardiovascular Diseases', 'Antihistamines may infrequently cause cardiovascular adverse effects related to their anticholinergic and local anesthetic (quinidine-like) activities.  Tachycardia, palpitation, ECG changes, arrhythmias, hypotension, and hypertension have been reported.  Although these effects are uncommon and usually limited to overdosage situations, the manufacturers and some clinicians recommend that therapy with antihistamines be administered cautiously in patients with cardiovascular disease, hypertension, and/or hyperthyroidism.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7378, 0, 'Hydroxyzine', 'Liver Diseases', 'Limited pharmacokinetic data are available for the older, first-generation antihistamines.  Many appear to be primarily metabolized by the liver, and both parent drugs and metabolites are excreted in the urine.  Patients with renal and/or liver disease may be at greater risk for adverse effects from antihistamines due to drug and metabolite accumulation.  Therapy with antihistamines should be administered cautiously in such patients.  Lower initial dosages may be appropriate.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7379, 0, 'Hydroxyzine', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7380, 0, 'Ibritumomab tiuxetan', 'Pancytopenia', 'The use of ibritumomab tiuxetan may result in severe and prolonged cytopenias.  Do not administer the ibritumomab tiuxetan therapeutic regimen to patients with >= 25% lymphoma marrow involvement and/or impaired bone marrow reserve.  It is recommended to monitor patients for signs of cytopenia for up to 3 months after treatment and for hematological toxicity including development of myelodysplastic syndrome and/or acute myelogenous leukemia.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7381, 0, 'Ibritumomab tiuxetan', 'Hematologic Diseases', 'The radiation dose resulting from therapeutic exposure to Y-90 radiolabeled ibritumomab tiuxetan may result in secondary malignancies.  Myelodysplastic syndrome (MDS) and/or acute myelogenous leukemia (AML) has been reported in clinical trials with ibritumomab tiuxetan.  It is recommended to monitor patients for hematological toxicity including development of MDS or AML.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7382, 0, 'Ibandronate', 'Bisphosphonate-Associated Osteonecrosis of the Jaw', 'Osteonecrosis of the jaw (ONJ), which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking bisphosphonates.  Known risk factors for osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures).  The manufacturers of bisphosphonates recommend discontinuation of bisphosphonate treatment for patients undergoing invasive dental procedures.  Patients who develop osteonecrosis of the jaw while on bisphosphonate therapy should receive care by an oral surgeon.  In these patients, extensive dental surgery to treat ONJ may exacerbate the condition.  Discontinuation of bisphosphonate therapy should be considered based on individual benefit/risk assessment.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7383, 0, 'Ibandronate', 'Hypocalcemia', 'The use of bisphosphonates is contraindicated for the treatment of osteoporosis in patients with hypocalcemia.  These agents increase bone mineral density, a process that requires an adequate supply of calcium in the body.  Following the initiation of therapy, a short-term reduction in serum calcium and phosphate levels usually occurs due to inhibition of bone resorption, especially in patients with Paget''s disease, in whom the pretreatment rate of bone turnover may be greatly elevated.  Hypocalcemia and other disturbances of mineral metabolism, such as vitamin D deficiency, should be treated prior to initiation of therapy.  Appropriate intake of calcium and vitamin D should be ensured throughout the course of treatment.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7384, 0, 'Ibandronate', 'Peptic Ulcer', 'Bisphosphonates may cause local irritation of the upper gastrointestinal mucosa.  Esophagitis and esophageal ulcers and erosions, occasionally with bleeding, as well as gastric and duodenal ulcers, have been reported, primarily with alendronate.  Because of their structural similarities, therapy with all bisphosphonates should be administered cautiously in patients with active upper gastrointestinal disorders.  The usual precautions should be followed closely to minimize the risk of irritation (i.e. taking the medication with a full glass of water after arising for the day and remaining upright for at least 30 minutes afterwards and until the first food intake of the day).  Therapy should be discontinued if dysphagia, odynophagia or retrosternal pain occurs.  The manufacturer of alendronate considers its use to be contraindicated in patients with abnormalities of the esophagus that may delay esophageal emptying, such as stricture or achalasia.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7385, 0, 'Ibandronate', 'Kidney Diseases', 'Ibandronate is not recommended for use in patients with severe renal impairment (creatinine clearance less than 30 mL/min).  The portion of ibandronate that is not removed from the circulation via bone absorption is eliminated unchanged by the kidney (approximately 50% to 60% of the absorbed dose).  Unabsorbed ibandronate is eliminated unchanged in the feces.  Renal clearance of ibandronate in patients with various degrees of renal impairment is linearly related to creatinine clearance (CrCl).  Treatment with intravenous bisphosphonates has been associated with renal toxicity manifested as deterioration in renal function and acute renal failure.  Obtain serum creatinine prior to each ibandronate sodium injection.  After ibandronate sodium injection, assess renal function, as clinically appropriate, in patients with concomitant diseases or taking medications that have the potential for adverse effects on the kidney.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7386, 0, 'Ibandronate', 'Asthma', 'There have been reports of bronchoconstriction in aspirin-sensitive patients receiving bisphosphonates.  Use of these agents in asthmatic and in aspirin-sensitive patients should be used with caution.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7387, 0, 'Acalabrutinib', 'Arrhythmias, Cardiac', 'Atrial fibrillation and atrial flutter have been observed in patients treated with acalabrutinib.  It is recommended to monitor patients with abnormal heart rhythm for atrial fibrillation and atrial flutter and manage as clinically appropriate.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7388, 0, 'Acalabrutinib', 'Hemorrhage', 'Serious hemorrhagic events, including fatal events, have occurred in patients treated with acalabrutinib.  Care should be exercised when using acalabrutinib in patients with bleeding disorders.  It is recommended to monitor for signs of bleeding and to consider the benefit-risk of withholding therapy for 3-7 days pre- and post-surgery depending upon the type of surgery and the risk of bleeding.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7389, 0, 'Acalabrutinib', 'Hepatic Insufficiency', 'Acalabrutinib is metabolized in the liver.  Based on the population pharmacokinetic analysis, no clinically relevant difference was observed in subjects with mild or moderate hepatic impairment.  The pharmacokinetic of acalabrutinib has not been evaluated in patients with severe hepatic impairment.  Close monitoring of liver function is recommended in these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7390, 0, 'Acalabrutinib', 'Infections', 'Serious infections (bacterial, viral or fungal), including fatal events and opportunistic infections have occurred in patients treated with acalabrutinib.  Care should be exercised in patients at risk as in those at increased susceptibility to infection, such as neutropenic patients or those with a prior history of hepatitis B virus infection.  It is recommended to monitor patients for signs and symptoms of infection and treat as medically appropriate.  Consider prophylaxis in patients who are at increased risk for opportunistic infections.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7391, 0, 'Acalabrutinib', 'Kidney Diseases', 'Acalabrutinib undergoes minimal renal elimination.  Based on the population pharmacokinetic analysis, no clinically relevant difference was observed in patients with mild or moderate renal impairment.  The pharmacokinetic of acalabrutinib has not been evaluated in patients with severe renal impairment or renal impairment requiring dialysis.  Close monitoring of renal function is recommended in these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7392, 0, 'Ibrutinib', 'Atrial Fibrillation', 'Atrial fibrillation and atrial flutter have occurred in patients treated with ibrutinib.  The risk is increased in patients with cardiac risk factors, hypertension, acute infections, and a previous history of atrial fibrillation.  It is recommended to monitor patients clinically for atrial fibrillation periodically and those patients who develop arrhythmic symptoms (e.g., palpitations, lightheadedness) or new onset dyspnea should have an ECG performed.  Atrial fibrillation should be managed appropriately, and if it persists to consider the risks and benefits of ibrutinib treatment and follow dose modification according to clinical guidelines.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7393, 0, 'Ibrutinib', 'Hemorrhage', 'Cases of bleeding, including bruising, petechia, intracranial hemorrhage, including subdural hematoma; gastrointestinal bleeding, hematuria, post procedural hemorrhage, some leading to fatal bleeding events have been reported in patients treated with ibrutinib.  Patients receiving antiplatelet or anticoagulant therapy may be at an increased risk of hemorrhage and these patients should be closely monitored for signs of bleeding.  It is recommended to consider withholding ibrutinib for at least 3 to 7 days pre- and post-surgery depending upon the type of surgery and the risk of bleeding.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7394, 0, 'Ibrutinib', 'Pancytopenia', 'Cytopenias including neutropenia, thrombocytopenia, and anemia have been reported with use of ibrutinib.  Care should be taken with patients at risk, and it is recommended to monitor for complete blood counts monthly or as clinically appropriate.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7395, 0, 'Ibrutinib', 'Hepatic Insufficiency', 'Ibrutinib is metabolized in the liver.  In clinical trials, patients with hepatic impairment showed an increase in ibrutinib exposure following a single dose administration.  It is recommended to monitor patients for signs of toxicity and follow dose modification as appropriate.  The use of ibrutinib is not recommended in patients with moderate or severe hepatic impairment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7396, 0, 'Ibrutinib', 'Hypertension', 'The use of ibrutinib may cause hypertension.  It is recommended to monitor for new onset hypertension or hypertension that is not adequately controlled after starting therapy and to adjust hypertensive medications and/or initiate antihypertensive treatment per clinical practices.  Close monitoring of blood pressure is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7397, 0, 'Ibrutinib', 'Infections', 'Fatal and non-fatal infections, including cases of progressive multifocal leukoencephalopathy (PML) and Pneumocystis jirovecii pneumonia (PJP), have been reported with the use of ibrutinib.  It is recommended to assess patients for fever and infections and treat appropriately.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7398, 0, 'Ibrutinib', 'Kidney Diseases', 'The use of ibrutinib in patients with mild to moderate renal impairment is not expected to influence on the exposure to ibrutinib.  Caution and close monitoring is recommended in patients with severe renal impairment or patients on dialysis as there are no data available for these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7399, 0, 'Ibrutinib', 'Tumor Lysis Syndrome', 'Tumor lysis syndrome has been reported with ibrutinib therapy.  It is recommended to assess the baseline risk (e.g., high tumor burden) and take appropriate precautions.  Monitor patients closely and treat as appropriate.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7400, 0, 'Ibrutinib', 'Lung Diseases', 'The use of certain multikinase inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.  Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7401, 0, 'Hyoscyamine', 'Diabetic Neuropathies', 'Agents with anticholinergic activity can exacerbate many of the manifestations of autonomic neuropathy, including tachycardia, anhidrosis, bladder atony, obstipation, dry mouth and eyes, cycloplegia and blurring of vision, and sexual impotence in males.  Therapy with antimuscarinic agents and higher dosages of antispasmodic agents (e.g., dicyclomine or oxybutynin) should be administered cautiously in patients with autonomic neuropathy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7402, 0, 'Hyoscyamine', 'Intestinal Obstruction', 'Anticholinergics are contraindicated in patients with obstructive diseases such as achalasia, esophageal stricture or stenosis, pyloroduodenal stenosis, stenosing peptic ulcer, pyloric obstruction, and paralytic ileus.  Anticholinergics may further suppress intestinal motility with resultant precipitation or aggravation of toxic megacolon.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7403, 0, 'Hyoscyamine', 'Glaucoma', 'Anticholinergic agents are contraindicated in patients with primary glaucoma, a tendency toward glaucoma (narrow anterior chamber angle), or adhesions (synechiae) between the iris and lens, as well as for the elderly and others in whom undiagnosed glaucoma or excessive pressure in the eye may be present.  Because anticholinergics cause mydriasis, they may exacerbate these conditions.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7404, 0, 'Hyoscyamine', 'Urinary Bladder Neck Obstruction', 'In general, the use of anticholinergic agents is contraindicated in patients with urinary retention and bladder neck obstruction caused by prostatic hypertrophy.  Dysuria may occur and may require catheterization.  Also, anticholinergic drugs may aggravate partial obstructive uropathy.  Caution is advised even when using agents with mild to moderate anticholinergic activity, particularly in elderly patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7405, 0, 'Hyoscyamine', 'Lung Diseases', 'The use of systemic anticholinergics is contraindicated in the treatment of lower respiratory tract symptoms including asthma.  Muscarinic receptor antagonists reduce bronchial secretions, which can result in decreased fluidity and increased thickening of secretions.  However, ipratropium does not produce these effects and can be used safely in treating asthma.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7406, 0, 'Hyoscyamine', 'Myasthenia Gravis', 'Because antimuscarinic agents have anticholinergic effects, they are contraindicated in patients with myasthenia gravis.  Their use may be appropriate to reduce adverse muscarinic effects caused by an anticholinesterase agent.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7407, 0, 'Hyoscyamine', 'Dysentery', 'The use of drugs with antiperistaltic activity (primarily antidiarrheal and antimuscarinic agents, but also antispasmodic agents such as dicyclomine or oxybutynin at high dosages) is contraindicated in patients with diarrhea due to pseudomembranous enterocolitis or enterotoxin-producing bacteria.  These drugs may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella and Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  In general, because antiperistaltic agents decrease gastrointestinal motility, they may delay the excretion of infective gastroenteric organisms or toxins and should be used cautiously in patients with any infectious diarrhea, particularly if accompanied by high fever or pus or blood in the stool.  Some cough and cold and other combination products may occasionally include antimuscarinic agents for their drying effects and may, therefore, require careful selection when necessary.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7408, 0, 'Hyoscyamine', 'Heart Diseases', 'Anticholinergics block vagal inhibition of the SA nodal pacemaker.  Therapy with anticholinergics should be administered cautiously to patients with tachycardia, congestive heart failure, or coronary artery disease.  Premature ventricular depolarization, ventricular tachycardia, and fibrillation associated with anticholinergics are rare.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7409, 0, 'Hyoscyamine', 'Tachycardia', 'Anticholinergics block vagal inhibition of the SA nodal pacemaker.  Therapy with anticholinergics should be administered cautiously in patients with tachycardia, congestive heart failure, or coronary artery disease.  Premature ventricular depolarization or ventricular tachycardia or fibrillation associated with anticholinergics is rare.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7410, 0, 'Hyoscyamine', 'Coronary Artery Disease', 'Antimuscarinic agents block vagal inhibition of the SA nodal pacemaker.  These agents should be administered cautiously in patients with tachycardia, congestive heart failure, or coronary artery disease.  Premature ventricular depolarization or ventricular tachycardia or fibrillation associated with antimuscarinic drugs is rare.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7411, 0, 'Hyoscyamine', 'Stomach Ulcer', 'Antimuscarinic agents may cause a delay in gastric emptying and possibly antral stasis in patients with gastric ulcer.  Therapy with antimuscarinic agents should be administered cautiously to patients with gastric ulcer.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7412, 0, 'Hyoscyamine', 'Gastroesophageal Reflux', 'Antimuscarinic agents decrease gastric motility and relax the lower esophageal sphincter which promotes gastric retention and can aggravate reflux.  These drugs should be administered cautiously in patients with gastroesophageal reflux or hiatal hernia associated with reflux esophagitis.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7413, 0, 'Hyoscyamine', 'Colitis, Ulcerative', 'Antimuscarinic agents may suppress intestinal motility and produce paralytic ileus with resultant precipitation of toxic megacolon.  These drugs should be administered cautiously to patients with ulcerative colitis.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7414, 0, 'Hyoscyamine', 'Liver Diseases', 'Atropine-like agents undergo significant hepatic metabolism.  Therapy with atropine-like agents should be administered cautiously to patients with liver disease.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7415, 0, 'Hyoscyamine', 'Renal Insufficiency', 'Atropine-like agents are primarily eliminated by the kidney.  Therapy with atropine-like agents should be administered cautiously to patients with renal disease.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7416, 0, 'Hyoscyamine', 'Hypertension', 'Cardiovascular effects of anticholinergics may exacerbate hypertension.  Therapy with anticholinergic agents should be administered cautiously in patients with hypertension.', '1', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7417, 0, 'Hyoscyamine', 'Hyperthyroidism', 'In general, agents with anticholinergic activity may exacerbate hyperthyroidism.  Therapy with anticholinergics should be administered cautiously in patients with hyperthyroidism.  Thyroid levels should be monitored if usage is prolonged.', '1', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7418, 0, 'Hyoscyamine', 'Diarrhea', 'Diarrhea may be a symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy.  Antimuscarinic agents may further aggravate the diarrhea.  Therefore, these drugs should be administered cautiously in patients with diarrhea.', '1', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7419, 0, 'Hyoscyamine', 'Fever', 'Atropine-like agents may increase the risk of hyperthermia in patients with fever by producing anhidrosis.  Therapy with atropine-like agents should be administered cautiously in febrile patients.', '1', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7420, 0, 'Ibuprofen', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7421, 0, 'Ibuprofen', 'Water-Electrolyte Imbalance', 'Fluid retention and edema have been reported in association with the use of nonsteroidal anti-inflammatory drugs (NSAIDs).  Therapy with NSAIDs should be administered cautiously in patients with preexisting fluid retention, hypertension, or a history of heart failure.  Blood pressure and cardiovascular status should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7422, 0, 'Ibuprofen', 'Peptic Ulcer', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal.  These serious adverse events can develop at any time, with or without warning symptoms.  Only 1 in 5 patients who develop a serious upper GI side effect on NSAIDs is symptomatic.  NSAIDs should be used with caution in patients with history of peptic ulcer disease and/or GI bleeding, as these patients had a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors.  Caution is also advised if NSAIDs are prescribed to patients with other factors that increase risk of GI bleeding, such as:  prolonged NSAID therapy; concomitant use of oral corticosteroids, antiplatelet agents (e.g., aspirin), anticoagulants, selective serotonin reuptake inhibitors; alcohol use; smoking; history of gastrointestinal surgery or anastomosis, older age; poor general health status; and advanced liver disease and/or coagulopathy.  Particular vigilance is necessary when treating elderly or debilitated patients since most postmarketing reports of fatal GI events occurred in these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7423, 0, 'Ibuprofen', 'Exanthema', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious skin adverse reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, and exfoliative dermatitis), which can be fatal.  These serious events may occur without warning.  Patients should be advised to discontinue the NSAID and seek medical attention promptly at the first sign of skin rash or any other sign of hypersensitivity.  NSAIDs are contraindicated in patients with previous serious skin reactions to these drugs.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7424, 0, 'Ibuprofen', 'Kidney Diseases', 'Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) has resulted in renal papillary necrosis and other renal injury.  Renal toxicity has been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion:  in such patients, NSAIDs may cause a dose-dependent reduction in prostaglandin synthesis and, secondarily, in renal blood flow, which may precipitate overt renal decompensation.  Patients at greatest risk for this reaction include the elderly, those with impaired renal function, dehydration, hypovolemia, heart failure, or liver dysfunction, and those taking diuretics, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers; discontinuation of NSAID therapy will usually lead to recovery to the pretreatment state.  No information is available regarding use NSAIDs in patients with advanced renal disease; the renal effects of NSAIDs may hasten the progression of renal dysfunction in patients with preexisting renal disease.  Volume status should be corrected in dehydrated or hypovolemic patients prior to initiating treatment.  Renal function should be monitored during therapy in patients with renal or liver dysfunction, heart failure, dehydration, or hypovolemia.  NSAIDs should be avoided in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function; if an NSAID is used in such patients, they should be monitored for signs of worsening renal function.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7425, 0, 'Ibuprofen', 'Thrombosis', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.  This risk may occur early in treatment and may increase with duration of use.  Clinical trials of several cyclooxygenase-2 (COX-2) selective and nonselective NSAIDs of up to 3 years duration have supported this increased risk.  It is unclear from available data if the risk for cardiovascular thrombotic events is similar for all NSAIDs.  Therapy with NSAIDs should be administered cautiously in patients with a history of cardiovascular or cerebrovascular disease.  Patients should be treated with the lowest effective dosage for the shortest duration necessary.  Appropriate antiplatelet therapy should be administered to patients requiring cardioprotection; however, there is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious cardiovascular thrombotic events associated with NSAID use, while the risk of serious gastrointestinal events is increased.  Physicians and patients should remain alert for the development of adverse cardiovascular events throughout the entire duration of therapy, even without prior cardiovascular symptoms.  Patients should be advised to promptly seek medical attention if they experience symptoms of cardiovascular thrombotic events (including chest pain, shortness of breath, weakness, or slurring of speech).NSAIDs are contraindicated in the setting of coronary artery bypass graft (CABG) surgery.  Two large clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10 to 14 days following CABG surgery found an increased incidence of myocardial infarction and stroke.The use of NSAIDs should be avoided in patients with a recent myocardial infarction unless the benefits are expected to outweigh the risk of recurrent cardiovascular thrombotic events.  If an NSAID is used in patients with a recent myocardial infarction, they should be monitored for signs of cardiac ischemia.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7426, 0, 'Ibuprofen', 'Phenylketonurias', 'Chewable products frequently may contain aspartame, which is metabolized in the gastrointestinal tract to phenylalanine.  Motrin (brand of ibuprofen) chewable 50 mg and 100 mg tablets provide the equivalent of 3 mg and 6 mg of phenylalanine each, respectively.  The aspartame/phenylalanine content should be considered when these and similar products are used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7427, 0, 'Ibuprofen', 'Anemia', 'Anemia has been reported in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  This may be due to fluid retention, occult/gross blood loss, or an incompletely described effect on erythropoiesis.  Hemoglobin or hematocrit should be monitored in patients with any signs/symptoms of anemia or blood loss, especially during long-term therapy.  NSAIDs may increase risk of bleeding events; comorbid conditions (e.g., coagulation disorders; concomitant use of warfarin/other anticoagulants, antiplatelet agents, serotonin/serotonin norepinephrine reuptake inhibitors) may increase this risk, and patients with these conditions should be monitored for signs of bleeding.  Therapy with NSAIDs should be administered cautiously in patients with or predisposed to anemia.  Clinical monitoring of hematopoietic function may be appropriate, particularly during chronic therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7428, 0, 'Ibuprofen', 'Heart Failure', 'Fluid retention and edema have been observed in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs), including some topical formulations.  These drugs should be avoided in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure.  If an NSAID is used in patients with severe heart failure, they should be monitored for signs of worsening heart failure.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7429, 0, 'Ibuprofen', 'Liver Diseases', 'Borderline elevations of 1 or more liver tests may occur in up to 15% of patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  These laboratory abnormalities may progress, remain unchanged, or regress with continuing therapy.  Elevations of ALT or AST (at least 3 times the upper limit of normal) have been reported in about 1% of patients in clinical trials.  In addition, rare (sometimes fatal) cases of severe hepatotoxicity, including liver necrosis, hepatic failure, jaundice, and fulminant hepatitis have been reported.  Therapy with NSAIDs should be administered cautiously in patients with preexisting liver disease.  Periodic monitoring of liver function is recommended during prolonged therapy.  NSAIDs are also highly protein-bound and some are extensively metabolized by the liver.  Metabolic activity and/or plasma protein binding may be altered in patients with hepatic impairment.  A dosage reduction may be required in some cases.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7430, 0, 'Ibuprofen', 'Hyperkalemia', 'Increases in serum potassium concentration (including hyperkalemia) have been reported with use of nonsteroidal anti-inflammatory drugs (NSAIDs), even in some patients without renal impairment.  In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.  Caution is advised in patients with hyperkalemia.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7431, 0, 'Ibuprofen', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7432, 0, 'Ibuprofen', 'Blood Platelet Disorders', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) reversibly inhibit platelet adhesion and aggregation and may prolong bleeding time in some patients.  With the exception of aspirin, the platelet effects seen with most NSAIDs at usual recommended dosages are generally slight and of relatively short duration but may be more pronounced in patients with underlying hemostatic abnormalities.  Thrombocytopenia has also been reported rarely during NSAID use.  Therapy with NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  NSAIDs that selectively inhibit cyclooxygenase-2 (i.e., COX-2 inhibitors) do not appear to affect platelet function or bleeding time at indicated dosages and may be preferable if risk of bleeding is a concern.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7433, 0, 'Ibutilide', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7434, 0, 'Ibutilide', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7435, 0, 'Ibutilide', 'Water-Electrolyte Imbalance', 'Electrolyte imbalance can alter the therapeutic effectiveness of antiarrhythmic agents.  Hypokalemia and hypomagnesemia can reduce the effectiveness of antiarrhythmic agents.  In some cases, these disorders can exaggerate the degree of QTc prolongation and increase the potential for torsade de pointes.  Hyperkalemia can potentiate the toxic effects of antiarrhythmic agents.  Electrolyte imbalance should be corrected prior to initiating antiarrhythmic therapy.  Clinical monitoring of cardiac function and electrolyte concentrations is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7436, 0, 'Ibutilide', 'Hepatic Insufficiency', 'The safety, effectiveness, and pharmacokinetics of ibutilide fumarate have not been established in patients with hepatic or renal dysfunction.  It is unlikely that dosing adjustments would be necessary in these patients.  Nonetheless, it should be administered cautiously in patients with abnormal liver or renal function, and monitoring is advised.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7437, 0, 'Idarubicin', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7438, 0, 'Idarubicin', 'Heart Diseases', 'Idarubicin can cause myocardial toxicity leading to congestive heart failure.  Patients with preexisting heart disease or prior anthracycline therapy are at increased risk of congestive heart failure.  Close clinical monitoring of cardiac function, such as an electrocardiogram and/or determination of left ventricular ejection fraction, prior to each course of therapy is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7439, 0, 'Idarubicin', 'Liver Diseases', 'Idarubicin undergoes extensive extrahepatic metabolism and is primarily eliminated by biliary excretion.  The pharmacokinetic disposition of idarubicin has not been studied in leukemia patients with hepatic impairment.  It is thought that the metabolism of idarubicin would be decreased in moderate to severe hepatic dysfunction and lead to increased systemic drug levels and toxicity.  Therapy with idarubicin should be administered cautiously and dosage reduction considered in patients with compromised hepatic function.  Idarubicin injection should not be administered if bilirubin level exceeds 5 mg %.  Clinical monitoring of hepatic function is recommended prior to and during therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7440, 0, 'Idarubicin', 'Bone Marrow Failure Disorders', 'Idarubicin induces severe myelosuppression at therapeutic doses.  Therapy with idarubicin should be withheld in patients whose bone marrow function is severely depressed by prior irradiation or chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  If the need outweighs the risk, extreme caution should be exercised in administering idarubicin.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitory of hematopoietic function is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7441, 0, 'Idarubicin', 'Kidney Diseases', 'Impaired renal function can affect the disposition of idarubicin.  Therapy with idarubicin should be administered cautiously and dosage modification considered in patients with compromised renal  function.  Clinical monitoring of renal function is recommended prior to and during therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7442, 0, 'Idarubicin', 'Hyperuricemia', 'Treatment with idarubicin may cause hyperuricemia as a result of rapid lysis of tumor cells.  Levels of serum uric acid should be monitored and appropriate therapy should be initiated before starting therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7443, 0, 'Icosapent', 'Atrial Fibrillation', 'Icosapent is associated with an increased risk of atrial fibrillation or atrial flutter requiring hospitalization.  In a cardiovascular outcomes trial, the incidence of atrial fibrillation was greater in patients with history of atrial fibrillation or atrial flutter; caution is recommended in these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7444, 0, 'Icosapent', 'Liver Diseases', 'In patients with liver dysfunction, ALT and AST levels should be monitored periodically during therapy with icosapent; caution is recommended in these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7445, 0, 'Iloperidone', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7446, 0, 'Iloperidone', 'Long QT Syndrome', 'Some atypical antipsychotic agents can prolong the QTc interval of the electrocardiogram in a dose-dependent manner.  Electrolyte disturbances such as hypokalemia and hypomagnesemia may augment the prolongation effect of these agents on the QT interval and should be corrected prior to institution of therapy.  In addition, patients who experience frequent, severe, or prolonged diarrhea may be subject to electrolyte losses and should be followed closely and managed accordingly during therapy with these agents.  Atypical antipsychotic agents should be avoided in patients with a history of cardiac arrhythmias or other conditions that may increase the risk of torsade de pointes and/or sudden death, including bradycardia; hypokalemia or hypomagnesemia; and congenital long QT syndrome.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7447, 0, 'Iloperidone', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7448, 0, 'Iloperidone', 'Pneumonia, Aspiration', 'Esophageal dysmotility and aspiration have been associated with the use of antipsychotic drugs.  These drugs should be administered cautiously in patients at risk for aspiration pneumonia.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7449, 0, 'Iloperidone', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7450, 0, 'Iloperidone', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7451, 0, 'Iloperidone', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7452, 0, 'Iloperidone', 'Hypotension', 'The use of atypical antipsychotic agents has been associated with orthostatic hypotension and syncope.  Therapy with atypical antipsychotics should be administered cautiously in patients with hypotension or conditions that could be exacerbated by hypotension, such as a history of myocardial infarction, angina, or ischemic stroke.  Patients with dehydration (e.g., due to severe diarrhea or vomiting) may be predisposed to hypotension and should also be managed carefully during therapy with atypical antipsychotics.  Blood pressure should be monitored at regular intervals, particularly during dosage escalation or whenever dosage has been altered, and patients should be advised not to rise abruptly from a sitting or recumbent position.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7453, 0, 'Iloperidone', 'Dyslipidemias', 'Atypical antipsychotic drugs have been associated with undesirable alterations in lipid levels.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  Before or soon after initiation of antipsychotic medications, a fasting lipid profile should be obtained at baseline and monitored periodically during treatment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7454, 0, 'Iloperidone', 'Priapism', 'Atypical antipsychotic agents with alpha-adrenergic blocking effects may cause priapism.  The condition is characterized by prolonged, often painful erections lasting longer than 4 hours.  If not treated promptly, priapism can cause irreversible damage to the erectile tissue.  Therapy with these agents should be administered cautiously in patients with a history of priapism, conditions that may predispose them to priapism (e.g., sickle cell anemia, multiple myeloma, leukemia, thalassemia), or anatomical deformations of the penis (e.g., angulation, cavernosal fibrosis, Peyronie''s disease).  Patients who experience an erection lasting longer than 4 hours, whether painful or not, should immediately discontinue the drug and seek emergency medical attention.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7455, 0, 'Iloperidone', 'Weight Gain', 'Weight gain has been observed with atypical antipsychotic use.  While all agents in the class have been shown to produce some changes, each drug has its own specific risk profile.  When treating pediatric patients with atypical antipsychotic agents, weight gain should be monitored and assessed against that expected for normal growth.  Monitor weight at baseline and frequently thereafter.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7456, 0, 'Iloperidone', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7457, 0, 'Iloperidone', 'Hyperprolactinemia', 'The chronic use of neuroleptic agents can cause persistent elevations in prolactin levels due to antagonism of dopamine D2 receptors.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation with respect to long-term neuroleptic therapy is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Until further data are available, therapy with neuroleptic agents should be administered cautiously in patients with a previously detected breast cancer.  Caution is also advised in patients with preexisting hyperprolactinemia.  Hyperprolactinemia may suppress hypothalamic gonadotrophin releasing hormone (GnRH), resulting in reduced pituitary gonadotropin secretion.  This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds; however, the clinical significance of elevated serum prolactin levels is unknown for most patients.  Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7458, 0, 'Iloperidone', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7459, 0, 'Iloprost', 'Hypotension', 'Iloprost should not be initiated in patients with systolic blood pressure below 85 mmHg.  The risk of syncope in association with physical exertion can occur in pulmonary arterial hypertension and the occurrence may reflect a therapeutic gap or insufficient efficacy.  The need to adjust dose or change therapy should be considered.  It is recommended to monitor vital signs when initiating treatment with iloprost in patients at risk.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7460, 0, 'Iloprost', 'Bronchial Spasm', 'Iloprost can induce bronchospasm and may be more severe or frequent in patients with history of hyperreactive airways.  Close monitoring is recommended when using iloprost in patients with chronic obstructive pulmonary disease, severe asthma, or with acute pulmonary infections.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7461, 0, 'Idelalisib', 'Colitis', 'Severe diarrhea or colitis have been reported in patients treated with idelalisib.  It is recommended to avoid concurrent use of idelalisib and other drugs that cause diarrhea.  Care should be taken when using this agent in patients with diarrhea or colitis.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7462, 0, 'Idelalisib', 'Stevens-Johnson Syndrome', 'Fatal cases of severe cutaneous reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have occurred in patients treated with idelalisib.  It is recommended that if SJS or TEN is suspected to interrupt therapy until the etiology of the reaction has been determined, and if SJS or TEN is confirmed to permanently discontinue treatment with idelalisib.  Monitor patients for the development of severe cutaneous reactions and discontinue idelalisib if clinically appropriate.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7463, 0, 'Idelalisib', 'Hepatic Insufficiency', 'Fatal and/or serious hepatotoxicity have been reported in patients treated with idelalisib.  Monitor ALT and AST in all patients as clinically appropriate.  Patients with baseline hepatic impairment should be monitored for signs of idelalisib toxicity and dose modification with idelalisib should be made accordingly.  It is recommended to monitor weekly for liver toxicity if the ALT or AST rises above 3 times the upper limit of normal until resolved and withhold therapy with idelalisib if the ALT or AST is greater than 5 times the upper limit of normal, and continue to monitor AST, ALT and total bilirubin weekly until the normal levels are attained.  Discontinue idelalisib for recurrent hepatotoxicity and to avoid concurrent use with other drugs that may cause liver toxicity.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7464, 0, 'Idelalisib', 'Infections', 'Fatal and/or serious infections, including pneumonia, sepsis, febrile neutropenia, Pneumocystis jirovecii pneumonia (PJP) or cytomegalovirus (CMV) have been reported in patients treated with idelalisib.  It is recommended to monitor patients for signs and symptoms of infection and to interrupt therapy with idelalisib for Grade 3 or higher infection.  Consider prophylaxis for PJP in patients at risk and interrupt therapy in patients with suspected PJP infection of any grade, and permanently discontinue treatment if PJP infection of any grade is confirmed or interrupt idelalisib in the setting of positive CMV PCR or antigen test until the infection has resolved.  If therapy is subsequently resumed, patients should be monitored (by PCR or antigen test) for CMV reactivation at least monthly.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7465, 0, 'Idelalisib', 'Intestinal Perforation', 'Fatal and serious intestinal perforations have been reported in patients treated with idelalisib, some patients reporting moderate to severe diarrhea at the time of perforation.  Advise patients to promptly report any new or worsening abdominal pain, chills, fever, nausea, or vomiting.  Discontinue therapy with idelalisib permanently in patients who experience intestinal perforation.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7466, 0, 'Idelalisib', 'Neutropenia', 'Cases of neutropenia have been reported with the use of idelalisib.  It is recommended to monitor blood counts at least every 2 weeks for the first 6 months of therapy, and periodically thereafter.  Care and close monitoring is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7467, 0, 'Idelalisib', 'Lung Diseases', 'The use of certain multikinase inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.  Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7468, 0, 'Amrinone', 'Arrhythmias, Cardiac', 'The use of milrinone both intravenously and orally has been associated with increased frequency of ventricular arrhythmias, including nonsustained ventricular tachycardia.  Long-term oral use has been associated with an increased risk of sudden death.  Hence, patients receiving milrinone should be observed closely with the use of continuous electrocardiographic monitoring to allow the prompt detection and management of ventricular arrhythmias.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7469, 0, 'Amrinone', 'Liver Diseases', 'The use of inamrinone (former amrinone) has been associated with hepatotoxicity, manifested as marked alterations in liver function tests and clinical symptoms suggestive of idiosyncratic hypersensitivity.  This especially after long-term use.  Therapy with inamrinone should be administered cautiously if at all in patients with liver disease and discontinuation of the drug may be required if symptoms worsen.  Monitoring of liver functions tests prior to and during therapy is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7470, 0, 'Amrinone', 'Hypotension', 'The use of amrinone or milrinone is associated with a fall in blood pressure.  Some patients have required correction by intravenous infusion of plasma.  Therapy with amrinone or milrinone should be administered cautiously in hypotensive patients.  Monitoring fluid and electrolyte status, renal function, blood pressure, and heart rate is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7471, 0, 'Amrinone', 'Thrombocytopenia', 'The use of amrinone, and infrequently, milrinone, can cause thrombocytopenia.  This appears to be dose-dependent and usually occurs during prolonged therapy.  Therapy with amrinone and milrinone should be administered cautiously in patients with thrombocytopenia.  The dosage may need to be reduced or the drug discontinued if platelet count falls below 150,000/mm3 or if symptoms develop.  Platelet counts prior and during therapy are recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7472, 0, 'Indacaterol', 'Cardiovascular Diseases', 'Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptors, resulting in adverse effects such as tachycardia, palpitation, peripheral vasodilation, blood pressure changes, and ECG changes (e.g., flattening of the T wave; prolongation of the QT interval; ST segment depression).  Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol.  However, beta-2-selectivity is not absolute and can be lost with larger doses.  High dosages of these agents have been associated with precipitation or aggravation of angina, myocardial ischemia, and cardiac arrhythmias.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, and/or underlying cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, or hypertension.  The recommended dosages should not be exceeded.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7473, 0, 'Indacaterol', 'Diabetes Mellitus', 'Adrenergic bronchodilators may cause increases in blood glucose concentrations.  These effects are usually transient and slight, but may be significant with dosages higher than those normally recommended.  Large doses of IV albuterol (not commercially available in the U.S.) and terbutaline sulfate have been reported to cause exacerbation of preexisting diabetes mellitus and ketoacidosis.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with diabetes mellitus.  Closer monitoring of blood glucose concentrations may be appropriate.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7474, 0, 'Indacaterol', 'Hypokalemia', 'Adrenergic bronchodilators may cause decreases in serum potassium concentrations, primarily when given by nebulization or intravenous administration.  Although this effect is usually transient and does not require supplementation, clinically significant hypokalemia may occur in some patients, with the potential to induce cardiovascular adverse effects.  The relevance of these observations to oral or oral aerosol/powder for inhalation therapy is unknown.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with or predisposed to hypokalemia.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7475, 0, 'Indacaterol', 'Seizures', 'Adrenergic bronchodilators may cause CNS stimulation.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with seizure disorders.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7476, 0, 'Inotersen', 'Kidney Diseases', 'Inotersen can cause glomerulonephritis that may result in dialysis-dependent renal failure.  The use of inotersen is contraindicated in patients with history of acute glomerulonephritis.  Caution is advised if used in patients with renal impairment.  Close monitoring of renal parameters is recommended.  If glomerulonephritis is suspected, pursue prompt diagnosis and initiate immunosuppressive treatment as soon as possible.  Inotersen- treated patients who develop glomerulonephritis will require monitoring and treatment for nephrotic syndrome and its manifestations.  If acute glomerulonephritis is confirmed, inotersen should be permanently discontinued.  Use caution with nephrotoxic drugs and other drugs that may impair renal function.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7477, 0, 'Inotersen', 'Thrombocytopenia', 'Inotersen causes reductions in platelet count that may result in sudden and unpredictable thrombocytopenia that can be life-threatening.  The use of inotersen is contraindicated in patients with a platelet count below 100 x 10^9/L.  Close monitoring is recommended and caution is advised in patients with history of thrombocytopenia or at risk.  If a patient develops signs or symptoms of thrombocytopenia, obtain a platelet count as soon as possible, and hold inotersen dosing unless the platelet count is confirmed to be acceptable.  Recheck the platelet count as soon as possible if a platelet measurement is uninterpretable (e.g., clumped sample).  Patients and caregivers should be instructed to be vigilant for symptoms of thrombocytopenia and seek immediate medical help if they have concerns.  Glucocorticoid therapy is strongly recommended in patients with a platelet count below 50 x 10^9/L, and in patients with suspected immune-mediated thrombocytopenia.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7478, 0, 'Inotersen', 'Hepatic Insufficiency', 'Inotersen has not been studied in patients with moderate or severe hepatic impairment.  Additionally, patients taking inotersen have shown elevation of hepatic enzymes.  Monitor alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin at baseline and every four months during treatment.  If a patient develops clinical signs or symptoms suggestive of hepatic dysfunction (e.g., unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, or jaundice and/or dark urine), promptly measure serum transaminases and total bilirubin and interrupt or discontinue treatment with inotersen.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7479, 0, 'Inotersen', 'Vitamin A Deficiency', 'Treatment with inotersen leads to a decrease in serum vitamin A levels.  Caution is advised in patients with history of vitamin A deficiency.  Supplementation at the recommended daily allowance of vitamin A is advised for patients taking inotersen.  Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7480, 0, 'Indinavir', 'Nephrolithiasis', 'Crystalluria and nephrolithiasis may occur during treatment with indinavir.  The cumulative frequency of nephrolithiasis is substantially higher in pediatric patients (29%) than in adult patients (12.4%; range 4.7% to 34.4% across individual trials) and increases with duration of exposure to indinavir; however, the risk over time remains relatively constant.  The incidence is also higher when indinavir is used in combination with ritonavir than when used alone at 800 mg three times a day.  In some cases, nephrolithiasis/urolithiasis has been associated with renal insufficiency or acute renal failure and pyelonephritis with or without bacteremia.  Therapy with indinavir should be administered cautiously in patients with a current or past history of nephrolithiasis.  It is crucial that patients receive adequate hydration.  Generally, at least 1.5 L (approximately 48 oz) of fluid per day is recommended for adults during indinavir therapy.  Those who are dehydrated may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid if necessary.  All patients receiving indinavir should be instructed to seek medical attention if they experience potential signs and symptoms of nephrolithiasis/urolithiasis such as flank pain, hematuria, dysuria, anuria, and urinary urgency.  A brief interruption (e.g., 1 to 3 days) or discontinuation of therapy may be required.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7481, 0, 'Indinavir', 'Hemophilia A', 'There have been postmarketing reports of increased bleeding, including spontaneous skin hematomas and hemarthrosis, in types A and B hemophiliac patients treated with protease inhibitors.  However, a causal relationship has not been established.  In some patients, additional Factor VIII was given.  In more than half of the reported cases, protease inhibitor therapy was continued or reintroduced following an interruption.  Hemophiliacs and patients with other coagulation defects should be monitored closely for bleeding during protease inhibitor therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7482, 0, 'Indinavir', 'Liver Diseases', 'Indinavir is primarily metabolized by the liver.  Patients with liver disease may be at greater risk for adverse effects from indinavir due to decreased drug clearance.  Therapy with indinavir should be administered cautiously in patients with liver disease.  A dosage reduction to 600 mg three times a day is recommended for patients with mild to moderate hepatic insufficiency due to cirrhosis.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7483, 0, 'Indinavir', 'Hyperglycemia', 'New onset diabetes mellitus, exacerbation of preexisting diabetes mellitus, glucose intolerance, hyperglycemia, and some cases of diabetic ketoacidosis have been reported during postmarketing surveillance in HIV-infected patients treated with protease inhibitors (PIs).  In some cases, glucose abnormalities/hyperglycemia persisted despite discontinuation of PI therapy.  Frequently, insulin resistance may accompany fat redistribution and serum lipid elevations in what is collectively termed the HIV-associated lipodystrophy syndrome.  Although a causal relationship has not been established, these metabolic disturbances have most often occurred in HIV-infected patients during treatment with potent antiretroviral regimens containing PIs.  Monitoring patients for hyperglycemia, new onset diabetes mellitus, or exacerbation of diabetes mellitus should be considered during PI therapy.  Dosage adjustments in insulin or oral hypoglycemic medications may be necessary in patients with diabetes.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7484, 0, 'Indinavir', 'Hyperlipidemias', 'Hyperlipidemia has been observed in 10% of patients receiving ritonavir during clinical trials.  Increases of 30% to 40% from baseline have been reported for total cholesterol and 200% to 300% or more for triglycerides.  These effects have also been reported during postmarketing experience with other protease inhibitors (PIs) but may be the most dramatic with ritonavir.  The clinical significance of these elevations is unclear.  Severe hyperlipidemia is known to sometimes cause pancreatitis.  In addition, some patients have reportedly developed symptomatic atherosclerosis and coronary artery disease after initiating PI treatment.  Patients with preexisting hyperlipidemia may require closer monitoring during PI therapy, and adjustments made accordingly in their lipid-lowering regimen.  PI therapy should be administered cautiously in patients with coronary artery disease or a history of ischemic heart disease.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7485, 0, 'Amyl Nitrite', 'Myocardial Infarction', 'The benefits of organic nitrates and nitrites in patients with acute myocardial infarction (AMI) or congestive heart failure have not been established and its use is not recommended in these settings.  If used, it should be accompanied by careful clinical and hemodynamic monitoring to avoid the hazards of systemic hypotension and tachycardia, which in AMI can exacerbate myocardial ischemia.  In general, oral or long-acting formulations of these drugs should not be used in the early management of AMI because of the difficulty in precisely controlling and rapidly terminating their hemodynamic effects should adverse reactions occur.  Sublingual and other immediate- onset nitrates or nitrites should typically be avoided in suspected AMI with marked bradycardia or tachycardia, and should be used with extreme caution, if at all, in patients with right ventricular or inferior wall infarction.  Rarely, sublingual nitroglycerin has produced hypotension accompanied by paradoxical bradycardia in patients with AMI and especially right ventricular infarction.  The latter group of patients are also particularly dependent on adequate right ventricular preload to maintain cardiac output and can experience profound hypotension with nitrate or nitrite administration due to reduction of right ventricular preload.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7486, 0, 'Amyl Nitrite', 'Anemia', 'Some manufacturers and medical references consider the use of nitrates and nitrites to be contraindicated in patients with severe anemia.  Nitrates and nitrites can cause methemoglobinemia, primarily in high-dose intravenous therapy or acute poisoning and in patients with NADH reductase deficiency.  However, elevations of methemoglobin may also occur with commonly used dosages.  While probably not of routine clinical significance, the increases may be important in certain patient populations such as those with coronary insufficiency or anemia.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7487, 0, 'Amyl Nitrite', 'Diseases requiring hemodialysis', 'The combined effect of organic nitrates or nitrites with hemodialysis, which often lowers blood pressure, can cause life-threatening hypotension.  Therapy with these agents should be administered cautiously in patients requiring hemodialysis.  The medication should be withheld before undergoing dialysis, and hemodynamic stability should be established prior to resumption of medication following dialysis.  Nitroglycerin and isosorbide dinitrate are moderately dialyzed.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7488, 0, 'Amyl Nitrite', 'Hypotension', 'Organic nitrates and nitrites may cause severe hypotension, syncope and shock, even with small doses.  Hypotension induced by these agents may be accompanied by paradoxical bradycardia and increased angina pectoris.  Therapy with nitrates and nitrites should be administered cautiously in patients who are volume-depleted or hypotensive (e.g., systolic blood pressure <90 mm Hg) or who, because of inadequate circulation to the brain or to other vital organs, would be unusually compromised by undue hypotension.  Patients should be in a sitting or recumbent position during and immediately after drug administration, and monitored for symptoms of severe hypotension such as nausea, vomiting, weakness, pallor, perspiration, and syncope.  Nitrate or nitrite therapy is considered contraindicated in patients with acute circulatory failure or shock.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7489, 0, 'Amyl Nitrite', 'Intracranial Hypertension', 'Organic nitrates and nitrites can increase cerebrospinal fluid pressure.  Therapy with these agents should be administered cautiously, if at all, in patients with or at risk for intracranial hypertension, including those with cerebral hemorrhage, intracranial lesions, or recent head trauma.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7490, 0, 'Amyl Nitrite', 'Cardiomyopathy, Hypertrophic', 'Organic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients with this condition.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7491, 0, 'Amyl Nitrite', 'Glaucoma', 'Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma.  However, the effect on intraocular pressure is variable and brief, and there is no evidence that these drugs precipitate narrow-angle glaucoma.  Amyl nitrate typically may cause a slight rise of 3+ mm for several seconds followed by a fall in intraocular pressure for 10 to 20 minutes, the latter secondary to a fall in blood pressure.  Nitroglycerin rarely produces ocular side effects, and oral nitroglycerin appears to have few to no significant ocular side effects.', '1', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7492, 0, 'Indapamide', 'Anuria', 'The use of thiazide diuretics is contraindicated in patients with anuria.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7493, 0, 'Indapamide', 'Water-Electrolyte Imbalance', 'The use of thiazide diuretics is commonly associated with loss of electrolytes, most significantly potassium but also sodium, chloride, bicarbonate, and magnesium.  The loss of other electrolytes such as phosphate, bromide and iodide is usually slight.  Potassium and magnesium depletion may lead to cardiac arrhythmias and cardiac arrest.  Other electrolyte-related complications include metabolic alkalosis and hyponatremia, which are rarely life-threatening.  Therapy with thiazide diuretics should be administered cautiously in patients with or predisposed to fluid and electrolyte depletion, including patients with primary or secondary aldosteronism (may have low potassium levels); those with severe or prolonged diarrhea or vomiting; and those with poor nutritional status.  Fluid and electrolyte abnormalities should be corrected prior to initiating therapy, and blood pressure as well as serum electrolyte concentrations monitored periodically and maintained at normal ranges during therapy.  Patients should be advised to immediately report signs and symptoms of fluid or electrolyte imbalance, including dry mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, arrhythmia, or gastrointestinal disturbances such as nausea and vomiting.  Digitalized patients and patients with a history of ventricular arrhythmias should be monitored carefully, since development of hypokalemia may be particularly dangerous in these patients.  The risk of hypokalemia may be minimized by slow diuresis, a lower thiazide dosage, potassium supplementation, or combined use with a potassium-sparing diuretic.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7494, 0, 'Indapamide', 'Liver Diseases', 'Patients with severe liver disease or cirrhosis are very susceptible to thiazide-induced hypokalemic hypochloremic alkalosis.  Blood ammonia concentrations may be further increased in patients with previously elevated concentrations.  Hepatic encephalopathy and death have occurred secondary to the electrolyte alterations accompanying diuretic use.  Therapy with thiazide diuretics should be administered cautiously in patients with impaired hepatic function or progressive liver disease, and discontinued promptly if signs of impending hepatic coma appear (e.g., tremors, confusion, and increased jaundice).', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7495, 0, 'Indapamide', 'Lupus Erythematosus, Systemic', 'The use of thiazide diuretics has been reported to possibly exacerbate or activate systemic lupus erythematosus.  Reported cases have generally been associated with chlorothiazide and hydrochlorothiazide.  Therapy with thiazide diuretics should be administered cautiously in patients with a history or risk of SLE.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7496, 0, 'Indapamide', 'Kidney Failure, Chronic', 'Thiazide diuretics may be ineffective when the glomerular filtration rate is low (GFR < 25 mL/min) because they are not expected to be filtered into the renal tubule, their site of action.  In addition, thiazide diuretics decrease the GFR and may precipitate azotemia in renal disease.  Cumulative effects may also develop because most of these drugs are excreted unchanged in the urine by glomerular filtration and active tubular secretion.  Therapy with thiazide diuretics should be administered cautiously at reduced dosages in patients with renal impairment.  If renal function becomes progressively worse, as indicated by rising BUN or serum creatinine levels, an interruption or discontinuation of thiazide therapy should be considered.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7497, 0, 'Indapamide', 'Asthma', 'Thiazide diuretics should be used with caution in patients with history of bronchial asthma as sensitivity reactions may occur.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7498, 0, 'Indapamide', 'Diabetes Mellitus', 'Thiazide diuretics may cause hyperglycemia and glycosuria in patients with diabetes.  They may also precipitate diabetes in prediabetic patients.  These effects are usually reversible following discontinuation of the drugs.  Therapy with thiazide diuretics should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during thiazide therapy, and their antidiabetic regimen adjusted accordingly.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7499, 0, 'Indapamide', 'Hyperlipidemias', 'Thiazide diuretics may increase serum triglyceride and cholesterol levels, primarily LDL and VLDL.  Whether these effects are dose-related and sustained during chronic therapy are unknown.  Patients with preexisting hyperlipidemia may require closer monitoring during thiazide therapy, and adjustments made accordingly in their lipid-lowering regimen', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7500, 0, 'Indapamide', 'Hyperparathyroidism', 'Urinary calcium excretion is decreased by thiazide diuretics during chronic administration.  Pathologic changes in the parathyroid gland with hypercalcemia and hypophosphatemia have been reported during prolonged therapy.  However, the common complications of hyperparathyroidism such as renal lithiasis, bone resorption, and peptic ulceration have not been seen.  Clinicians should be cognizant of these effects when prescribing or administering thiazide therapy to patients with hyperparathyroidism.  These drugs should be discontinued before carrying out tests for parathyroid function.', '2', 'DDInter');
